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liver, spleen and bone marrow parasite load on DAI 
23 and DAI 39
Figure 34. The effect of DFMO (4% soln. x 14 days,
DAI 6-DAI 19, x 30 days, DAI 6-DAI 35), BSO 
(4 x 20 mg/kg, three times daily) and fexinidazole, 
(4 x 200 mg/kg, DAI 16-DAI 19) in combination, on 
liver, spleen and bone marrow parasite load on DAI 
23 and DAI 39
Figure 35. The effect of Berenil (4 x 20 mg/kg,
three times daily, DAI 16-DAI 19) and fexinidazole 
(DAI 15-DAI 19), in combination, on liver, spleen 
and bone marrow parasite load, on DAI 23 and DAI 70
Figure 36. Comparison of Pentostam (P) and (P)/ Octyl 
Degrol oil (0) on L. donovani-infected Balb/c mice.
I. Various dose levels of Pentostam
Figure 37. Comparison of Pentostam (P) and (P)/
Octyl Degrol oil (0) on L. donovani-infected Balb/c 
mice. II. Various numbers of doses of Pentostam
Figure 38. The effect of DNA intercalators against 
promastigotes of L. donovani
Figure 39. The effect of platinum and rhodium drug 
complexes against the promastigotes of L. donovani
Figure 40. The effect of 8-hydroxyquinoline compounds 
against the promastigotes of L. donovani
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SUMMARY
The hypothesis that compounds that inhibit the synthesis or 
interfere with the activity of trypanothione are likely to act 
synergistically against trypanosomatids was tested using Leishmania 
donovani as the target organism. Studies involved determining the 
efficacy of drugs and drug combinations against L. donovani growing 
in mice and as promastigotes and amastigotes in vitro.
The compounds tested included the antitrypanosomal drugs 
DL-CC-difluoromethylornithine (DFMO, Eflornithine^), diminazene 
diaceturate (Berenil^), pentamidine (Lomidine^) (pentamidine is also 
recognised as antileishmanial drug), melarsonyl potassium
(Trimelarsan^, Mel W^), other experimental compounds reported to 
have activity against trypanosomes (various nitroimidazoles and 
guanylhydrazones, DL-buthionine-(S,R)-sulfoximine), and also the 
established antileishmanial drug, sodium stibogluconate 
(Pentostam^). Most of these compounds were reported recently to be 
highly successful in the combination chemotherapy of experimental 
murine trypanosomiasis with central nervous system involvement.
Many of the compounds were shown to have antileishmanial 
activity but none of the combinations appeared to be synergistic 
under the conditions used. However, at high concentrations, some 
were more effective than the recognised antileishmanial drug sodium 
stibogluconate.
The antileishmanial activity of DFMO was studied in more detail 
using different regimens to assess the potential of the drug for 
treating visceral leishmaniasis and prevent relapse. DFMO showed 
good activity but did not give a total clearance of parasites from 
all tissues.
The potential of some promising drug combinations was also 
tested for clearing the parasites from tissues other than the liver, 
such as the spleen and the bone marrow. These combinations reduced 
significantly the number of parasites but without giving a total 
clearance.
An experimental compound, octyl degrol oil, which allowed a slow 
release of the drugs, was also investigated and the results showed
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a beneficial effect when it was used with sodium stibogluconate.
A number of experimental compounds with potential 
antitrypanosomal activity were available in limited quantities. 
These included DNA intercalators, platinum and rhodium drug 
complexes and 8-hydroxyquinolines and were tested as potential 
antileishmanials. The results from this study suggested that the DNA 
intercalators and the 8-hydroxyquinolines have antileishmanial 
activity and further studies evaluating these compounds would be 
worthwhile.
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INTRODUCTION
1.1. THE PARASITE
1.1.1. EVOLUTION, CLASSIFICATION, GEOGRAPHICAL DISTRIBUTION, 
TRANSMISSION AND VECTORS
1.1.1.1. The systematic position of the genus Leishmania
It is now generally accepted that living organisms are separated 
into five kingdoms: Monera, Protista, Plantae, Fungi and Animalia. 
Protozoa were regarded as a phylum within the kingdom Animalia, in 
classifications accepted until 1960's. After that time it became 
increasingly apparent that a new classification was necessary to 
take into account the enormous number of species of protozoa being 
reported for the first time and our increasing understanding of the 
biology and structure of unicellular organisms.
Protozoa are now best considered as a subkingdom within the 
Protista and seven distinct phyla have been recognised (Levine 
et al.. 1980): Sarcomastigophora, Labyrinthomorpha, Apicomplexa,
Microspora, Ascetospora, Myxozoa and Ciliophora.
Leishmanias are included in the Sarcomastigophora and a recent 
classification is outlined in Table 1.
The genus Leishmania may be defined as follows: parasitic
protozoa of the order Kinetoplastida, family Trypanosomatidae: 
heteroxenous, with promastigotes and paramastigotes in the 
alimentary tract of an insect host and rounded amastigotes living 
and dividing in the macrophage cells of a vertebrate host.
As far as is known, the only invertebrate hosts are the 
blood-sucking phlebotomine sand-flies (Diptera: Nematocera:
Pshychodidae: Phlebotominae) of the genera Lutzomvia. Phlebotomus
and Psychodopvgus. The males feed on fruit juices only, and 
therefore play no direct role in transmission of leishmaniasis. The 
probable evolutionary history of Leishmania from parasites of 
insects and eventually to one of mammals, implies that infected 
sand-flies are primary hosts, though for convenience they are termed 
vectors.
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Table 1
The revised scheme for the classification of Leishmania spp. 
(From Levine jlL & l , f 1980; Lainson and Shaw, 1987).
Kingdom PROTISTA Haeckel, 1866
Sub-Kingdom PROTOZOA Goldfuss, 1817
Phylum SARCOMASTIGOPHORA Honigberg and Balamuth, 1963
Sub-phylum MASTIGOPHORA Deising, 1866
Class ZOOMASTIGOPHOREA Calkins, 1909
Order KINETOPLASTIDA Honigberg, 1963, emend. Vickerman, 1976 
Sub-order TRYPANOSOMATINA Kent, 1880
Family TRYPANOSOMATIDAE Doflein, 1901, emend. Grobben, 1905 
Genus Leishmania Ross, 1903
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The vertebrate hosts are a variety of mammals. The parasites are 
particularly common in canids (visceralising species) and rodents
(mainly species causing cutaneous disease). Important hosts also
occur in edentates, marsupials, procyonids, primitive ungulates and 
primates. Rare infections are recorded in New World chiropterans.
Until recently, it was considered that there are no sexual
processes and multiplication in both the invertebrate and the
vertebrate host is by binary fission. Recent unpublished findings,
however, now suggest that sexual processes do occur.
Transmission among the mammalian reservoir hosts is 
predominantly by the bite of the infected insect. The mechanism of 
transmission has been the subject of much debate for many years. The 
understanding of the mechanisms of and factors influencing
transmission remain to be fully investigated.
Distribution is through most tropical and sub-tropical America,
Africa, India and parts of eastern Asia (but unknown in
Australasia), in central Asia, the Mediterranean basin and some 
neighbouring European countries.
1.1.1.2. Evolution of the genus Leishmania
It is now generally accepted by most protozoologists, that the
eukaryote Protista evolved from a flagellate stock (Butschli, 1882) 
and that the promastigote of the Trypanosomatidae probably
approximates most closely to the ancestral form. However, opinions 
are divided regarding the origin of the trypanosomatids. Basically 
there are two schools of thought:
1. an origin from monogenic parasites of the invertebrates, with 
subsequent adaptation to vertebrates;
2. an origin in vertebrates, with secondary transmission by
blood-sucking invertebrates.
There is unlikely ever to be any conclusive evidence on one side 
or the other, however, and the best one can suggest is that the 
modern trypanosomatids might have stemmed from both sources, with
the weight of present-day opinion favouring an evolution from 
monogenic invertebrate flagellates (Lainson and Shaw, 1987).
All the known leishmanias develop as promastigotes, or 
morphological modifications of the form, in species of phlebotomine 
sand-flies. Speculations on the evolution of the existing species of 
Leishmania are only possible after a comparative study of a large 
number of these organisms. However, although we are at last 
beginning to appreciate the multiplicity of leishmanial parasites, 
our knowledge of the biology and biochemistry of most of them is 
still very poor. This is particularly the case with the 
developmental stages in the sand-fly which, if we are right in 
regarding these insects as the primitive and primary hosts, are most 
likely to provide us with evolutionary clues.
1.1.1.3. Classification of subgenera and species of the genus 
Leishmania
It is very obvious that the genus Leishmania is comprised of quite a 
considerable number of species. It is becoming increasingly apparent 
that these species are themselves made up of lower categories which 
might variously be regarded as subspecies, serological 
("serodemes"), enzyme ("zymodemes"), or genetic ("schizodemes”) 
variants; a situation that reflects the continuing process of 
speciation.
The taxonomic division of Leishmania into species is complicated 
due to morphological similarities of the organisms and the 
relatively few easily recognisable characters by which one species 
can be distinguished from another. Early classifications were based 
on the pathology of the diseases and the parasite's geographical 
distribution.
The more important characters used today for classification of 
the leishmanias are listed in the Table 2.
It has been particularly difficult to establish an adequate 
classification of Leishmania in the New World. There, the speciation 
of the genus has developed greatly, mainly due to the availability 
of an abundant variety of possible vectors and the multiplicity of 
reservoir hosts of the parasites. In addition, the ecological 
conditions have changed constantly as a result of deforestation and
Table 2
Charactersa used in the classification and identification of 
the subgenera and/or species of the genus Leishmania.
A. Morphology
B. Behaviour of the parasite in:
1. The natural sand-fly host
2. The vertebrate host
3. Specified in vitro culture media
C. Host response
D. Biochemistry
E. Geographical distribution
F. Clinical features in human infections
a Modified from W. Peters (1982).
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settlement by humans (Riggione and Hernandez, 1981).
Diverse classifications have been proposed for the leishmanias. 
Recently Lainson and Shaw (1987) proposed a new classification which 
is as follows:
1. The subgenus Leishmania Saf'janova 1982
Definition: With the characters of the genus: life cycle in the
insect host limited to the midgut and foregut of the alimentary 
tract: type-species Leishmania (Leishmania) donovani (Laveran and
Mesnil, 1903) Ross, 1903. Old and New World.
The Leishmania (L.) donovani complex:
L. (L.) donovani (Laveran and Mesnil, 1903) Ross, 1903. (Old 
World).
L. (L.) infantum Nicolle, 1908 (Old World).
L. (L.) chagasi Cunha and Chagas, 1937 (New World).
Other possible species:
L. (L.) archibaldi Castellani and Chalmers, 1919. Sudan: in 
rodents, the genet, the serval-cat, and man.
Leishmania (L.) sp. Kenya: in man, and occasional dogs.
Leishmania (L.) sp. Eastern Pyrenees: in man.
Leishmania (L.) sp. Italy: in foxes and dogs.
Leishmania (L.) sp. Iraq: in canids and man.
Leishmania (L.) sp. China; Inner Mongolia: in man.
Other species, outside the donovani complex:
L. (L.) tropica (Wright, 1903) Luhe, 1906.
L. (L.) aethiopica Bray, Ashford and Bray, 1973.
L. (L.) gerbilli Wang, Qu and Guan, 1964.
L. (L.) maior Yakimoff and Schokhor, 1914 emend. Bray, Ashford
and Bray, 1973.
Leishmania (L.) sp. Namibia: in man and the sand-fly (Phlebotomus 
rossi).
Leishmania (L.) sp. Namibia: in the hyrax (Procavia capensis).
Leishmania (L.) sp. Ethiopia: in the rodent (Arvicanthis sp.).
The Leishmania (L.) mexicana complex (New World)
L. (L.) mexicana Biagi, 1953 emend. Garnham, 1962.
L. (L.) enriettii Muniz and Madina, 1948.
L. (L.) amazonensis Lainson and Shaw, 1972.
L. (L.) aristidesi Lainson and Shaw, 1979 emend. Lainson and 
Shaw, 1986
L. (L.) venezuelensis Bonfante-Garrido, 1980.
Leishmania (L.) sp. Dominican Republic: in man
Leishmania (L.) sp. Belize, Central America: in man.
Possible additional members of the L. (L.) mexicana complex:
L. (L.) pifanoi Medina and Romero, 1959 emend. Medina and Romero, 
1962.
L. (L. ) garnhami Scorza et. ., 1979.
Leishmania (L.) sp. Trinidad: in the sand-fly (Lutzomvia 
flaviscutellata)f rodents and marsupials.
Leishmania (L.) sp. Vale do Ribeiro, Sao Paulo State, Brazil: in 
man.
Leishmania (L.) sp. Caratinga, Minas Gerais State, Brazil: in 
the rodent Proechimvs dimidiatus.
Leishmania (L.) sp. Caratinga, Minas Gerais State, Brazil: in 
man.
The Leishmania (L.) hertigi complex (New World):
L» (L») hertigi Herrer, 1971.
L. (L.) deanei Lainson and Shaw, 1977.
2. The subgenus Viannia n. subgen.
Definition: With the characters of the genus: Life cycle in the 
insect host including a prolific and prolonged phase of development 
as rounded or stumpy paramastigotes and promastigotes,
attached to the wall of the hindgut (pylorus and/or ileum) by 
flagellar hemidesmosomes, with later migration of flagellates to 
the midgut and foregut. Type-species Leishmania (Viannia)
braziliensis Vianna, 1911, emend. Matta, 1916.
Distribution: the American tropics and sub-tropics.
The Leishmania (3£») braziliensis complex:
L. (Y.) braziliensis Vianna, 1911 emend. Matta, 1916.
L. (Y.) guvanensis Floch, 1954.
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L. (V.) panamensis Lainson and Shaw, 1972.
L. (Y.) peruviana Velez, 1913.
Unnamed species of the L. (Y» ) braziliensis complex:
Leishmania (V.) sp. Belize, Central America: in man.
Leishmania (Y*) sp. Para State, Brazil (south of the Amazon 
River): in the sloth (Choloepus didactvlus).
Leishmania (Y*) sp. Itaituba, Para State, Brazil: in the common 
opossum (Didelphis marsupialis).
Unnamed species of the subgenus Viannia:
Leishmania (L.) sp. Para State, Brazil: in the sand-fly 
(Lutzomvia tuberculata).
Leishmania (Y*) sp. Para State, Brazil: in an unidentified 
sand-fly (Psychodopvgus sp.).
Leishmania (Y») sp. Para State, Brazil: in the sand-fly 
(Lutzomvia ubiquitalis).
Leishmania (Y») sp. Para State, Brazil: in the nine banded 
armadillo (Dasvpus novemcinctus).
Leishmania (Y*) sp. Para State, Brazil: in man.
Leishmania (Y*) sp. Para State, Brazil: in man.
Questionable leishmanial parasites:
Leishmania herreri Zeledon, Ponce and Murillo, 1979.
In the sand-flies (Lu. vlephiletor: Lu. shannoni: Lu. trapidoi) 
and the sloths (Choloepus hoffmani: Bradvpus griseus).
Leishmania sp. (Barbosa fii.* > 1976). From man, Mato Grosso 
State, Brazil.
In contrast to the mammalian Leishmania species, the taxonomic 
status of lizard leishmanias is uncertain, mainly because the 
presence of intracellular amastigotes within the lizard host has 
never been well established. Some authorities maintain that the 
Leishmania species of lizards form a sufficiently distinct group to 
be ranked as Sauroleishmania at generic level (Ranque, 1973; Lainson 
and Shaw, 1987) while others (Wallbanks gt ai., 1985) suggested 
that such species might be classified within the genus
Trypanosoma. This suggestion followed from work showing that 
promastigotes of Trypanosoma platvdactvli and Leishmania tarentolae 
had similar isoenzyme profiles. Recent studies (Simpson and Holz,
1988) of DNA and lipid composition, however, do not support the 
suggestion of Wallbanks gt. ai* > but give conflicting evidence that 
the lizard leishmanias are more closely related to mammalian 
leishmanias than to trypanosomes.
1.1.2. MORPHOLOGY, ULTRASTRUCTURE AND LIFE CYCLES
1.1.2.1. Morphology
The basic organelles of the leishmanial parasites are essentially 
similar and morphological differences at light-microscope level 
largely consist of differences in size and disposition of the
nucleus and the kinetoplast.
Electron micrographs of the amastigote and promastigote stages 
have confirmed size differences seen at light-microscope level and 
have also disclosed differences in the number of subpellicular 
tubules (peripheral fibrils) and the distance between these
structures (Gardener et. ul., 1977; Veress et. al., 1980, see section
1.1.2.2. below).
By ordinary transmitted-light microscopy, amastigotes of
Leishmania are best studied in impression-smears and sections after 
staining with the Romanowsky stains (Giemsa's or Leishman's stain). 
The organisms appear as round or oval bodies 2 to 5 fim in length 
which contain a nucleus and a kinetoplast and lie within vacuoles in 
the cytoplasm of the host cell. However, in impression smears, 
large numbers of extracellular forms following the rupture of 
infected cells are commonly seen. Leishmania donovani is the
smallest (2-3 Jim) (Simpson, 1968) of all leishmanias, whereas the 
relatively large size of the amastigotes of L. deanei in Brazilian 
porcupines (Lainson and Shaw, 1977) sets it apart from all other 
known leishmanias.
The promastigotes of all Leishmania species are fairly similar 
in size and morphology, possessing a long anterior flagellum and
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Fig.  1. A t r a n s m i s s i o n  e l e ct r on  m i c r o g r a p h  of  l on g i t u d i n a l  s e c t i o n  
of L. d on ov ani  a m a s t i g o t e s .  N ot e  k i n e t o p l a s t  (K),  m i t o c h o n d r i o n  (m),  
n uc l e u s  (N),  s u b p e l l i c u l a r  m i c r o t ub ul e s  ( p m t) ,  Gol gi  a p p a r a t u s  (G),  
e n d o p l a s m i c  re t ic u l u m (E.R)  and f l ag e l l um (F)  in f l a g e l l a r  p o c k e t  ( fp) .  
x 4 4 , 0 0 0 .
( M i c r o g r a p h  c o u r t e s y  of  L. Tet ley) .
having the approximate dimensions of 2 x 20 fim. However, in some 
species of Leishmania. distinct forms (nectomonad promastigotes, 
haptomonad promastigotes, paramastigotes) do occur in the sand-fly 
midgut and these are thought to correspond to different parts of the 
developmental cycle (Killick-Kendrick £t. &!•, 1974).
A wide variety of promastigotes is seen in in vitro cultures 
(usually nectomonad promastigotes, haptomonad promastigotes and 
rosettes of promastigotes). However, in cultures it is not possible 
to relate such forms to a particular sequence of development as in 
the sand-fly.
Transformation of amastigotes to promastigotes in vitro has been 
described in detail for L. mexicana by Hart (1981c). The
process of differentiation was reported to involve three 
morphologically distinct intermediates, including a division stage.
1.1.2.2. Ultrastructure
Both of the stages are typical of all trypanosomatids, in having 
many sub-cellular structures in common with most eukaryotic cells 
(See Figure 1). They do, however, have some unique features.
The plasma membrane of all stages of Leishmania is a typical, 
trilaminar unit membrane 2-4 nm in width, beneath which lies an 
array of subpellicular microtubules. The subpellicular microtubules 
impart a high degree of cell rigidity often making it difficult to 
disrupt leishmanial cells properly for cell fractionation and 
probably serve as a cytoskeleton (Vickerman and Preston, 1976). 
They have been used as potential means of separating Leishmania 
species. Various workers have counted these tubules. L. donovani 
had the smallest microtubule count of the species investigated. 
Veress sJl slL. , (1980) found 91-93 in L. donovani from human cases 
with either mucocutaneous or visceral infections in Sudan. The 
practical value of these techniques, however, compared with other 
specific methods of characterisation is limited.
Cytochemical and lectin-binding studies reveal that the unit 
membranes of amastigotes and promastigotes have polysaccharide 
components (Dwyer &1., 1974).
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Uptake of macromolecules is by pinocytosis, but no detailed 
study of this process accompanied by cytochemical analysis appears 
to have been made.
A contractile or pulsatile vacuole lies next to the plasma 
membrane of the reservoir of promastigotes, but little is known of 
its true function in pathogenic flagellates, nor if its role is 
other than osmoregulatory (Molyneux and Killick-Kendrick, 1987).
At the anterior end of the parasite the plasma membrane is 
invaginated to form the flagellar pocket, from which the flagellum 
emerges. In this region, the network of subpellicular microtubules 
is absent. The characteristic axonemal structure of the flagellum is 
observed in Leishmania promastigotes; nine pairs of peripheral 
axonemal doublets encircle a central pair. This arrangement is 
observed distal to the basal plate.
The flagellar apparatus facilitates locomotion and attachment to 
the substratum and may also play a part in feeding mechanisms 
(Vickerman and Preston, 1976).
In the amastigote, the flagellum is not "free" or outside the 
body of the parasite and thus has no locomotory function.
The flagella of all paramastigotes and promastigotes are 
modified within the sand-fly for attachment to cuticular surfaces of 
the hind and foregut with the formation of hemidesmosomes. This 
modification of the flagella for attachment is a phenomenon common 
to all associations between trypanosomatids and invertebrates, with 
the attachment by hemidesmosomes to cuticle apparently being 
present in all trypanosomatids in insects.
There are three features of Leishmania structure that have been 
found in no other eukaryotic organism other than trypanosomatids. 
These are: the exceptional organisation of the mitochondrion and its 
DNA, the kinetoplast DNA (kDNA), and the presence of glycosomes and 
megasomes (Alexander and Vickerman, 1975; Vickerman and Preston, 
1976; Opperdoes and Borst, 1977; Coombs ££. al., 1986).
The single highly branched mitochondrion, approximating to 10% 
of the total cell volume in the amastigote (Coombs gt. &L., 1986) 
contains larger quantities of mitochondrial DNA than that found in
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other cells (Vickerman and Preston, 1976). The DNA present in the 
mitochondrion is arranged in a slightly concave disc (0.83 Jim in 
depth), called the kinetoplast, which lies just posterior to the 
basal body of the flagellum and within a constant spatial distance 
throughout the life cycle.
By rotary shadowing or darkfield electron microscopy, this 
fibrous kDNA disc of kinetoplastid flagellates, has been shown to be 
made up of several thousand mini-circles and a small number (50) of 
maxi-circles, organised in a characteristic network structure 
(Barker £t. al., 1982). The contour length of mini-circles of kDNA, 
which is group rather than species specific (as is the number of 
mini-circles), is 0.29 Jim. During division the kinetoplast divides 
before the nucleus (Vickerman, 1974).
The process of transformation of leishmanias from amastigotes to 
promastigotes has been reported to be associated with an increase in 
the number of mitochondrial profiles per section of flagellate 
(Vickerman, 1974). In both forms of the parasite, the mitochondrion 
contains plate-like cristae and respiration is cyanide-sensitive 
(Vickerman, 1974; Hart al., 1981c).
Ultrastructural studies of Leishmania reveal the presence within 
the cytoplasm of membrane-associated organelles such as the 
endoplasmic reticulum and Golgi apparatus, characteristic of other 
eukaryotes. Golgi products are packaged as lysosomes and play a role 
in intracellular digestion. Lysosomes of Leishmania have been little 
studied and assumptions to date have been made by comparison with 
what is known of their role in other kinetoplastids. This relates 
with digestion of ingested macromolecules after fusion with 
Golgi-derived primary lysosomes and also to the exocytosis of 
multivesiculate bodies into the flagellar reservoir. Vickerman and 
Preston (1976) also suggested that primary lysosomes may control 
organelle turnover, after fusing with organelles or structures 
within the parasite to form autolysosomes, in a material recycling 
process.
Alexander and Vickerman (1975) first reported the presence of 
megasomes in L. m. mexicana amastigotes.
13
Megasomes are lysosome-like organelles variable in shape but 
often large, occupying as much as 15% of the amastigote cell volume 
(Coombs ££. al., 1986). They contain several putative lysosomal
enzymes including arylsulphatase and a cysteine proteinase (Pupkis 
et al. f 1986). It has been suggested that they may play a role in 
the survival of L. mexicana amastigotes within the host (Coombs and 
Pupkis, 1986; Coombs and Baxter, 1984).
Glycosomes are specialised membrane-bound organelles which 
contain a number of enzymes associated with several important 
biochemical pathways such as glycolysis (Opperdoes, 1984; Mottram 
and Coombs, 1985) and ds. novo purine and pyrimidine biosynthesis 
(Hassan g t al., 1985; Opperdoes, 1987).
They appear to be unique to trypanosomatids. They were first 
identified in Trypanosoma brucei (Opperdoes and Borst, 1977) and 
reported since then in T. cruzi. Crithidia fasciculata and 
£. luciliae (Taylor at aL • > 1980) and L. m. mexicana (Coombs e£ al. f 
1982).
There appears to be large variation between trypanosomatids in 
the abundance of these organelles and this is probably an indication 
of their importance to different species and stages. Bloodstream 
forms of T. brucei have an average of 240 (Opperdoes a t a l • > 1984), 
L. tropica promastigotes are reported to contain 50-100 (Opperdoes, 
1987) whereas the amastigotes of L. m. mexicana were found to have 
only around 10 (Coombs at a l •» 1986).
Although symbionts have not been observed in Leishmania 
species, Molyneux (1974) reported the presence of virus-like 
particles (VLPs) throughout the cytoplasm of L. hertigi cultured 
promastigotes, initially isolated from the tropical porcupine 
(Coendou rothschildi) in Panama and Brazil. It is not known if 
L. hertigi acquired the VLPs from a sand-fly vector or from the 
mammalian host. All stocks examined had VLPs organised in 
paracrystalline arrays or associated with induced tubules, in the 
cytoplasm of promastigotes (Molyneux and Ashford, 1983). The number 
of VLPs was drastically reduced upon transformation of promastigotes 
to amastigotes. VLPs were not transmissible to other Leishmania nor
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to cells or lines susceptible to viruses (Molyneux and Killick- 
Kendrick, 1987).
1.1.2.3. Life cycles
The behaviour and life cycles of different species of Leishmania in 
the invertebrate host are not uniform. Defined sequences of 
morphological types occur within the sand-fly vector and life cycles 
of different species differ in the initial sites of establishment. 
In the vertebrate host, the parasite's life cycle involves existence 
in the reticulo-endothelial (RES) system. In this location, the 
parasites cause damage to a greater or a lesser extent.
The disease is initiated in the vertebrate host by the bite of 
an infected female phlebotomine sand-fly in search of a blood meal. 
The elongated, flagellated, extracellular promastigote forms of the 
parasite that occur in the sand-fly's foregut are known as 
metacyclics and are particularly adapted for surviving in mammals. 
They are inoculated into the mammalian skin during the blood meal 
whereupon they are rapidly phagocytosed by mononuclear phagocytes.
Having been taken into mononuclear phagocytes, the promastigotes 
transform into the amastigote form.
Lysosomes fuse with the phagosomes containing the organisms but 
the amastigotes resist phagolysosomal enzymes by unknown mechanisms. 
Leishmania amastigotes are remarkable in that, they are obligate 
intramacrophage-phagolysosome microorganisms.
The amastigote form divides by binary fission eventually 
causing the infected cell to rupture and release amastigotes which 
can be phagocytosed and so infect further macrophages. 
Multiplication of the amastigotes within the phagolysosomes of the 
macrophages of the skin, mucosa and viscera, gives rise to 
cutaneous, mucosal and visceral leishmaniasis, respectively. In the 
case of mucocutaneous leishmaniasis, primary infections occur at the 
level of the skin and later spread to the soft parts of the nasal 
septum, palate and pharynx (Mauel, 1979).
Amastigotes taken up by a feeding sand-fly transform back to 
promastigotes within the insect's midgut, after at least one initial
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division. They then multiply, undergo developmental changes and 
depending on the species of Leishmania. colonise the pylorus and 
ileum (L. braziliensis complex) and/or the abdominal midgut 
(mammalian leishmanias other than the braziliensis complex) and 
finally migrate to stomodaeal valve, oesophagus, pharynx and 
proboscis where they are found as metacyclics.
A variety of morphological changes occur within the 
promastigotes as they divide and establish themselves within the 
sand-fly. They have been described in detail by Molyneux and 
Killick-Kendrick (1987). Most of the experimental work on the 
developmental changes that occur in promastigotes, however, has been 
carried out using promastigotes grown in vitro. The biochemical 
differences between the developmental stages of promastigotes and 
amastigotes are discussed in section 1.1.3..
The change from infective promastigote to the 
intracellular amastigote is the most important developmental change 
that occurs in terms of the clinical disease and is associated with 
large changes in morphology and several metabolic switches. At the 
light-microscope level, this process was found to be completed 
within 12-24 hours (Alexander, 1975; Ardehali and Khoubyar, 1978).
The factors that initiate the promastigotes to amastigotes 
transformation have not been yet fully elucidated. Temperature 
appears to play a very important role, the change in temperature 
from the sand-fly (27°C) to the definitive host (37°C) is 
considerable. It has been reported that a rise in temperature 
of a L. braziliensis panamensis promastigote culture from 26°C to 
35°C resulted in amastigote-like forms (Darling and Blum 1987; 
Smejkal al al., 1988). A similar effect had been shown previously by 
various other workers with several other species of Leishmania 
(Hunter at al., 1984; Lawrence and Robert-Gero, 1985). This
temperature change also induces the synthesis of several heat shock 
proteins which are thought to play a part in the transformation of 
the parasite (Hunter al al* > 1984; Lawrence and Robert-Gero, 1985; 
van der Ploeg al al* > 1985; Shapira al al* > 1988; Toye and Remold, 
1989).
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Although amastigote type forms can be produced axenically from 
promastigotes in culture (see above) there has been great difficulty 
in attempting to culture these extracellular forms. Probably the 
most successful has been the growth of L. m. pifanoi (Pan, 1984) 
and L. braziliensis (Eperon and McMahon-Pratt, 1989) in cell free 
media although it is unknown how closely related these are to the 
intracellular amastigotes (Evans, 1987).
The in vitro culture of Leishmania species is also 
temperature-dependent. L. donovani amastigotes grow best in 
macrophages at temperatures ranging between 35°C and 37°C (Berman 
and Neva, 1981) while L. m. mexicana and L. tropica, at 34-35°C 
(Biegel et. al., 1983). It has been suggested that this temperature 
sensitivity may account for the site specificity of the different
cutaneous and visceral forms of leishmaniasis, presumably a
cutaneous site would be several degrees cooler than a visceral site 
(Biegel aL al*> 1983).
1.1.3. PHYSIOLOGY AND BIOCHEMISTRY
Biochemical and physiological studies of leishmanial parasites began 
in the late 1940s. There were various reasons for these studies.
(1). Leishmanial parasites represent an interesting model system 
of cell development as they readily transform in vitro.
(2). They are involved in a complicated form of. intracellular 
parasitism and an understanding of the biochemistry behind the 
survival mechanism could lead to the development of ways of
interfering with it.
(3). Biochemical differences between parasite and host could 
represent potential targets for further drug development.
Since that time, the relationship between promastigote 
metabolism and amastigote function within a host cell has continued 
to be a concern among investigators. The knowledge of promastigote 
metabolism has increased considerably and techniques to investigate 
amastigote biochemistry both in vitro and within host cells have 
begun to appear. Some differences between multiplicative
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promastigotes and metacyclic promastigotes have been reported 
(Mallinson and Coombs, 1989), but as yet the specific
characteristics of metacyclic forms have not been extensively 
studied. The question of promastigote-amastigote correlations, 
however, remains an overriding consideration.
As there is a general lack of information on the amastigote
stage, most of the work discussed here, except where stated
otherwise, refers to promastigotes in general.
1.1.3.1. Energy metabolism
The energy metabolism of Leishmania has been quite extensively 
studied and has been reviewed by Mukkada (1985) and Glew et. al. 
(1988). Leishmania species studied to date take up glycerol, 
glucose, and a number of related monosaccharides (von Brand ££. al.. 
1967). The work of Zeledon (1960a, b, c, d) has also shown the 
uptake of numerous amino acids by promastigotes. Enzymes of 
the glycolytic and tricarboxylic acid (TCA) cycle are present in 
both the amastigote and promastigote and their respiration is 
cyanide sensitive. Promastigotes contain enzymes that allow them to 
utilise carbohydrates or amino acids as energy substrates. With 
some species, amino acids appear to be used mainly during the
earlier stages of promastigote growth in vitro whereas glucose tends 
to be utilised more during the stationary phase of growth (Marr and 
Berens, 1977; Cazzulo iLL • > 1985). Mukkada (1985) suggested that 
Leishmania promastigotes utilise amino acids rather than 
carbohydrates as their respiratory substrate. However, it has 
been suggested that these findings reflect the length of time that 
the promastigotes have been maintained in continuous culture in 
vitro. Hart and Coombs (1982) reported that low sub-passage 
promastigotes of L. m. mexicana preferentially utilised glucose 
rather than amino acids whilst the reverse was true for high 
sub-passage promastigotes.
Meade ££. & l. (1984) studied some of the enzymes involved in the 
carbohydrate and amino acid metabolism of the amastigotes and 
promastigotes in L. donovani and showed that there are quantitative
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rather than qualitative differences between the stages. However, the 
amastigotes of L. m. mexicana do appear to differ considerably from 
promastigotes. The amastigotes, unlike promastigotes, utilise fatty 
acids in preference to glucose for their energy metabolism. There 
are also higher levels of enzymes responsible for the (3-oxidation 
of fatty acids in the amastigote than in the promastigote (Hart 
et al . t 1981b; Hart and Coombs, 1982). This may reflect differences 
in the respective environments of the different stages: the sand-fly 
gut may be rich in amino acids and/or carbohydrates whereas the 
lysosomes may have a plentiful supply of fatty acids.
1.1.3.2. Surface Membrane Biochemistry
The interest in leishmanial parasite membranes, especially their
external surfaces, stems from the potential role that these 
organelles play in allowing the parasite to evade macrophage 
digestive systems. Furthermore, knowledge of the nature and sources 
of leishmanial antigens and their processing by host
macrophages is essential to a complete understanding of the various
immune responses to infection. Finally, the development of 
techniques for the isolation of amastigotes stimulated an 
interest in the kinetics of various molecular exchanges which 
must occur between parasite and host cell through membranes 
maintained by both participants.
Pioneering studies on leishmanial membrane structure and
chemistry are reported in the papers of Dwyer and his associates 
on L. donovani (Dwyer, 1980; Dwyer and Gottlieb, 1983, 1984, 1985; 
Gottlieb and Dwyer, 1981a,b). L* donovani membranes contain about 
40 peptides which can be separated as distinct bands by 
electrophoresis (SDS-PAGE) and at least 24 glycoprotein/ 
glycopeptides. The extent to which these macromolecular components 
are involved in determining the clinical infection has yet to be 
determined, but Dwyer (1981) has reported several of them to be 
external, antigenic, and responsible for antigenic crossreactivity 
between L. donovani and L. tropicar L. braziliensis and Trypanosoma 
cruzi.
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Three phosphomonoesterase activities have been shown to be 
present on the external surface of promastigotes (Dwyer and 
Gottlieb, 1985). There is a non-specific acid phosphatase as well as 
distinct 5'- and 3'-nucleotidases (Gottlieb and Dwyer, 1981a, b). 
These enzymes were clearly external with their active sites 
directed into the extracellular environment (Gottlieb and Dwyer, 
1981a). Although exact functions of these enzymes are unknown, 
attractive hypotheses concern their potential role in purine uptake 
and an alteration of the phagolysosomal contents to enhance survival 
of the parasite. Equivalent 3'-nucleotidases are not found in 
mammalian cells and so may prove useful in diagnosis or as a target 
for chemotherapy.
An ATPase which is thought to be responsible for proton 
pumping, an adenylate cyclase which may be involved in the 
regulation of cyclic AMP levels and three phospholipases which have 
been implicated in the pathology of trypanosomatid infections, are 
also associated with surface membrane (Dwyer and Gottlieb, 1985).
A limited amount of information on the transport of exogenous 
materials across the parasite surface membrane reveals the active 
uptake of several nutrients, notably the amino acids methionine and 
proline (Simon and Mukkada, 1984; Law and Mukkada, 1979), hexose 
sugars (Zilberstein and Dwyer, 1985), alpha-aminoisobutyric acid 
(Lepley and Mukkada, 1983), purines and nucleosides (Hansen et al. r 
1982; Aronow ££. al., 1987).
The major cell surface glycoconjugate of leishmanial 
promastigotes is lipophosphoglycan (LPG) (King et. al., 1987).
Amastigotes were also reported (Schnur et. al., 1972) to express 
LPG, however, it is not clear which of the two forms of the parasite 
produces it more efficiently. LPG has a highly immunogenic nature 
and as an antigen is useful for serotyping Leishmania strains 
(Greenblatt et &1., 1983) and was found to protect mice against
cutaneous leishmaniasis (Handman and Mitchell, 1985), suggesting the 
possibility of a molecular defined Leishmania vaccine (see section
1.3.2.). Turco (1988) reviewed the current information about the 
activities and functions that have been demonstrated or suggested
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for LPG. Several are believed to involve attachment and entry of the 
parasite into the macrophage, while the others are thought to be 
crucial in enabling the parasite to survive within the 
phagolysosomal system (see section 1.1.4.).
The finding of a proteinase (gp63) on the surface of 
promastigotes and amastigotes has stimulated much interest in its 
biological function. Its role in parasite attachment and survival 
are discussed elsewhere.
1.1.3.3. Purine and Pyrimidine metabolism
Purine and pyrimidine nucleotides can be synthesised els. novo in 
mammalian cells from simple precursors (glycine, formate, CO2 , 
glutamine and aspartate). Alternatively, bases and nucleosides can 
be "salvaged" from exogenous sources or they may be the products of 
DNA and RNA breakdown within the cell. These can be converted to the 
appropriate nucleotides which are then used in the synthesis of DNA 
and RNA.
There have been extensive reviews recently on the purine 
and pyrimidine metabolism of parasitic protozoa (Hassan and Coombs, 
1987) and the leishmanias in particular (Marr and Berens, 1985). 
Like most parasitic protozoa, the leishmanias appear to be unable to 
synthesise the purine ring ds. novo and so rely on exogenous sources 
for DNA and RNA synthesis. However, they do appear to be able to 
synthesise d£ novo at least part of their pyrimidine requirements.
Leishmania purine metabolism has been investigated extensively 
and several differences from the mammalian system have been 
identified and offer opportunities for chemotherapeutic attack (see 
section 1.3.). Work on L. m. mexicana amastigotes and promastigotes 
has shown only quantitative differences between the stages in the 
enzymes involved in these pathways. However, this is not the case 
with L. donovani for which differences have been reported. Notably, 
promastigotes contain adenine aminohydrolase whereas amastigotes 
contain adenosine deaminase.
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1.1.3.4. Polyamines
The occurrence, metabolism and function of polyamines in 
trypanosomatids have captured the interest of a number of current 
investigators. These low molecular weight aliphatic compounds, 
include simple diamines such as putrescine and the common polyamines 
spermidine and spermine. Spermidine, spermine and their precursor 
putrescine, are ubiquitous components of mammalian cells. They 
appear to play important roles in cellular phenomena such as 
replication and differentiation. Studies with specific inhibitors of 
polyamine biosynthesis and with mutants unable to synthesise 
polyamines, have demonstrated that both differentiation and a normal 
rate of growth require polyamines. Polyamine content, especially of 
putrescine and spermidine, varies with the type of cell and its 
division state and its synthesis is closely controlled during the 
cell cycle and, in higher eukaryotes, is hormonally regulated (Tabor 
and Tabor, 1976; Janne et. al., 1978; Bacchi et. &1., 1979).
The metabolic pathways of polyamine synthesis are given by 
Bacchi (1981). The main routes of polyamine biosynthesis in animals 
and microorganisms originate from ornithine and methionine. 
Ornithine is decarboxylated by ornithine decarboxylase (ODC) to 
yield putrescine. Methionine is phosphorylated and combined with 
adenosine to form S-adenosyl-L-methionine (SAM). Decarboxylated 
SAM, generated through SAM decarboxylase, provides aminopropyl 
groups for spermidine and spermine synthesis. The latter are formed 
by the addition of one or two aminopropyl groups to putrescine 
catalysed by spermidine and spermine synthetase, respectively.
Polyamines have been detected in several species of 
trypanosomatids and they are formed by this same route (see
above). Initial studies on polyamine metabolism in T. &. brucei 
bloodstream forms revealed that putrescine and spermidine but not 
spermine were present (Bacchi ££. ., 1977) and that there was
sufficient ornithine decarboxylase (ODC) activity to account for 
dfi. novo synthesis of polyamines. S-adenosyl-L-methionine 
decarboxylase (SAM decarboxylase) was present as indicated by 
blockade by methylglyoxal bis (guanylhydrazone) (MGBG) of
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[ Jmethionine incorporation into spermidine in intact cells and 
of CO2 production from [^-^C]SAM in cell extracts (Bacchi a£. al. , 
1979; Bitonti et. al», 1986a) and by MGBG inhibition of cell growth 
(Chang a£. al., 1978).
Putrescine and spermidine have been detected in both amastigote 
and promastigote stage of Leishmania spp., however, reports 
regarding the presence of spermine are conflicting. Krassner and 
Morrow (1977) initially detected putrescine, spermidine and spermine 
in L. donovani amastigotes and recently transformed promastigotes; 
spermine was not found in established promastigote cultures. Schnur 
et al. (1979) found all three polyamines in serially cultured
promastigotes of L. tropica, and L. aethiopica. Bachrach at al. f 
(1979) identified these polyamines in promastigotes of several 
Leishmania spp.. Coombs and Sanderson (1985) observed high 
intracellular and extracellular putrescine levels in L. mexicana 
late log phase promastigotes and it was suggested that these may be 
responsible for the insensitivity of promastigotes of this species 
to a-difluoromethylornithine (DFMO) (Coombs at.ill., 1983). Polyamine 
levels have been found to be higher in promastigotes than 
amastigotes and the relative levels of each polyamine do vary with 
species and stage of Leishmania. During promastigote growth in 
culture, polyamine levels are highest in exponential phase.
The polyamine biosynthesis inhibitors have some potential as 
therapeutic agents against diseases, including cancer, that 
involve deranged cellular proliferation. However, their most 
promising use is for the treatment of diseases caused by parasitic 
protozoa. These organisms appear to be particularly sensitive to the 
interruption of polyamine synthesis, and the biochemical reasons for 
this sensitivity are under active investigation. Bacchi (1981) 
reviewed possible polyamine functions unique to trypanosomatids, and 
thus of potential interest as chemotherapeutic targets. One 
promising polyamine function is the activation of (X-glycerophosphate 
dehydrogenase, a key respiratory enzyme, by spermidine or spermine 
in bloodstream Trypanosoma brucei (Bacchi al al., 1979). The pathway 
involved has not been demonstrated in Leishmania. It also has been
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demonstrated that spermidine synthesis can be blocked in two ways, 
namely through inhibition of ornithine-putrescine conversion by DFMO 
(Bacchi £t jil•> 1980) or through inhibition of the methionine-
spermidine pathway by methylglyoxal bis guanylhydrazone (MGBG) 
(Chang ££. fll., 1978).
1.1.3.5. Proteinases
These degradative enzymes hydrolyse proteins into peptides and amino 
acids for nutritional purposes and are implicated in a number of 
cellular processes including post-translational modification of 
proteins, rapid turnover of cellular proteins which allows rapid 
adaptation to environmental changes and in the pathogenicity of 
various microorganisms (North, 1982).
Interest has been greatly stimulated recently by the findings 
that the major surface antigen of Leishmania. known as gp63, is a 
proteinase (Etges ££, > 1986). Two models for the binding of
infective promastigotes to macrophages propose that this enzyme is a 
key surface molecule of the parasite during the initial phases of 
infection (Bordier, 1987). The molecular weight of this proteinase 
has been variously reported as varying between 63 kDa (Etges et. al.. 
1986) and 68 kDa (Fong and Chang, 1981). Similar enzymes appear to 
be present in all species (Bouvier £t. fil•> 1987) and the proteinase 
has been shown to be apparently present in promastigotes and 
amastigotes of L. donovani r L. major and L. m. mexicana (Lockwood 
SL &1• t 1987). It has been recently shown that the proteinase is a 
zinc metalloproteinase (Bouvier ££. al• > 1987). Jahnig and Etges
(1988) determined the secondary structure of this surface proteinase 
and showed that it appears to be a novel kind of membrane-anchored 
proteinase.
The role of this proteinase has not been yet elucidated. It has 
been proposed that it plays a role in protecting the parasite from 
microbicidal enzymes in the sand-fly gut (Bordier, 1987). However 
the findings that it is more abundant on the surface of the virulent 
than avirulent promastigotes of L. m. amazonensis (Chaudhuri and 
Chang, 1987) and that it appears to be more abundant on the surface
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of the more infective stationary phase promastigotes than log phase 
promastigotes of L. braziliensis (Kweider gt al., 1987) argues that 
it may play a role in protecting the parasite in the macrophage.
It has been also recently shown that the enzyme 
incorporated into liposomes prevents breakdown of protein inside the 
vesicle by macrophages (Chaudhuri q 1., 1989). This strongly
supports the theory that the enzyme aids survival by protecting the 
parasites from microbicidal attack.
A species and stage specific cysteine proteinase was found 
localised in megasomes of amastigotes of L. mexicana and not in any 
other stage or either L. donovani or L. ma jor (Pupkis et. &1., 1986). 
More recently it has been shown that L. m. mexicana contains 
multiple cysteine proteinases that are of three types (Robertson and 
Coombs, 1990). The finding that cysteine proteinase inhibitors have 
antileishmanial activity against amastigotes of L. m. mexicana 
in vitro (Coombs and Baxter, 1984) shows the importance of these 
proteinases.
A large degree of developmental regulation of proteinases 
occurs in different species of Leishmania (Lockwood at al., 1987; 
North at SLI•> 1988) and it has been suggested that the synthesis of 
these proteinases may be a prerequisite for the successful 
transformation to the amastigote and survival in macrophages. The 
appearance of a proteinase in stationary phase promastigotes of 
L. donovani that is not present in the log phase organisms or the 
amastigotes is particularly interesting but as yet unexplained.
Other aspects on the biochemistry of Leishmania are dealt with 
in section 1.3.3..
1.1.4. LEISHMANIA AND THE MACROPHAGE
The interaction of Leishmania with its host cell, the macrophage, is 
one of the most interesting aspects of leishmaniasis. Macrophages 
are involved in several areas of the host's immune response to 
invading micro-organisms. These cells have a wide array of 
antimicrobial defences which include phagocytosis and the
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concomitant production of oxygen free radicals with subsequent 
exposure to the degradative enzymes of the lysosomal system. Thus, 
the cell types that are largely responsible for the killing of 
invading microorganisms are also the host cells for leishmaniasis. 
The parasite itself displays a number of highly elaborate strategies 
that enable evasion of the host’s defence system during all stages 
of the immune response. Basically, the evasion mechanisms can be 
attributed to three principles:
(1). evasion from cytotoxic serum components,
(2). strategies for survival within macrophages, and
(3). modulation of the T-cell immune response.
1.1.4.1. Entry of Leishmania into the macrophage
Immediately after transmission by the vector and before entry into 
macrophages, extracellular promastigotes are exposed to and escape 
from the cytotoxic environment of the serum. This serum resistance 
of infective promastigotes is not caused by their failure to bind 
and activate complement (Bogdan ££. ai., 1990), but rather appears to 
be linked to the expression of developmentally regulated surface 
antigens (da Silva al., 1989). It is also possible that the
saliva of the insect vector somehow contributes to the relative 
serum resistance of metacyclics, since salivary gland lysates
enhance their infectivity (Titus and Ribeiro, 1988). Preliminary 
experiments revealed species-specific differences between the serum 
resistance of metacyclics from various Leishmania isolates that do 
not, however, strictly correlate with the severity of the disease 
(Franke ££. ai., 1985). In contrast, amastigotes of L. donovani and 
L. mexicana. were shown to resist lysis by human serum despite
efficient complement component type 3 (C3) fixation and binding, 
whereas amastigotes of L. major were readily killed (Mosser €LtL al..
1985). It is assumed that the high serum sensitivity of amastigotes 
of L. maior may contribute to the limitation of the disease to the 
skin (oriental sore) as opposed to the visceralization seen in
L. donovani infections.
The two major surface glycoconjugates of Leishmania. gp63
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(Bordier, 1987) and the lipophosphoglycan (LPG) (Turco, 1988), 
mediate the uptake of different developmental stages of 
promastigotes (log phase and metacyclics), (on which the expression 
of the LPG is developmentally modified), by macrophages. They
function either directly or indirectly (via bound host proteins) as 
ligands for various macrophage receptors among which the complement 
receptors CR1 and CR3 appear to be the most important (Bordier, 
1987; da Silva e£. ai • , 1989). "Serum-independent binding of
Leishmania promastigotes to the CR3 receptor is mediated by a 
sequence containing arginine-glycine-aspartic acid (RGD) in gp63 or 
iC3b which are deposited on LPG or gp63 due to activation of
locally produced complement components" (Tait and Sacks, 1988). 
Synthetic peptides based on this sequence competitively inhibited 
the serum independent binding to CR3 of gp63 coated beads, 
C3b-coated erythrocytes and whole parasites (Russel, 1987). The 
binding of promastigotes was also reported to be inhibited by 
anti-fibronectin (Fn) antibodies (Quaissi, 1988) although it is now 
unclear whether this is because attachment is mediated via Fn, iC3b, 
or gp63, since all share cross-reactive RGD sequences and all these 
ligands are thought to be expressed or deposited on the surface of 
infecting promastigotes.
Serum-dependent binding is mediated primarily by C3b (which 
accounts for 80% of the C3 deposited on macrophage) deposition on 
LPG and binding to CR1 receptor (Puentes et. sJi., 1988). Secondary 
interactions might involve fibronectin receptor binding to
surface-bound plasma fibronectin (Wyler al., 1985), and
mannose-fucose receptor binding to mannose-containing 
oligosaccharides on LPG or gp63 (Blackwell gt & l,, 1985).
Despite a great number of studies on the receptor-ligand 
interactions, the results are somewhat conflicting since they are 
influenced by the species and growth phase of the parasite, the 
source of the macrophages investigated (human versus mouse) and the 
culture conditions (presence or absence of serum).
In the future a critical area of study will be to define 
receptors and ligands involved in infection by Leishmania
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amastigotes.
1.1.4.2. Strategies for survival of Leishmania within macrophages
1.1.4.2.1. Inhibition of the oxidative burst
Phagocytosis of Leishmania by macrophages involves specific 
receptors (Chang, 1981; Klempner ., 1983). These receptors
have been reported (Wright and Silverstein, 1983; Bryant et al..
1986) to differ in their capacity to elicit specific cellular 
responses, such as the triggering of the respiratory burst. Thus, 
the initial engagement of "appropriate" receptors, may play a 
critical role in determining the subsequent intracellular fate of 
the parasite. The development into metacyclic stage promastigotes 
is associated with the primary use of the CR1 and C3bi-binding site 
of CR3 that have been reported to be poor in triggering a 
respiratory burst and this may be critical for the subsequent 
survival of the parasite (da Silva ££. al., 1989).
The species and stage of Leishmania and source of macrophages 
also play an important role in the size of the oxidative burst 
stimulated (Bray and Alexander, 1987). Metacyclics stimulate a 
respiratory burst that is intermediate between amastigotes and 
non-infective promastigotes in magnitude (Mallinson and Coombs,
1989).
Leishmania also appear to be able to downregulate the 
oxygen-dependent killing mechanisms of macrophages. It has been 
shown (Remaley Qt al., 1984) that the surface acid phosphatase of 
L. donovani is capable of blocking the production of 02~ and H2O2 
by phagocytes. Interestingly, cellular and membrane activity of acid 
phosphatase of L. donovani correlates well with the virulence 
(Katakura and Kobayashi, 1988). Another potent inhibitor of the 
oxidative burst is LPG that interacts with the regulatory domain of 
protein kinase C, one of the key enzymes involved in the generation 
of oxidative metabolites (McNeely and Turco, 1987).
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1.1.4.2.2. Scavenging of oxidative metabolites
Avoidance of exposure to oxygen metabolites may be part of the 
survival mechanism. However, some cells that do stimulate a 
respiratory burst manage to survive. Leishmania are provided with a 
number of substances that serve to neutralise or eliminate oxidative 
metabolites.
Superoxide dismutase and possibly catalase are thought to play a 
role in the detoxification of these radicals by the parasite 
(Murray, 1981; Haidaris and Bonventre, 1982). The role of 
glutathione in free radical scavenging is well documented in 
prokaryotes and eukaryotes (Meister and Anderston, 1983) and 
recently differences between this and the equivalent in 
trypanosomatids, trypanothione, have been highlighted but the role 
of trypanbthione in the survival of Leishmania, is as yet unclear.
Recent experiments by Chan qX XL* > (1989), have illuminated
another important parasite-protective mechanism: the LPG of
Leishmania. which scavenges oxygen radicals and prevents the 
killing of the parasite by hydroxyl radicals.
1.1.4.2.3. Inactivation of lysosomal enzymes and maintenance of a pH 
homeostasis within the phagolysosome
Once phagocytosed the parasites are enclosed in the parasitophorous 
vacuoles and lysosomal fusion follows with the subsequent formation 
of the phagolysosome, thus exposing the parasite to the microbicidal 
mechanisms of the lysosomal system. A number of phagolysosomal 
factors such as acid pH, osmotic stress or lytic enzymes contribute 
to the antiparasitic activities of the macrophages. Leishmania have 
developed a variety of escape mechanisms against these. LPG clearly 
inhibits the lysosomal hydrolytic enzyme P~galactosidase (El-On, 
et al. r 1980) and erythrocytes coated with LPG are protected from 
lysis by the macrophage (Eilam gX al., 1985). In addition to having 
a direct inhibitory effect on lysosomal enzymes, it is possible that 
LPG may act as a cell surface barrier preventing lysosomal enzymes 
from attacking the parasite (Turco, 1988). The gp63 molecule may 
also have parasite-protective function in the phagolysosome. Its
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protease activity, with an optimum at pH 4, inactivates proteolytic 
host enzymes and thus may protect parasite proteins from 
phagolysosomal degradation (Chaudhuri gt. q I ., 1989). It has also
been suggested (Coombs and Pupkis, 1986) that in the amastigotes of 
some species of Leishmania and in particular of the L. mexicana 
complex, proteolysis involving a cysteine proteinase may result in 
changes in the lysosomal pH and hence lysosomal function, thereby 
being of especial importance to the parasites survival in 
macrophages. L. donovani amastigotes are highly adapted to the 
acidic medium inside the phagolysosome, without blocking its 
acidification, and at the same time they are able to maintain a 
neutral intracellular pH (Mukkada &1., 1985).
These biochemical processes may further explain the amazing 
capacity of amastigotes to survive and multiply within macrophages.
1.1.4.2.4. Modulation of the T-cell immune response
Macrophages are not only host cells for Leishmania and antiparasitic 
effector cells but they also present antigen in the context of MHC 
class II molecules to T-cells that, together with interleukin I 
(IL-1), leads to T-cell activation (Bogdan ££. &1., 1990).
Leishmania are able to modulate the T-cell immune response by 
inhibition of T-cell activation. Infection of murine macrophages 
with L. donovani has been shown to reduce both MHC class II 
expression and IL-1 secretion. In addition, L. donovani-infected 
macrophages are refractory to the activating potential of 
interferon-y (iFN-y) (Reiner £j: a_l., 1988). However, this is not 
the case for all Leishmania species (Ciliary et. al., 1989) and the 
molecular basis of these differential features is yet unknown. 
Leishmania are also able to modulate the T-cell immune response by 
induction of functionally distinct T-cell subsets in the host. The 
predominance of one or the other functionally distinct T-cell 
subsets and the respective lymphokines promotes either 
susceptibility (TH2~ceH s) or resistance (Tjji-cells) to infection, 
as shown with L. maior in mice (Moll and Mitchell, 1988).
Current studies are concentrated on this area of research and
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the results from these studies will have implications for the 
formulation of future vaccines and for immunobiology in general. 
From the known primary structure of the major surface glycoprotein 
(gp63) of L. mexicana. potential T-cell epitopes have been 
identified, synthesised and shown to be capable of stimulating the 
proliferation of mouse CD4+ Tjj cells. One peptide, PT3, specifically 
stimulates IL-2 secretion and Tjji cell subset proliferation (Jardim 
et al. r 1990). Vaccination with PT3 in the presence of adjuvant, 
partially protects mice from infection with either L. mexicana or 
L. major (Ash, 1990).
1.2. THE DISEASE IN HUMANS AND IN DOGS
The leishmaniases form a family of diseases which predominantly 
involve the parasitisation of the reticuloendothelial system by 
species of the genus Leishmania. The worldwide prevalence of the 
different human leishmaniases is unknown but thought to exceed 12 
million cases (WHO, 1989). An incidence of 400,000 new infections 
per year has previously been reported (WHO, 1982). The three basic 
types of leishmanial disease have a geographical distribution 
determined by the occurrence of the appropriate insect vector. 
Biological and biochemical criteria suggest that L. tropica. 
L. maior and L. aethiopica cause cutaneous leishmaniasis in the Old 
World, the L. mexicana and the L. braziliensis complexes cause 
cutaneous leishmaniasis and mucosal disease in the New World and 
the L. donovani complex causes visceral leishmaniasis. The 
leishmaniases can be broadly categorised epidemiologically as 
anthroponotic, with man as the only or main source of infection and 
transmission occurring mainly in settled communities, or zoonotic, 
with domestic animals (in settled communities) or wild mammals (in 
new urban developments, forestry areas, etc.) serving as the 
important source of infection. Clinically, several forms of 
infection are recognised in man, ranging from the single cutaneous 
ulcers caused by L. major to the hideously disfiguring and sometimes 
fatal mucocutaneous form in L. braziliensis infection, or to the
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visceral infection, kala-azar, associated with L. donovani. which 
entails a high mortality rate if it is not successfully treated.
Dogs are also severely affected by visceral leishmaniasis (VL) 
caused by parasites of the L. donovani complex. Their role as 
reservoirs or victims of other species of Leishmania is less clear 
since few canid isolates have been adequately identified and most of 
the information discussed here refers to Mediterranean kala-azar 
(VL) caused by parasites of the L. donovani complex and particularly 
L. infantum. The first dog infection by Leishmania was reported 
(Nicolle and Comte, 1908) in Tunisia. Since then evidence has 
accumulated showing the diffusion of the infection in the 
Mediterranean area and its close relationship with human visceral 
leishmaniasis. There seems to be no doubt nowadays that canine 
infections are the major reservoir of the disease. Cats may also be 
infected with Mediterranean leishmanias but reports of clinical 
cases are rare (Holzworth, 1987). Wild carnivores and rodents like 
the fox and the black rat, have been suspected or incriminated as 
wild reservoirs in a number of Mediterranean countries and these 
could constitute the primary reservoir from which the secondary, 
synanthropic, canine reservoir could have developed. Generally, 
canine leishmaniasis foci maintain a constant level over a long 
period and epidemic outbreaks have never been reported (Adler, 
1936). In Mediterranean foci, the frequency of infection in dogs has 
been reported to range between 3.7% (Bettini et. al., 1980) to 23.9% 
(Pozio at al •> 1981). The canine isolates in a number of
Mediterranean countries have shown an isoenzyme pattern identical 
to that of reference strains causing canine and human VL of this 
area and have been typed as L. infantum. The infection rate in dogs 
does not correlate with the incidence of the disease in man in the 
Mediterranean countries (Pozio aL a!• > 1981). In areas with a high 
infection rate among dogs the infection of human native inhabitants 
does not exceed 1-2% and includes mainly young children and babies 
(Levine, 1985; Molyneux and Ashford, 1983; Zuckerman and Lainson, 
1977). The positivity of the Leishmanin or Montenegro skin test 
that detects cell mediated immunity, confirms that transmission to
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man occurs as well. Since in some foci the vectors are known to be 
both zoophilic and anthropophilic it has been suggested that 
general resistance factors, such as nutrition or genetic resistance, 
could influence the course of the human disease. In a typical 
Mediterranean focus, patent cases represent 40-50% of the infected 
canine population, the remaining fraction being represented by 
latent pre-clinical forms (30-40%) or by resolutive cases (10-30%) 
(Lanotte &1., 1979; Pozio al•, 1981). Sand-flies get infected 
at significant rates only when fed on patent cases (Rioux gt al.. 
1972). However, preclinical cases are of great epidemiological 
importance, since they represent a latent reservoir which if left 
untreated, evolve towards infective cases in the course of 1 year or 
more (Adler and Theodor, 1932). It is difficult to estimate the 
prevalence of imported leishmaniasis in dogs in non-endemic 
countries. In the United Kingdom, where the import of pets is 
strictly controlled, at least 7 cases were recognised among 4000 
imported dogs, including animals imported from leishmania free 
countries (Longstaffe and Guy, 1986).
Proven or suspected vectors of L. infantum in man and dog in the 
Mediterranean area belong almost wholly to the genus Phlebotomus. 
subgenus Laroussius (WHO, 1984). Autochthonus leishmaniasis in 
sand-fly free areas has occurred sporadically in man (Longstaffe and 
Guy, 1986) and probably also in dogs (Zuckerman and Lainson, 1977). 
These infections may result from mechanical transmission, either 
direct from vertebrate to vertebrate or via insects. These modes of 
transmission seenuto be rare, but have been documented (Longstaffe 
and Guy, 1986).
Canine leishmaniasis is characterised by a visceral distribution 
of parasites followed by a massive localisation in the parasitised 
macrophages in the skin. Depending on host resistance, clinical 
signs become evident within a period of a month to many years 
(Kammermann-Luscher, 1980; Lanotte ££. &1., 1979).
Little is known about the pathogenesis of leishmaniasis in dogs. 
In man, the pathogenesis and clinical picture of the disease not 
only vary according to organotropism and other properties of the
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infecting Leishmania species, but also depend upon the immunological 
competence of the host (Bryceson, 1979; Heyneman, 1982; Molyneux 
and Ashford, 1983). Since Leishmania is an obligatory intracellular 
parasite, host defence strongly depends upon T-cell activity. 
Without the support of T-cells, macrophages are not able to kill the 
amastigote stage of the parasite (Maul, 1980). Abundant B-cell 
activity but complete absence of cell mediated immunity (CMI) to 
leishmanial antigens characterises one pole of the clinical spectrum 
of leishmaniasis in man (Bryceson, 1979; Heyneman, 1982; Molyneux 
and Ashford, 1983). This so called "anergic state", allows 
unrestricted multiplication and dissemination of the parasites, 
initially with little organ damage. At the other end of the 
spectrum, CMI increases and B-cell activity decreases. A CMI which 
is inadequate but responsive to numerous parasitic antigens results 
in destructive leishmanial ulcers. With more effective CMI, 
processes are more localised, contain less parasites and may even 
tend to self cure. At the ultimate end of the spectrum, B-cell 
activity is virtually absent but delayed hypersensitivity is 
pronounced. Non-ulcerating granulomatous nodules with hardly any 
parasites characterises what is called allergic state (Bryceson, 
1979; Heyneman, 1982). In some patients, medication seems to shift 
the immunopathologic state from the anergic to "allergic stage" 
without accomplishing definite cure. This may result in the 
development of so called post kala-azar dermal leismaniasis (PKADL) 
(Bryceson, 1979; Heyneman, 1982).
In dogs, leishmaniasis seems to develop mainly following the 
"anergic” model. Experimental infections with L. chagasi and 
L. donovani. caused rapid depletion of the T-cell regions and 
proliferation of B-cell regions in the lymphoid organs (Keenan et. 
ai.., 1984b). In naturally infected dogs, the parasites disseminate 
all over the body despite high levels of circulating antibodies. 
Ulcers are common but granulomatous nodules seem to be rare 
(Kammer mann-Luscher, 1980; Lanotte et al.. 1979).
An enormous production of immunoglobulins is observed 
(Kammer mann-Luscher, 1980) but rather harms than protects the
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patient. Specific antibodies may enhance phagocytosis by 
macrophages, however, and it is precisely the macrophage that seems 
to be essential for the survival of the parasite. The production of 
antibodies unrelated to parasitic antigens have also been reported 
(Molyneux and Ashford, 1983) and these are thought to include 
autoantibodies that may be associated with the development of 
pathologic phenomena (Mischer and Belehu, 1982).
A potential hazard of disturbed T-cell regulation and exuberant 
B-cell activity is the generation of large amounts of circulating 
immune complexes (CIC). The production of antigen-antibody complexes 
is probably quite common in infectious diseases, but symptoms rarely 
result from their presence (Drutz and Graybill, 1982). In some
circumstances, however, CIC deposition on the walls of blood vessels 
may cause vasculitis, polyarthritis or glomerulonephritis (Drutz and 
Graybill, 1982; Marcussen al., 1989). CIC may also bind
complement to blood cells and hence shorten their life span (Mischer 
and Belehu, 1982).
In visceral leishmaniasis in man, CIC can readily be 
demonstrated (Neva, 1985) and this has been connected with 
leucopenia, anaemia and thrombocytopenia in patients suffering from 
leishmaniasis (Mischer and Belehu, 1982). The kidneys of these 
patients may show pathologic changes secondary to CIC deposition 
(Neva, 1985), yet proteinuria and renal failure seem to be rare
(Bryceson, 1979). Probably CIC play a major role also in the
pathogenesis of canine visceral leishmaniasis and the renal failure 
and some other clinical manifestations of canine leishmaniasis, 
such as the bleeding tendency present in many leishmaniotic dogs, 
are CIC-induced. CIC may cause vasculitis and thrombocytopenia and, 
by way of renal failure, uraemia and hence platelet dysfunction. All 
of these impair haemostasis.
High concentrations of so called "cryoglobulins" may be present 
in the serum of patients with CIC. During cold weather these
proteins may precipitate in the blood vessels in the extremities of 
the body and cause local ischaemia and necrosis (Stites, 1982). In 
dogs, emaciation and cachexia may occur despite normal or even
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ravenous appetite. This has been ascribed to possible parasite-host 
competition for some essential nutrients. Tryptophan, an essential 
amino-acid, was significantly decreased in experimentally infected 
dogs (Keenan £t. al., 1984a).
Canine leishmaniasis has a variable and long incubation time and 
an insidious onset, and it is difficult to determine whether earlier 
anamnestic data are related to the disease. Most dog owners sought 
veterinary help because of a combination of problems such as 
listlessness, skin lesions, disturbed appetite, weight loss and 
chronic conjuctivitis or rhinitis. Skin problems are variable in 
character and extension but the most prominent feature is 
hyperkeratosis, presented as excessive scaling of the epidermis and 
thickening, depigmentation and chapping of the nozzle and the foot 
pads. The hair coat is dry and brittle with diffuse hair loss and 
appearance of ulcers is not uncommon (Figures 2a and 2b). 
Onychogryphosis(abnormally long curved nails) is considered very 
characteristic and present in the great majority of leishmaniotic 
dogs. The clinical course of the disease in dogs after a natural 
infection leads to death in 3-24 months if left untreated.
Canine leishmaniasis is diagnosed directly by microscopical 
observation of amastigotes in Giemsa-stained smears from lymph node 
aspirates. In case of negative results, inspection of stained bone 
marrow smears may still reveal parasites. If parasites cannot be 
detected by direct examination, the diagnosis may sometimes be
established with cultivation of biopsy material from bone
marrow or lymph nodes aspirates in specific media (Zuckerman and 
Lainson, 1977). Culture tests in Schneider's Drosophilla medium have 
been reported recently to be very successful in detecting parasites
(von Reiter, 1985). A wide range of serological tests such as the
indirect immunof luorescent test (IFT), can be used for the 
immunodiagnosis of leishmaniasis (Kammermann-Luscher, 1980;
Zuckerman and Lainson, ,1977). A positive reaction indicates that a 
dog has been infected but does not necessarily prove that the 
parasites are still present in the body. Once infected, however, 
over 90% of dogs will eventually develop clinical signs (Lanotte
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Fig.  2 a .  C a n i n e  l e i s h m a n i a s i s  in S e n e g a l :  N o t e  t he  u l c e r a t e d  l e f t  
p in na  (u), r e l a t i ve  o v e r g r o w t h  o f  nai ls  (n) a nd  f ac i a l  a nd  l o we r  l imb  
h y p e r k e r a t o s i s  (h).  In a d d i t i o n  t h e r e  w a s  g e n e r a l i s e d  l oss of  c o n d i t i o n  
a nd  p e r i o r b i t a l  a l o p e c i a .
( P h o t o g r a p h  c o u r t e s y  of  W H O ) .
Fig.  2b .  C a n i n e  l e i s h m a n i a s i s  in G r e e c e :  I. & II. I n i t i a l  s t a g e s  of  
u l c e r a t i o n ,  III. S e v e r e  u l c e r a t i o n  d e v e l o p e d  d ur in g a 4 w e e k  p e r i o d ,  
( P h o t o g r a p h  c o u r t e s y  of  V.  C o n t o s ) .
et al.. 1979). Hence a positive IFT in a clinically suspect dog is 
strong support for the preliminary diagnosis. Also, some of the 
initially seronegative animals may become seropositive after some 
weeks. The diagnosis of leishmaniasis can hardly be missed in dogs 
with characteristic features of the disease, provided one is 
familiar with the clinical picture. However, signs are often non 
specific and vague and may be confused with other skin diseases, 
myelo- and lympho-proliferative diseases and endocrine disorders. It 
is rather difficult to distinguish from canine systemic lupus 
erythematosus (SLE), since almost any sign present in leishmaniasis 
may also occur in SLE.
Treatment of leishmaniasis is at best difficult, usually 
involving toxic drugs based on heavy metals such as antimony. The 
lack of progress in development of better antileishmanial agents is 
illustrated by the fact that all the drugs in current use were 
introduced in the late 1940s. These are limited to four - sodium 
stibogluconate, meglumine antimoniate, pentamidine and amphotericin 
B. In general, response to antimonials varies according to the type 
of disease and various regimens are recommended in different 
geographical areas (Bryceson, 1979; WHO, 1984; Berman, 1988). 
Toxicity and variable activity attend the use of antimony in 
visceral leishmaniasis and many cases of muco-cutaneous 
leishmaniasis remain refractory to any therapy (Bryceson, 1979; 
Berman, 1988). The drugs used to treat human visceral leishmaniasis 
are poorly effective in the radical treatment of canine 
leishmaniasis. Antimonials, especially meglumine antimoniate 
(Glucantime^) are considered the most effective drugs for the 
treatment of canine leishmaniasis (Kammermann-Luscher, 1980; 
Lanotte sll.• > 1979; Longstaffe and Guy, 1986). Dosage regimens 
vary. Meglumine antimoniate (Glucantime^) is usually injected im or 
iv at a dose rate of 100 mg/kg body weight per day for 2 or 3 
courses of 10-14 days, each course separated by injection-free 
intervals of 10-14 days. Higher doses, up to 300 mg/kg every other 
day for 30-40 days as well as doses of 60-100 mg/kg daily for a 
course of 3 months have also been suggested (Euzeby, 1986). Dogs may
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become stiff and painful when Glucantime is injected deeply in 
the thigh and abscess formation or severe lameness due to muscle 
fibrosis may occur (Kammermann-Luscher, 1980; Longstaffe and Guy,
1986). Sodium stibogluconate (Pentostam^) is administered iv or im, 
in a course of 8 daily doses of 20-50 mg/kg which is repeated after 
a week's interval (Euzeby, 1986; von Reiter gt. a J L . , 1985).
Pentamidine (Lomidine^) is given at the dose level of 4 mg/kg with 
deep im injections, every other day and for a minimum of 15 
injections (Euzeby, 1986). Many dogs become free of signs within a 
few weeks especially if treatment is undertaken at early stages 
(subclinical cases), however, a high incidence of relapses has been 
reported (Euzeby, 1986; Giauffret Qt. q I ., 1976; Levine, 1973;
Longstaffe and Guy, 1986). As these drugs are hepato-nephrotoxic, in 
clinical cases with parenchymal lesions, in order to avoid any 
additional parenchymal damage due to drug toxicity, the treatment 
profile includes antimonials for a week, 1 week without treatment 
and diamidines for 1 week (Euzeby, 1986). It is generally accepted 
that treatment leads only to a prolongation of the life time in most 
cases, radical cures are not obtained, and destruction of the 
infected dogs is recommended as the only effective measure to 
control epidemics in man (WHO, 1984). However, in Mediterranean foci 
where seropositive prevalence rates of canine leishmaniasis of 
15-20% are common, the destruction of all serologically positive 
dogs is not possible. In a control study (Gradoni et. al.., 1988) in 
the isle of Elba, Italy, treatment with antimonials of prepatent 
cases and destruction of patent cases resulted in a two-third 
reduction of the disease frequency in dogs and it has been suggested 
(Gradoni ££. ai.., 1988) that wherever human VL, caused by L. infantum 
represents a serious health problem, continuous serological 
monitoring of the dog population followed by treatment and 
suppression activities should be integrated into those of the 
veterinary health services.
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1.3. THE LEISHMANIASES: CONTROL
Control of human leishmaniasis depends on the particular syndrome 
and epizootiological situation, and measures are directed towards 
the organism, the vector and the reservoir host. Opportunity and 
feasibility for control of each of these components, singly or 
together, varies in different parts of the world. Control must be 
adapted to local situations in each endemic area once baseline data 
of the various components are available.
1.3.1. Control of vectors and reservoir hosts
Although the weakest link is the relatively fragile vector, the 
extensive technology required for its control is frequently 
unavailable. At best, control is feasible with the mature stages 
with variability and inaccessibility of the breeding and resting 
sites making it difficult. Also, every sand-fly colony requires it's 
own specific control strategy (Molyneux and Ashford, 1983). Control 
of reservoir hosts such as rodents and dogs (see section 1.2.), 
usually involves eradication of all the potential reservoirs. This 
measure accompanied by insecticide spraying proved effective in a 
few cases, notably in the USSR (Molyneux and Ashford, 1983). To 
support field studies of leishmaniasis ecology and epidemiology, 
new methods have been developed in order to identify the mammalian 
species on which a sand-fly has fed within the past 24-48 hours and 
research is also continuing on sand-fly pheromones that may prove 
useful in traps for sampling or controlling vectors (WHO, 1989).
1.3.2. Vaccination
There is, as yet, no good antileishmanial vaccine generally 
available for most of the diseases. There is extensive immunological 
crossreactivity between different species but they do not generate 
crossprotection. The development of vaccines against leishmaniasis 
continues to be a research priority by the WHO Special Programme 
for Research and Training in Tropical Diseases (TDR), with several 
candidate preparations entering trials in nonhuman primates. The
39
candidate vaccines in these trials are:
* Killed whole parasite preparations with or without BCG
* Promastigote fractions of L. infantum shown to be protective 
in mice and able to immunise dogs in L. infantum endemic areas
* Purified promastigote surface protease (gp63) incorporated 
into liposomes (Russel and Alexander, 1988) and used with or without 
muramylpeptide as adjuvant
* Promastigote lipophosphoglycan (LPG) which has proved 
protective in mice (Handman and Mitchell, 1985).
At the laboratory level protective Leishmania-specific T-cell 
clones, capable of transferring resistance to highly sensitive 
normal animals, have also been developed (WHO, 1989).
1.3.3.1. Chemotherapy
Antimonial compounds have formed the basis for the treatment of 
leishmaniasis since 1911. The pentavalent antimonials, sodium 
stibogluconate (Pentostam^) and meglumine antimoniate (Glucantime^) 
are still the drugs recommended for initial systemic therapy 
(Marsden and Jones, 1985; Berman, 1988). These drugs are composed of 
pentavalent antimony complexed to carbohydrates, however, the 
precise structure of these complexes are as yet unknown (Berman,
1988).
Their mechanism of action has not yet been fully elucidated. A
recent work by Berman £t al., (1987) has shown that Pentostam
inhibits the glycolytic pathway and fatty acid oxidation in
L. mexicana amastigotes. It has been suggested (Berman and Grogl,
1988) that the specific binding of Pentostam to polypeptides
involved in the glycolytic and oxidative pathways may contribute to
the cytotoxic effects of the drug. It has also been suggested
(Berman and Grogl, 1988) that Pentostam may interact with the
parasite nucleic acids or with low molecular wp.ieht oarasite
type 1 DNA-topoisomerase 
components. Topoisomerisation of DNA catalysed by L. donovani was
specifically inhibited by the pentavalent antimonials sodium
stibogluconate and urea stibamine (Chakraborty and Majumber, 1988).
Antimonials are far from ideal drugs as several limitations are
associated with their use. They are not active orally and they 
require prolonged treatment. Also, they are not consistently 
effective, infrequent side effects such as cardiotoxicity and renal 
toxicity have been reported and they are excreted rapidly from the 
body. A 10 mgSbv /kg body weight dose given intramuscularly produces 
a 10 |ig/ml peak in the blood after 2 hours but over 80% of the 
antimony is excreted within 24 hours often leaving subtherapeutic 
plasma levels for much of the treatment (WHO, 1984). Recently the 
pharmacokinetics and toxicity of Pentostam have been reassessed 
(WHO, 1984) and this has shown that more frequent higher doses 
(10-20 mgSbv /kg three times daily), help to ensure higher 
therapeutic plasma concentrations of antimony and are better 
tolerated than was first thought. The implementation of these 
findings has considerably reduced the failure rates of treatment.
The recommended second line drugs, pentamidine (in the treatment 
of visceral leishmaniasis), mepacrine and amphotericin B (in the 
treatment of Latin American cutaneous leishmaniasis), are even less 
acceptable requiring long-term parenteral administration and their 
toxicity is more pronounced.
There is a wide variability in the susceptibility not only of 
different species but also different isolates of the same species, 
to antimonials. Visceral leishmaniasis is usually responsive to 
antimonial therapy with cure rates of 70-100%, however, relapses and 
diffuse cutaneous forms of the disease are often difficult to treat 
due to apparently defective immunity (Marsden and Jones, 1985). 
Also, pharmacokinetic properties may account for the different 
responses of parasites in different tissue locations or between 
different individuals or host species.
Little experimental work has been done on mechanisms of 
resistance in Leishmania species and to antiprotozoan drugs in 
general. Preliminary data indicate that drug resistance may be a 
problem in leishmaniasis. Berman q 1. (1982) have shown that
variable susceptibility to pentavalent antimonials in infected 
macrophages in vitro correlates with the patient's response to 
treatment.
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There is clearly a need for novel approaches to chemotherapy of 
these organisms. At present, there are at least two new promising 
areas in the liposome presentation of current antileismanial drugs 
and in novel chemical series (8-aminoquinoline and 
allopurinol-related compounds). However, it seems unlikely that 
effective new treatment will be available in the near future.
1.3.3.2. Biochemical strategies in search for new treatments 
As with several other parasites, research aimed in finding new drugs 
has, in recent years, been focussed on defining metabolic
differences between parasite and host that could represent good 
targets for chemotherapy. Unfortunately, relatively little is known 
about the biochemistry of the amastigotes of Leishmania and so only 
a few possible targets have been recognised. Rather more information 
is available on the promastigotes and this has been used to identify 
other possibilities. Leishmania species have several relatively
parasite-specific biochemical pathways that are related to the 
metabolism of glucose, purines, pyrimidines, lipids and polyamines 
and these are or may be the biochemical basis of action(s) of the 
major clinical agents. The ones more relevant to this study are
summarised here. Biochemical investigations have demonstrated 
several parasite specific features relevant to the mechanism of 
action of chemotherapeutic agents:
1. Glycolytic enzymes and some enzymes Of fatty acid catabolism 
occur in organelles (glycosomes) in Leishmania but not in mammalian 
cells. Berman §£ al. (1985) reported that antimony inhibited both 
amastigote catabolism of glucose via glycolytic enzymes and 
catabolism of fatty acids and suggested that the mechanism of action 
of antimony may relate to alteration of glycosomal structure or 
function.
2. Leishmanias are incapable of synthesising purines dg. novo.
Purine analogues can be utilised by the salvage pathways for purines 
in amastigotes in a greater extent than in mammalian cells and 
allopurinol and allopurinol ribonucleoside are metabolised into 
presumably toxic metabolites by these means. This has led to the
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discovery that several purine and purine nucleoside analogues, 
including allopurinol and formycin B, have potent antileishmanial 
activity (Nelson et. a l ,, 1979; Carson and Chang, 1981). Initial
trials using allopurinol against antimony-resistant cases of 
visceral leishmaniasis (Kager e£. al., 1981) showed some success. 
Clinical trials of the more active ribonucleoside analogues have 
also proved promising and are being followed up (Modabber, 1986). 
A multicenter trial of combined regimes of allopurinol and 
antimonials is being conducted in Colombia, Peru and Bolivia (WHO,
1989).
3. Amastigote sterol biosynthesis is akin to that of such fungi 
as Candida in that the major dimethylated sterol is of the ergostane 
series. The presence of fungus-like sterols as the primary 
leishmanial demethylated sterols provides a rationale for the 
antileishmanial activity of amphotericin B, ketoconazole and other 
antifungal agents that act on fungal sterols. As three orally active 
azoles (ketoconazole, itraconazole and fluconazole) are already 
licensed and a number of others are undergoing clinical evaluation, 
the potential use of azoles alone or in combination for the 
treatment of leishmaniasis should be investigated experimentally and 
clinically.
4. Some years ago interest in glutathione metabolism in 
trypanosomes was stimulated by observations that trypanosomes 
appeared to have a deficient capacity to withstand oxidative stress. 
This is due to the fact that in African trypanosomes, catalase and 
glutathione peroxidase are completely lacking or present only in 
trace amounts and these parasites appear to depend on reduced 
glutathione (GSH) to scavenge free radicals produced from hydrogen 
peroxide and superoxide anions (Meshnick et gX., 1978). Many of the 
known trypanocidal drugs are thought to exert their toxic effects by 
generating highly reactive forms of oxygen such as H2O2 , dioxygen 
anion and hydroxyl radical.
Glutathione is found in virtually all cells in millimolar 
quantities and is, involved directly or indirectly in many important 
biological roles, including protein and DNA synthesis, metabolism
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and protection of cells. African trypanosomes, however, are more 
susceptible to the effects of GSH depletion than the mammalian host 
cells, since administration of buthionine sulfoximine (BSO), an 
inhibitor of GSH synthesis, to mice infected with Trypanosoma brucei 
leads to prolonged survival times or cures (Arrick et. §X., 1981). In 
the presence of oxygen radicals and hydrogen peroxide, oxidised 
glutathione is formed. Oxidised glutathione (GS-SG) itself, can be 
toxic to cells by inducing disulfide exchange with key proteins and 
interfering with cellular metabolism and function (Meister and 
Anderson, 1983). Under normal conditions, oxidised glutathione does 
not accumulate in cells because it is reduced back to GSH by the 
NADPH-dependent enzyme, glutathione reductase (Williams, 1976). 
Thus this enzyme is of great importance in the maintenance of normal 
glutathione status within most cells and could present a potential 
target for the development of new drugs.
Recent studies (Fairlamb and Cerami, 1985) have shown that in 
trypanosomatids reduction of oxidised glutathione is unusual in 
that it is absolutely dependent on a low molecular weight co-factor 
which is a complex between GSH and the polyamine spermidine and 
contains an enzymatically reducible sulfhydryl group (or groups) 
which is essential for activity. This co-factor, initially isolated 
from the nonpathogenic haemoflagellate Crithidia fasciculata but 
also subsequently found in T. k. brucei. T. cruzi and Leishmania 
mexicana, was given the trivial name trypanothione and is unique to 
trypanosomatids.
In the light of these findings it is of great interest to 
determine to what extent trypanothione protects trypanosomatids from 
oxidative damage. If many of the existing trypanocidal drugs work by 
producing radicals or toxic metabolites, then a potent synergism 
might be predicted between these compounds and inhibitors of 
trypanothione metabolism.
An overall metabolic scheme for the biosynthesis of 
trypanothione [T(SH)2l and its possible functions is illustrated 
diagrammatically in Figure 3. Trypanothione is maintained 
exclusively in the reduced form T(SH)2, by means of the
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Fig. 3. Metabolism and functions of trypanothione, showing possible 
sites of action of trypanocidal compounds.
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NADPH-dependent enzyme, trypanothione reductase (reaction 6, Figure 
3). T(SH)2 reduces other disulphides, including glutathione (GS-SG) 
and cystine, by means of non-enzymatic thiol-disulphide exchange 
(reaction 5, Figure 3) (Fairlamb and Cerami, 1985). T(SH)2 also is 
the electron donor for removal of H2O2 and other peroxides catalysed 
by trypanothione peroxidase (reaction 4, Figure 3). T(SH)2, like
GSH, would also be expected to act as a free radical scavenger to 
remove oxygen radicals such as 0H“ (Henderson and Fairlamb, 1987). 
Figure 3 also shows points at which trypanocidal compounds are 
thought to act. With the exception of suramin, all the major 
classes of trypanocidal compounds are reported to have an inhibitory 
effect on this metabolic scheme. With the exception of DFMO, the 
target sites of these drugs are not known with certainty. It should 
be emphasised that some of these targets may not be the only ones 
with which these drugs interact.
It is difficult to see how DFMO could be synergistic with such 
disparate groups of compounds as arsenicals, nitroheterocyclics, 
diamidines and guanylhydrazones, and yet it had been shown to 
be so with African trypanosomes (Jennings, 1990). It is hypothesised 
that the polyamine-containing peptide dihydrotrypanothione, may 
provide a common biochemical link between polyamine metabolism, 
thiol metabolism and oxidative stress.
1.4. OBJECTIVES OF THIS PROJECT
The first successful treatment of chronic T. brucei CNS-infections 
in mice (Jennings, 1988b; 1991b) with a combination of DFMO and
sodium stibogluconate (Pentostam^) led us to the decision to 
utilise the information which is accumulating on the synergistic 
effects of compounds which affect trypanothione metabolism in 
trypanosomes and to see if they act similarly against Leishmania 
spp..
The main objectives of this project were to evaluate 
trypanocidal compounds including DFMO, nitroheterocyclics, 
guanylhydrazones, arsenicals and diamidines, both alone and in
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combination using a L. donovani mouse, model and L. donovani 
promastigotes and amastigotes in culture, and to use the knowledge 
gained from these studies and also from studies on trypanosomes, in 
order to gain a better understanding of the mode of action of these 
drugs and to attempt to develop new therapeutic combinations as 
potential antileishmanial agents.
There is a body of evidence on the biological activities of each 
of the compounds or groups chosen for study.
1.4.1. DL-ct-difluoromethylornithine, (DFMO), (Eflornithine^)
DL-CC-difluoromethylornithine (DFMO; Eflornithine^) is an enzyme 
activated irreversible inhibitor of ornithine decarboxylase (ODC), 
the first enzyme in the biosynthetic pathway of polyamine 
biosynthesis (reaction 9, Figure 3). Inhibition of this enzyme leads 
to a depletion of putrescine and spermidine and consequent cessation 
of macromolecular biosynthesis (Bacchi and McCan, 1987). 
Subsequent studies have shown that T(SH)2 is also significantly 
depleted following exposure of T. brucei to DFMO (Fairlamb et a l .,
1987). Reduction in T(SH)2 levels would therefore compromise the 
parasites ability to defend itself against oxidative stress by 
reducing the intracellular concentration of T(SH)2 as a radical 
scavenger and by decreasing the intracellular activity of 
trypanothione peroxidase.
DFMO was developed by the Merrell Dow Research Institute as a 
potential anticancer agent; the company had carried out all the 
necessary preclinical toxicology and development. Although the 
antineoplastic effects of DFMO alone have been disappointing, the 
therapeutic value in combination with other drugs remains a strong 
possibility. DFMO is highly effective treatment of both early and 
late stages of T. k. gambiense trypanosomiasis, with dramatic 
efficacy noted even in arsenical-refractory cases, but it is 
relatively ineffective to the rhodesiense type of disease. Studies 
began in 1979 with experimental murine infections and with isolated 
parasites, and these studies have demonstrated the possibility of 
synergy with bleomycin Clarkson ., 1983), suramin (Clarkson
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et al. . 1984) and 9-deazainosine (Bacchi et, al* > 1987). The first 
two combinations were reported (Jennings, 1990) to give 100% cures 
after the infected mice were kept under a 2h light/4h dark regimen 
which insured a more even uptake of the drug (Gillet et. & l., 1986). 
Additional studies (Jennings, 1988a; Jennings, 1988b) have shown 
that using a combination of DFMO/arsenicals (i.e. melarsoprol) in 
the late stage trypanosomiasis with CNS-involvement, can make it 
possible to reduce the dosage of the toxic arsenical drug and at the 
same time reduce the number of relapse infections.
The activity of DFMO against some Leishmania species has 
recently been shown in rodent models (Keithly and Fairlamb, 1988). 
Two percent DFMO in drinking water was active against L. donovani 
alone and showed synergy with bleomycin and an additive effect with 
sodium stibogluconate. The observation that DFMO alone also proved 
to be very effective against L. guvanensis is of great interest. 
Other probable potential uses of DFMO include treatment of 
cryptosporidiosis, malaria and hyperproliferative diseases (Bacchi 
and McCann, 1987).
1.4.2. Nitroheterocyclic compounds
Several nitroimidazoles are antiprotozoal compounds and have been 
used variously for the treatment of human trichomoniasis, 
giardiasis, amebiasis and Chagas' disease. Nifurtimox, nitrofurazone 
and MK 436 have been successfully used in experimental mouse 
infections with African trypanosomes.
The 2-substituted 5-nitroimidazoles (Cuckler e£. ., 1970;
Jennings ££. al., 1980; Jennings and Urquhart, 1983) and
5-substituted 2-nitroimidazoles (Richie and Hofheinz, 1983; 
Zweygarth and Rottcher, 1987a), were shown to have a trypanocidal 
activity against T. brucei spp..
Nitrocompounds are thought to exert their cidal action against 
trypanosomes by "futile redox-cycling" (Docampo and Moreno, 1984). 
They undergo 1-electron reduction in enzyme catalysed reactions 
involving NADPH or NADH as electron donor (reaction 1, Figure 3). 
The enzymes catalysing these reactions are not known. In the
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presence of dioxygen, the 1-electron reduced compound is reoxidised 
generating superoxide anion, (reaction 2, Figure 3). This is 
removed by means of superoxide dismutase (reaction 3, Figure 3), 
with the production of ^2^2* which is in turn removed by 
trypanothione peroxidase (reaction 4, Figure 3). If superoxide anion 
and H2O2 accumulate, then radical species (presumably hydroxyl 
radical) are formed according to the metal-catalysed Haber-Weiss 
reactions. The highly reactive hydroxyl radical (or another 
unidentified radical species) is then thought to react with 
essential membrane lipids or DNA, leading to death of the cell. If 
this mechanism operates in trypanosomes, then a synergistic effect 
between nitroheterocyclics and DFMO is to be expected.
A report indicated that the mammalian enzyme glutathione 
reductase is capable of reducing nitro compounds using NADPH as 
electron donor (Carlberg and Mannervik, 1986). Henderson al. 
(1988) also reported that trypanothione reductase can be induced to 
catalyse 1-electron reduction of functional groups including 
suitably substituted naphthoquinone and nitrofuran derivatives and 
nitroimidazoles.
1.4.3. Arsenicals
Until recently it has been generally accepted that aromatic 
arsenicals kill African trypanosomes by inhibition of the key 
glycolytic enzyme, pyruvate kinase (Flynn and Bowman, 1974). But as 
this conclusion is no longer acceptable, the mechanism by which 
melarsen oxide induces rapid lysis of trypanosomes, remains unclear.
Ehrlich was the first to recognise that trivalent arsenicals 
have an affinity for sulphydryl groups. Since that time, it has 
been demonstrated that trivalent arsenicals form considerably more 
stable complexes with dithiols rather than with simple monothiols 
(Fairlamb ££. & l., 1989). Dihydrotrypanothione would therefore seem 
to be an ideal candidate for interaction with arsenical drugs. Such 
counteraction may be involved in the selective toxicity of aromatic 
arsenicals against African sleeping sickness trypanosomes (Fairlamb 
et al., 1989).
48
1.4.4. Diamidines
Pentamidine is currently used in the treatment of primary stage 
Gambian trypanosomiasis, antimony-resistant leishmaniasis and 
Pneumonocvstis carinii pneumonia. The mechanism of action is unclear 
(Sands §£. &!., 1985). It may compete with polyamines for binding to 
nucleic acids and may also bind to kDNA (Meshnick and Cerami, 1984). 
More recently, the diamidines pentamidine and diminazene aceturate 
(Berenil^) have reported to inhibit S-adenosylmethionine 
decarboxylase in T. brucei (Bitonti £t al., 1986), (reaction 8,
Figure 3).
1.4.5. Guanylhydrazones
Guanylhydrazones also interfere with the polyamine biosynthesis 
at S-adenosyl-L-methionine decarboxylase (SAM-decarboxylase). 
SAM-decarboxylase was reported (Bacchi £t. &1., 1979; Bitonti ££. al.f 
1986a) to be present in T. h. brucei bloodstream forms, as indicated 
by blockade of [ -^C]methionine incorporation into spermidine in 
intact cells and by reversible inhibition of CO2 production from 
[ jadenosylmethionine in cell extracts by methylglyoxal-bis 
(guanylhydrazone) (MGBG), and by MGBG inhibition of cell growth 
(Chang ££. ., 1978).
MGBG has only been used in limited experimental testing (Chang 
et al.. 1978; Nathan gt. al., 1979) against relatively lethal
trypanosome infections where efficacy was assessed by a prolongation 
of survival time.
Of several aromatic guanylhydrazones found to have 
antitrypanosomal activity (Ulrich £t &1., 1982; Ulrich and Cerami, 
1984), one compound, 1,3,5-triacetylbenzene tris (guanylhydrazone) 
trihydrochloride i.e. [TBG], proved especially active against acute 
T. brucei infections in mice. TBG has also shown (Jennings 
SL al« y 1987; Jennings, 1988b) to be capable of curing T. brucei 
CNS-infections in mice if combined with DFMO and arsenicals.
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2. MATERIALS AND METHODS
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2.1. PARASITES: CULTIVATION AND MAINTENANCE
2.1.1. Amastigotes
Leishmania donovani (MHOM/ET/67/L82) amastigotes were maintained by- 
serial sub-passage in female Golden Syrian hamsters (Bantin and
Kingman Ltd., Grimsden, Hull, England). Amastigotes were released by 
gentle homogenisation of the spleen from an infected hamster, at
room temperature, between two pieces of stainless steel gauze, in 
approximately 50 ml of PSGEMKA (20 mM sodium phosphate buffer, pH
7.3, 104 mM NaCl, 10 mM MgCl, 10 mM KC1, 0.5 mM D-glucose, 1 mM 
ethylenediamintetraacetic acid [EDTA], 0.02% bovine serum albumin) 
until all but connective tissue was disrupted. The resulting 
suspension was then filtered through a No 1 Whatman filter paper to 
remove large debris and washed twice by centrifugation at 2500 x g
for 10 minutes and resuspension in PSGEMKA buffer at 4°C, before
being used to infect 4-10 week old hamsters by intraperitoneal 
inoculation of 2-4 x 10® amastigotes in 0.4 ml per animal. Infected 
animals were killed within 2-5 months, the spleen was excised and 
used as a source of amastigotes for experimental work or for 
transformation to promastigotes (section 2.1.2.). The condition of 
the hamsters was a good indicator of the progress of the infection: 
hamsters remained healthy until a few days before death. Hamsters 
were routinely used at the first signs of ill health to obtain the 
maximal yield of parasites.
2.1.2. Promastigotes
Promastigotes of L. donovani were obtained by the transformation 
in vitro of amastigotes obtained from an infected animal. A small 
piece of infected tissue was aseptically removed and placed in 5 ml 
of transformation medium: HOMEM medium (Berens al al., 1976)
supplemented with 20% (v/v) heat-inactivated foetal calf serum
(HIFCS) and antibacterials (25 |ig gentamycin sulphate/ml, 1 mg 
streptomycin sulphate/ml and 1000 units benzylpenicillin/ml). The 
infected tissue was then incubated at 25°C for 48-96 hours during 
which transformation and replication of promastigotes occurred. For 
some experimental work, in vitro transformation of amastigotes was
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used in order to assess the parasites viability.
Promastigotes were sub-passaged and cultured in HOMEM medium 
with 20% (v/v) HIFCS and 25 Jig gentamycin sulphate/ml at 25°C.
Cultures were normally initiated at a density of 1 x 10^ 
promastigotes/ml and sub-passaged upon reaching early to 
mid-logarithmic phase of growth (density of approximately 10^/ml).
2.2. HARVESTING PARASITES
2.2.1. Amastigotes
Amastigotes used for the infection of animals were isolated from the 
spleen of infected animals. This involved gentle homogenisation, at 
room temperature, between two pieces of stainless steel gauze in 
approximately 50 ml of PSGEMKA buffer as previously described (see 
section 2.1.2.).
Amastigotes used for the in vitro infection of peritoneal 
exudate cells (PECs), (see section 2.3.2.), were also obtained from 
the spleen of infected animals. The infected tissue was excised 
aseptically and placed in a sterile hand-held homogeniser with 10-15 
ml of RPMI 1640 supplemented with 10% (v/v) HIFCS (see section
2.3.1.) and antibiotics. The amastigotes were released by several
strokes of the homogeniser pestle and the residual large particulate 
matter removed by centrifugation (1000 x g for 5 minutes, at 4°C). 
The amastigotes remained in suspension free of large debris, they 
were then washed twice by centrifugation (2100 x g for 10 minutes, 
at 4°C) and kept at 4°C in cold RPMI medium before being used to 
infect the PECs.
2.3. MACROPHAGE-PARASITE INTERACTIONS IN VITRO
2.3.1. Macrophage maintenance
The medium used for macrophage culture was RPMI 1640, pH 7.2-7.3, 
supplemented with 10% (v/v) HIFCS, 50 Jig benzylpenicillin/ml, 50 Jig 
streptomycin sulphate/ml, 25 Jig gentamycin sulphate/ml, 2 mM
L-glutamine, 25 mM HEPES and 20 mM sodium hydrogen carbonate. The 
medium was adjusted to the appropriate pH using 1 M sodium
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hydroxide.
Mouse resident peritoneal exudate cells (PECs) were obtained 
from female Balb/c mice by peritoneal lavage using 5 ml of complete 
medium (RPMI 1640, with all the supplements) per mouse. The number 
of mice used in each experiment varied between 2 and 4, depending 
upon the number of PECs required. The lavages from the mice were 
pooled and diluted with complete medium to give a cell density of 
2.5 x 105 PECs/ml.
Eight-chamber Lab-Tek tissue culture slides were used for the 
maintenance of the PECs: 1 x 10^ PECs in 0.4 ml were plated into 
each chamber. The cells were allowed to adhere overnight by 
incubation at 37°C, with a gas phase of 95% air, 5% CO2 • 
Non-adherent cells were removed the next day by vigorous washing 
with complete medium and the adherent cells remaining were then 
used. These cells were mainly macrophages but other cell types were 
present and such preparations will be referred to as the PECs.
2.3.2. Infection of the PECs
In calculating the ratios of parasites to PECs for experiments, the 
initial number of PECs plated out was taken to be the number of PECs 
present after washing, despite the removal of non-adherent cells. 
PECs were infected by adding appropriate numbers of L. donovani 
amastigotes in the complete RPMI medium used for PEC culture. The 
number of parasites used for the infective period of 24 hours were 
at a ratio between 1 PEC: 2-3 amastigotes. At the end of the 
exposure period, the free parasites were removed by washing with 
RPMI medium and 0.4 ml of fresh RPMI medium was added to each well. 
The cells were incubated at 37°C and at the end of the experimental 
periods the PECs were air dried, fixed in absolute methanol and 
stained with Giemsa/May-Griinwald stain.
2.4. DETERMINING ANTILEISHMANIAL DRUG ACTIVITY
2.4.1. In vivo model
The activity of potential antileishmanial agents against L. donovani 
was determined using the visceral leishmaniasis model. In these
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studies, 2 x 10^ L. donovani amastigotes isolated from hamster 
spleens and resuspended in 0.2 ml PSGEMKA were inoculated 
intravenously, via the tail vein, into each female Balb/c mouse 
(Department of Zoology, University of Glasgow). The number of mice 
used in each experimental group was either 5 or 6. On day 14 
post-infection, the appropriate treatment regimen was started and 
four days after the last day of treatment, the animals were 
sacrificed, after being anaesthetised, by cervical dislocation. 
Impression smears of the first prominent lobe of the liver, and in 
some cases also from spleen, were made, air dried and fixed in 
methanol before being stained for 20 minutes in 10% Giemsa's stain. 
The number of amastigotes per 100 infected cell nuclei were counted 
in duplicate smears for each experimental animal. In a number of 
experiments, the parasite load in bone marrow was also determined. 
In these cases, the left femur of the sacrificed animal was 
separated from the rest of the body after being exposed and cut free 
at the hip and the femoro-tibial joints. The femur was scraped clean 
of muscle and ligament and severed near its ends, a 26 g needle on a 
1 ml heparinised syringe, containing 0.3 ml of 0.2% bovine serum 
albumin (BSA), was inserted through the cartilage at the knee joint 
of the femur and the plug of marrow was expelled into a plastic 
tube. The bone marrow cells were suspended using a Pasteur pipette 
and 2-3 drops of the bone marrow cell suspension were added to 
cuvettes of a cytocentrifuge (Cytospin 2, Shandon Southern Ltd., 
Runcorn, Cheshire). The cells were then spun on to a clean glass 
slide at 600 rpm for 5 minutes. Smears were allowed to air dry for 
10 minutes before being fixed in absolute alcohol and stained with 
50% May-Griinwald (pH 6.8) and 10% Giemsa (pH 6.8) for 10 minutes. 
The cell smears obtained tended to show an increasing cell density 
from the centre to the periphery of the smear. This, coupled with 
the fact that mast cells tend to aggregate, meant that care had to 
be taken to select representative areas of the smear in order to 
obtain more accurate parasite counts. 1000 cells were counted in 
each slide, moving from the periphery of the smear to the centre.
The results for each treated group were compared with the mean 
of the pooled results of an untreated control group, and were
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expressed as either a percentage of the mean of the controls or as 
percentage reduction compared to the controls, so allowing the 
degree of antileishmanial activity to be quantified.
Drugs diluted or suspended in distilled water were made up 
freshly at the appropriate concentration so that they could be 
injected intraperitoneally (ip) in a ratio of 0.05 ml/5g body 
weight. DFMO was given orally in the drinking water, starting on day 
5 after infection, usually for a period of 15 days. The mice were 
kept under a four hour dark and two hour light regimen, which 
ensured a more even intake of DFMO over each 24 hour period.
2.4.2. In vitro models
In vitro antileishmanial activity was determined by multipoint 
assays in which the drug concentration was reduced at two-fold 
intervals. The highest concentration tested for each drug was 100 
Hg/ml.
2.4.2.1. Promastigotes in vitro
The activity of a compound against promastigotes of L. donovani was 
assessed by monitoring its effect on promastigote growth. A 
promastigote suspension of 1 x 10^ cells/ml in HOMEM growth medium 
was dispensed into each well of a 96 well microtitre plate, in a 
volume of 180 Jll. Drugs were dissolved in water wherever
possible, but several were dissolved in dimethyl sulphoxide (DMSO). 
In such cases controls were carried out to ensure that the final
concentrations of this solvent had no effect on the parasites. Stock
solutions of the compound being tested were normally filter
sterilised (0.22 flm pore size filter) and diluted to give the 
necessary concentration so that the drugs were added as 20 |ll 
volumes in each well to give a final volume of 200 Jil, at the start 
of the experiment. In all cases 20 JLll of the growth medium was 
added to control cultures. The plate was placed into a sealed 
plastic box with moist tissue paper on the bottom to maintain a 
humid atmosphere and incubated at 25°C, with air as the gas phase. 
The cell density of each culture was measured on day 6 and in some 
experiments daily for a period of five days, using an Improved
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Neubauer Haemocytometer. The density and morphology of the parasites 
at various times during the experiments was observed by phase 
contrast microscopy of living parasites using a Leitz inverted 
microscope.
2.4.2.2. Amastigotes in vitro
In vitro investigations using PECs infected with L. donovani were 
carried out using standard conditions. Compounds under investigation 
were added during preparation of the standard medium. Drugs were 
dissolved in water wherever possible but several were dissolved in 
dimethyl sulphoxide (DMSO). In such cases controls were carried out 
to ensure that the final concentrations of this solvent had no 
effect on the parasites. Stock solutions of the compounds being 
tested were normally filter sterilised (0.22 Jim pore size filter) 
and diluted in medium to give the necessary concentration so that 
the drugs were added as 0.4 ml volumes 24 hours after the infection 
of macrophages with amastigotes. In all cases 0.4 ml of the growth 
medium was added to control cultures. 48 hours after the addition of 
the drug solutions, the medium was replenished and the incubation 
continued for up to a further 72 hours before the experiment 
terminated. Cells were then fixed and stained (section 1.2.2.) and 
the number of amastigotes per 100 infected cells and the percentage 
of the cells infected determined by microscopic observation. The 
results for treated cells were expressed as a % of the mean of the 
controls, allowing the degree of antileishmanial activity to be 
quantified.
2.5. STATISTICAL ANALYSIS OF DATA
Statistical analyses were carried out by using the computer programs 
"Animal Designs" (developed by Dr. G. Gettinby, Department of 
Statistics and Modelling Science, Strathclyde University), and 
"SPSS". One way and two way analysis of variance tests in 
conjunction with the Neuman Keuls procedure were used to analyse 
the significance of data. The F value, on which the significance is 
based, is given with the degrees of freedom in subscript. The
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probability (P) was taken as significant when P<0.05.
2.6. MATERIALS
The 5-nitroimidazole compounds, L611,744 [3cc,4,5,6,7,8,9,9cc-
octahydro-3-(l-methyl-5-nitroimidazol-2-yl)cycloocta(D)isoxazole],
MK 436 [ 3ot,4,5,6,7,70C-hexahydro~3-(l-methyl-5-nitro-lH-imidazole-2- 
yl)-l,2-benzisoxazole] and L634,549 [cis-3oc,4,5,6,7,7cc-hexahydro- 
3-(l-methyl-5-nitro-lH-imidazole-2-yl)-l,2-benzisoxazole-6,7-diol], 
a dihydroxy analogue of MK 436, were supplied by Merck Sharp & Dohme 
Research Laboratories (Rahway, N. Jersey, U.S.A.). Fexinidazole 
[l-methyl-2-(4-methyl-thiophenoxy-methyl)-5~nitroimidazole, HOE 239] 
and diminazene diaceturate (Berenil^), pure sample, were supplied 
by Hoechst, Frankfurt, West Germany. Metronidazole and dimetridazole 
were given by RMB Ltd., England, whereas satranidazole and 
Go 10,213 [l-methane-sulphonyl-3-(l-methyl-5-nitro-14-imidazole-2- 
yl)-2-imidazolidinone], were a gift from Ciba-Geigy, Switzerland.
The 2-nitromidazole compounds, Ro 15-0216 [2-(dimethylamino)~ 
CC-(l-methyl-2-nitroimidazole-5-yl)-p-acetanisidide], Ro 15-6547 
[OC-(l-methyl-2-nitroimidazol-5-yl)-l-pyrolidine-p-acetanisidide],
Ro 17-1051, (N-benzyl-2-nitro-l-imidazole acetamide; benznidazole) 
and Ro 16-5304, were given by Hoffmann-La Roche A.G., Switzerland.
Nitrofurazone (5-nitro-2-furaldehyde semicarbazone, 98%), was 
supplied by Aldrich Chemical Company, U.S.A..
Trimelarsan(^) (Mel W^, melarsonyl potassium) and Moranyl 
(suramin sodique) were obtained from Specia, France.
The guanylhydrazones TBG [1,3,5-triacetylbenzene tris 
(guanylhydrazone) trihydrochloride], DBG [1,3-diacetylbenzene bis 
(guanylhydrazone) 2.HCL], 5-decNH-DBG [5-decanoamido-3- 
diacetylbenzene bis (guanylhydrazone).2HCL], AMPA-DBG [1,3-diacetyl- 
5-(2-amino-4-methylpyrimidine-6-ylamino) benzene], 5-amino-DBG 
[5-amino-l,3-diacetylbenzene bis (guanylhydrazone).2HCL] and TBHG 
[(1,3,5-triacetylbenzene tris (N-hydroxy-guanylhydrazone) 
tritosylate], were supplied by Profs. Ulrich and Cerami of the 
Rockefeller University, New York, U.S.A.
DL-OC-difluoromethylornithine (DFMO, Eflornithine^), was supplied
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by Merrell Dow Pharmaceuticals, Inc., Ohio, U.S.A.
Sodium stibogluconate (Pentostam^), equivalent to 100 mg of 
pentavalent antimony/ml, was supplied by the Wellcome Foundation, 
Ltd., U.K..
Lomidine(^) injectable soln., equivalent to 6.259 g of 
pentamidine methanesulfonate/100 ml, was supplied by Rhone Merieux, 
Lyon, France.
The platinum [pt(Il)-DAP-SSHS, pt(H)-DAP-SDI ] and rhodium 
[Rh(lll)-Ethyl-Xanthate, Rh(lIl)BT] drug complexes were supplied by 
Dr. D.G. Craciunescu, University of Madrid, Spain.
The DNA intercalators (diminazene derivatives) BSU-1041, 
BSU-1021, BSU-1006, BSU-1002, BSU-1037, BSU-1030, were supplied by 
Dr. T.C. Jenkins, ICR, Sutton.
The 8-hydroxyquinoline compounds, compound 1 (mwt. 524.4), 
compound 2 (mwt. 492.4), compound 3 (mwt. 506.4) and compound 4 
(mwt. 519.3), were supplied by Dr. J.P. Dheyongera, University of 
the North, South Africa.
DL-buthionine-(S,R)-sulfoximine (BSO), No. B-2640, gentamycin 
sulphate, No. G-7632 and bovine serum albumin, No A-4503, were 
obtained from Sigma chemical company, St. Louis, Mo., USA. Other 
chemicals were obtained from BDH chemicals, Ltd., U.K.
The octyl degrol oil was supplied by Prof. N.B. Graham, 
Department of Pure and Applied Chemistry, Strathclyde University, 
Glasgow.
Benzylpenicillin sodium B.P., 600 mg, equivalent to 1,000,000
units, was obtained from Glaxo Laboratories Ltd., Greenford, 
England. Streptomycin sulphate B.P., equivalent to streptomycin base 
of 1 g, was obtained from Evans Medical Ltd., Greenford, England.
The principal components of the growth culture medium for 
Leishmania promastigotes, i.e. foetal calf serum, MEM Eagle 
suspension powder, MEM (50x) amino acids, MEM (50x) amino acids 
solution, RPMI 1640 were obtained from Gibco-Biocult, Scotland.
Lab-Teck 8-chamber tissue culture slides and Flow Pore D or 
single use 0.22 fim filter units, were obtained from Flow 
laboratories, England. Millex-GV non-pyrogenic, single use 0.22 Jim 
filter units, were obtained from millipore, France.
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3. RESULTS
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3.1. PARASITE ISOLATION, GROWTH AND VIABILITY
3.1.1. Isolation of amastigotes
The method for isolating L. donovani amastigotes used in this study 
was a modification of that developed by Hart et. (1981a). There
was an approximately 80% recovery of the amastigotes in the final 
preparation of purified amastigotes. The yield of amastigotes 
obtained was sufficient allowing infection of animals and mouse 
peritoneal exudate cells (PECs) in culture, similar to that reported 
previously (Hart et. &Y. 1981a) and with relatively little host cell 
contamination, although this in practice, was higher than that 
reported by Hart et. al. (1981a).
3.1.2. Growth of promastigotes
Promastigotes of L. donovani cultured in HOMEM medium had an average 
doubling time of approximately 10.5 hrs during the log phase of 
growth. On average, the maximum cell density reached, was 
2.4 x 10^/ml.
3.1.3. Growth of amastigotes
Amastigotes of L. donovani growing in mouse peritoneal exudate 
cells (PECs) in RPMI 1640 medium, reached an average cell 
density of 811 amastigotes/100 infected macrophages at the end of 
the experiment (day 5 after infection). Amastigotes of L. donovani 
growing in Balb/c mice, reached an average of 158 parasites/100 
host cell nuclei in liver, 39.3 parasites/100 host cell nuclei in 
spleen and 13.6 parasites/100 cell nuclei in bone marrow, 23 days 
after the infection.
3.1.4. Viability of parasites
Exclusion of the vital stain trypan blue was proved to be useful as 
a test for testing the viability of amastigotes before being 
used for infecting macrophages (PECs). No loss of amastigote 
viability was observed, as measured by this test and, in some
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experiments, by their ability to transform to promastigotes. 
Flagellum motility was also a useful indication for viable 
promastigotes.
3.2. TRYPANOTHIONE METABOLISM AS A CHEMOTHERAPEUTIC TARGET FOR 
LEISHMANIASIS: THE EFFECT OF COMPOUNDS THOUGHT TO INHIBIT
TRYPANOTHIONE METABOLISM IN VIVO AND IN VITRO
The main objective of this project was to evaluate compounds which 
are thought to affect trypanothione metabolism in trypanosomes 
against L. donovani and develop new therapeutic combinations as 
potential antileishmanial agents. In pursuing this, a number of 
trypanocidal compounds including arsenicals, 5-nitroimidazoles, 
2-nitroimidazoles, guanylhydrazones, DL-CC-difluoromethylornithine 
(DFMO) and diamidines, were tested jji vitro and jji vivo individually 
and in a series of combination experiments.
3.2.1. THE NITROIMIDAZOLES
3.2.1.1. The 5-Nitroimidazoles
Seven 5-nitroimidazole compounds; MK 436, fexinidazole (Hoe 239), 
L611,744, L634,549 (a dihydroxymetabolite of MK 436), metronidazole, 
dimetridazole and satranidazole (Go 10,213), were tested in vitro 
and in vivo using L. donovani promastigotes in culture (see section
2.4.2.) and L. donovani-infected Balb/c mice (see section 2.4.1.).
3.2.1.1.1. The 5-Nitroimidazoles in monotherapy experiments
3.2.1.1.1.(a) Effect of the 5-nitroimidazoles upon the growth of 
L. donovani promastigotes
The in vitro activities of the compounds tested are summarised in 
Table 3 and Figure 4. One way analysis of variance and then Neuman
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Table 3
The effect of the 5-nitroimidazoles, at various concentrations, against 
L. donovani promastigotes.
Drug conc. Percentage  red uction  com pared to con tro ls
|ug /  ml L611.744 MK 4 3 6 D im etrid azo le Go 10,213 M etro n id azo le
1 0 0 9 9 .7  i  0 .4 9 9 .5  1 0 .3 4 5 .5  1 7 .9 9 9 .8  1 0.1 - 9 .9  1 4 .6
50 9 8 .9  i  0 .1 9 9 .5  1 0 .3 1 5 .7  1 1 4 .1 9 9 .2  1 0 .4 - 6 .0  1 4 .9
25 9 4 .1  1 0 .2 9 9 .6  - 0 .4 2 .5  1 1 2 .7 9 6 .3  1 1.3 - 6 .6  1 2 .7
10 8 4 .2  1 0 .7 9 7 .6  1 2 .4 - 7 .6  1 1 5 .2 2 5 .6  1 3 .8 - 4 .7  i  2 .7
5 5 5 .1  1 6 .7 8 4 .6  1 8 .5 - 4 .0  1 3 2 .3 3 1 .5  1 3 .2 - 3 .5  1 0 .3
2 .5 3 5 .4  1 3 .9 8 3 .0  - 7 .8 - 1 .2  1 1 0 .8 7 .2  1 1 5 .7 - 1 .9  1 2 .6
1 .2 5 8.1 1 1 0 .7 4 0 .6  1 1.8 - 1 1 .0  1 1 1 .1 - 0 .5  1 0 .9 - 0 .3  1 0 .4
C ontro l 2 2 6 1 .0  1 2 4 1 .8 2 3 8 1 .0  1 6 0 2 .5 2 6 1 5 .0  1 3 5 3 .5 2 7 8 7 .5  1 4 5 .9 2 8 2 5 .0  1 2 4 7 .5
Drug conc. 
pg /  ml
Percentage  red uc tion  com pared to con tro ls
L 6 3 4 .5 4 9 Fex in idazo le  (H oe  2 3 9 )
1 00 1 00 1 00
50 100 9 9 .8  1 0 .2
25 9 9 .6  1 0 .4 9 7 .8  1 0 .6
10 9 8 .2  1 2 .5 9 7 .4  1 0 .4
5 9 7 .5  1 3 .5 8 7 .2  1 4 .9
2 .5 9 5 .4  1 5 .9 5 0 .9  1 1 1 .4
1 .2 5 8 8 .6  1 9 .8 2 3 .2  1 4 .1
0 .5 8 5 .6  1 7 .7 1 3 .3  1 8 .9
0 .2 5 4 4 .8  1 2 6 .7 6 .6  1 1 2 .3
0 .1 2 5 2 5 .5  1 6 .9 4 .4  1 0 .8
0 .0 8 1 2 .7  1 7 .6 3 .9  1 2 .7
0 .0 3 8 .3  1 1 1 .7 8 .6  1 7 .2
0 .0 1 8 3 .8  1 8 .6 3 .4  1 8.1
0 .0 0 8 - 2 .2  1 4 .2 0 .5  1 2 2 .9
C ontro l 2 5 2 0 ,0  1 4 5 8 .9 2 3 6 8 .0  1 3 2 8 .8
4
“ M ean num ber of paras ites  x 10 /m l ± SO
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Fig. 4. The effect of 5-nitroimidazoles against the promastigotes of 
L. donovani
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Keuls multiple range test were used for data analysis. Promastigotes 
were incubated at 25°C in the presence of each compound at
concentrations ranging from 1.25 |ig/ml to 100 Hg/ml, in complete
HOMEM medium (see section 2.4.2.I.). Five of these compounds showed 
marked antileishmanial activity against promastigotes; the best, 
judged on a weight to weight basis, was L634,549 and in descending 
order of efficacy MK 436, fexinidazole, L611,744 and Go 10,213. 
Metronidazole and dimetridazole showed no appreciable activity. The 
activity of fexinidazole was monitored also over the 5 day 
incubation period and these data are summarised in Table 4 and 
Figure 5. There was no detectable activity during the first 24 
hours of incubation but a marked growth inhibition was
observed in 48 hours, at concentrations of 10 Hg/ml and above
(F (7 f is) =37.7, P<0.05).
3.2.1.1.1.(b) Effect of the 5-nitroimidazoles against L. donovani in 
mice
Balb/c mice were infected with L. donovani (see sections 2.1.1.,
2.4.1.) and treated with L611,744 (12 consecutive daily doses), 
L634,549, fexinidazole and MK 436 (4 consecutive daily doses) at 
different dose levels. One way analysis of variance and the 
Neuman Keuls multiple range test were used to analyse the data. The 
treatment regimen and the percentage suppression in the liver 
parasite burden as compared with untreated controls, are shown in 
Table 5 and Figure 6 (for comparison, results using Pentostam are 
also shown). It can be seen that a 60-80% reduction can be achieved 
with all of them. The best result was with fexinidazole (Hoe 239) 
but the other nitroimidazoles were nearly as efficient. No 
statistically significant difference was observed between different 
dose levels tested when L634,549, MK 436 and fexinidazole were used.
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Table 4
The effect of the 5-nitroimidazole fexinidazole, at various concentrations
and time intervals, against L. donovani promastigotes.
Drug conc. Percentage reduction  com pared  to co n tro ls
pg /  ml DAY 1 DAY 2 DAY 3 DAY 4 DAY 5
1 00 3 5 .1  1 1 2 .3 8 5 .3  1 8 .9 9 6 .2  1 1.4 1 0 0 1 00
50 - 7 .0  - 1 2 .3 8 2 .8  1 6 .4 9 3 .9  1 0 9 6 .2  1 4 .6 1 00
25 - 3 .5  - 1 2 .3 7 1 .9  1 1.7 9 3 .2  1 2 .8 9 5 .6  1 3.1 9 7 .8  1 0 .6
10 - 1 0 .5  1 4 2 .1 6 8 .6  i  11 .4 9 0 .2  1 2 .3 9 6 .3  1 2 .3 9 7 .4  1 0 .4
5 - 2 1 .8  1 2 2 .4 5 0 .0  1 1 3 .9 8 7 .2  1 3.1 8 1 .3  1 2.5 8 7 .2  1 5 .0
2 .5 - 2 4 .8  - 7 .4 3 7 .1  1 6 .8 48 .1  1 1 1 .8 4 5 .8  1 1.2 5 0 .9  1 11 .4
1 .25 - 2 3 .9  1 4 0 .0 9 .0  1 1.7 -3 0 .1  1 1 2 .3 - 9 .3  1 4 3 .5 2 3 .2  1 4.1
C ontro l 6 1 .0  t 4 .2 1 6 7 .0  1 5 .7 4 5 7 .5  1 9 5 .4 9 1 7 .5  1 9 5 .4 1 2 0 0 .0  1 1 2 0 .0
M ean num ber of parasites  x 10 /m l 1 SD
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Fig. 5. The effect of the 5-nitroimidazole fexinidazole, at various
concentrations and time intervals, against L. donovani promastigotes.
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Table 5
The effect of the 5-nitroimidazoles L611,744, L.634,549, fexinidazole and 
MK 436, given individually and at different dose levels, against L. donovani 
in mice.
TR EA TM EN T REGIM EN
Infection —« 7 days —► | n | n | n | n | n | n |N n |n | n | n | n | —► [ k]
DO D8 D19 D23
NITROIMIDAZOLE DOSE GROUP SIZE % SUPPRESSION
0 (mg/kg)
100 6 8 8 .4 i 1 0 .2
L611.744 5 0 6 7 1 .7 + 1 3 .8
25 6 5 4 .8 * 1 4 .7
Infection 13 days —► |N | N n | n | —  [ k]
DO 014 D17 D21
2 0 0 6 7 6 .3 + 1 8 .7
100 6 5 9 .0 + 2 3 .3
L 6 3 4 .5 4 9 5 0 6 4 7 .8 + 2 0 .7
25 6 4 0 .8 + 2 9 .4
Infection —*• 13 days —«- | n | n n | n | —  0
DO D14 D17 D21
2 0 0 6 7 9 .5 + 1 6 .2
100 6 7 1 .7 + 1 0 .2
Fexin idazo le 5 0 6 6 1 .5 * 1 6 .3
25 6 5 4 .6 + 2 6 .7
Infection —► 13 days —♦  | n | n n | n | —  [k ]
DO 014 D17 D21
2 0 0 6 4 8 .4 4 2 0 .5
1 00 6 65.1 4 1 5 .8
MK 4 3 6 5 0 6 3 4 .5 4 3 3 .2
25 6 5 0 .7 4 2 9 .5
0  : 5 -n itro im id a zo le  [k]  : K ill
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Fig. 6. The effect of 5-nitroimidazoles given at various dose levels on 
L. donovani -  infected Balb/c mice.
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3.2.1.1.2. The 5-nitroimidazoles in combination experiments
3.2.1.1.2.(a) Effect of the 5-nitroimidazoles in combination with 
DFMO against L. donovani in mice
In combination experiments using DFMO, the DFMO was given as a 2% 
solution in the drinking water and mice were kept under a 4 hour 
dark, 2 hour light regimen that ensured a more even uptake of the 
drug. Infected mice were treated with the 5-nitroimidazoles 
fexinidazole, MK 436, L634,549 and L611,744 individually and in
combination with DFMO. The treatment regimen and the percentage 
suppression of liver parasite burdens are shown in Table 6 and 
Figure 7. Fexinidazole (F(7 f 1 5 ) =37.7, P<0.05), L634,549
F (4 f 5 9 ) =10.3, P<0.05) and L611,744 showed similar activities
whereas MK 436 was comparatively less active. Combination with DFMO 
produced only a marginal decrease in liver parasite burden which 
was statistically significant only when MK 436 was involved. 
Percentage decrease in parasite load using 5-nitroimidazoles 
monotherapy gave such high value that it is no wonder that DFMO 
addition did not show any potentiaton.
3.2.1.1.2.(b) The effect of L611,744 alone and in combination with 
DFMO and sodium stibogluconate (Pentostam^) against L. donovani in 
mice
This nitroimidazole was studied in a greater detail. Two experiments 
were carried out and the treatment regimen and the percentage 
suppression in liver parasite load are given in Tables 7 and 8 and 
Figures 8 and 9. In the first experiment (Table 7, Figure 8 ), 
L611,744 was given ip for 12 consecutive days as a monotherapy and 
also in combination with DFMO. The nitroimidazole alone at 100 mg/kg 
reduced the parasite burden by 88% of that in the controls. 
Combination treatment with DFMO only marginally increased the 
effect to 95.4% at the highest concentration used. DFMO alone 
reduced the liver parasite load by 50%. Thus, under these 
conditions, DFMO appeared to be neither synergistic nor additive.
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Table 6
The effect of 5-nitroimidazoles individually and in combination with DFMO 
against L. donovani in mice.
TR EA TM EN T REGIM EN
Infectlon(DO) —*■ 4 daya —*
_ ^ |d | d | d | d |d | d | d | d | d | d | d |d | d | d | d 1 -*■ 0
DRUG
DFMO
DIO D23
% S U P P R E S S IO N  
5 4 .4  ♦ 10 .6
Infection (DO) — *■ 14 daye 
—  | N | N | N | N | —  0
D16 D19
DRUG
Fexin idazo le  
MK 4 3 6  
L 6 3 4 , 5 4 9  
L611.744
D23
% SU PPRES SIO N
8 6 .5  ± 2 .9
7 6 .0  t 6 .3  
8 6 .7  1 5 .2
8 7 .1  ± 2 .9
Infection (DO) 4 daya
d [ d [ d | d | d | d | d | d [ d | d 0
D23
DRUG COM BINATION  
Fex in idazo le  * DFM O  
MK 4 3 6  «■ DFM O  
L 6 3 4 , 5 4 9  ♦ DFM O  
L611.744 + DFM O
Die
% S U P P R E S S IO N  
8 9 .3  1 5 .9
9 2 .0  j  3 .7  
8 6 .9  ? 3 .8
9 3 .1  f  3 .4
D FM O [ d ] : 2% soln. in the drin king  w ater. M ice  kept under 4 hours d a rk , 2 hours lig h t regim en. 
5 -n itro im id a zo le  0  : 2 0 0  m g/kg 0  : K ill
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Fig. 7. Effect of the 5-nitroimidazoles fexinidazole, MK 436, 
L634.549 and L611.744, alone and in combination with DFMO, on 
L. donovani -  infected Balb/c mice.
100 Percentage reduction in liver parasite load
A: D F M O  B: Fexinidazole C: Fexin idazole  + D F M O  D: MK 4 3 6  
E: MK 4 3 6  + D F M O  F: L 6 3 4 .5 4 9  G: L 6 3 4 .5 4 9  + D FM O  H: L611.744  
I: L611.744 + D F M O  DFM O : 2%  soln.in drink, water x 15 days (N): 4 x 2 0 0  mg/kg
Table 7
The effect of the 5-nitroimidazole L611.744 Individually and in combination
with DFMO, against L. donovani in mice.
TREATM ENT R EG IM EN  
Infection (DO) —► 4 day* —►
| d | d | d | d | d | d | d | d | p | d | d |d | d | d | d | —► [F]
D6 D18 D23
DFMO* GROUP SIZE % SUPPRESSION
2% soln. 6 4 8 .0  * 2 5 .0
Infection (DO) 4 daye
Infection (DO) — 4 daya —>
| t | L | L | L | L | L | L | L | L l L | L | L |  
D8 P I#
L611.744 GROUP SIZE
0
D23
100 ( m g/kg)
5 0
25
% SUPPRESSION
8 8 .4  + 1 0 .2
7 1 .7  t 13 .8
5 4 .8  I  1 4 .7
D6 D8 
1.611,744 ♦ DFMO
100 (m g/kg)
50
25
E
D23
GROUP SIZE 
6 
6 
6
D19
*  SUPPRESSION
9 5 .4  ± 6 .2
7 2 .6  i  1 5 .6
6 3 .6  t 9 .7
In the  d rin k ing  w ater. M ice kept under 4 hours d a rk , 2 hours lig h t reg im en, [ l]  : L611.744 0  : K ill
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Fig. 8. Effect of the 5-nitroimidazole L611,744, alone and in combination 
with DFMO, against L. donovani in Balb/c mice.
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Table 8
The effect of the 5-nitroimidazole L611,744 individually and in combination
with DFMO and Pentostam, against L. donovani in mice.
TREATM ENT R EG IM EN  
Infection (00)  —► 4 daye —►
| d | d | d | d |d [ d | d | d | p | p | p |d | o | d | —► [ k]
06 018 022
DRUG *  SUPPRESSION
* DFM O 2 % soln . 2 2 .7  t 2 5 .3
Infection (DO)
DRUG
L611.744
4 daye H M l I l I
014 017
0
D22
% SUPPRESSION 
6 9 .4  +  1 4 .0
Infection (DO) —► 4 daye
[d | d | p | d | p | d | d | d fp- 0
022D6 D14 D17
DRUG COMBINATION % SUPPRESSION
L611.744 ♦ D FM O 9 6 .7  + 6 .2
Infection (DO) 
DRUG
Pentostam
13 daye —► |p |p |p |p  | —*■ [ k]  
014 017 D22
% SUPPRESSION
- 6 .0  + 3 4 .0
Infection (DO) —► 4 daya
p P P P
|d |d |d |d |d |d |d |d |d D D D D Dl
D6 
DRUG
Pentostam  + DFM O
D14 D17 D22
% SUPPRESSION
2 4 .0  t 1 7 .3
Infection (DO) —► 13 daya
DRUG COMBINATION 
L611.744 + Pentostam
-  0
D22
% SUPPRESSION 
7 4 .0  ± 3 2 .6
Infection (DO) —► 4 daya
|d | d | d | p | d [ d | d | p  |~d' 0
D22D6 D14 D17
DRUG COMBINATION «  SUPPRESSION
L611.744 + D FM O  + 
Pentostam
8 8 .7  + 8 .0
In the  d rin king  w ater. M ice kept under 4 hours d a rk , 2 hours lig h t reg im en.
0  : L 611,744 (2 0 0  m g/kg) 0  : Pentostam  (5  m g/kg) [k]  : K ill. Group size: 6
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Fig. 9. The effect of DFMO alone and in various combinations with the 
5-nitroimidazole L611.744 and Pentostam, on L. donovani -  infected 
Balb/c mice.
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In the second experiment (Table 8 , Figure 9), L611,744 was used
in combination with Pentostam and DFMO. Surprisingly, in this 
experiment DFMO monotherapy showed no statistically significant 
effect on liver parasite load. In monotherapy using 4 consecutive 
daily doses of 200 mg/kg of L611,74^, a 69% reduction in parasite 
burden was achieved. This was substantially improved when the 
nitroimidazole was combined with DFMO therapy, increasing the 
percentage reduction in liver parasite burden to 96%. Combination 
of L611,744 with Pentostam and DFMO resulted to almost 89% reduction 
in parasite load. In no case the parasites were totally cleared.
3.2.1.1.2.(c) Effect of the 5-nitroimidazole L634,549, diminazene 
diaceturate (Berenil^) and melarsonyl potassium (Trimelarsan^), 
alone and in combination, against L. donovani in mice
The treatment regimen and the percentage suppression in liver 
parasite burden are detailed in Table 9. The results which are 
illustrated in Figure 10 showed only a relatively minor effect on 
liver parasite burden for both Berenil and Trimelarsan when they 
were used as monotherapy, giving between 40-50% reduction 
(F (9 , 113)=47.1, P<0.05). In combination with the 5-nitroimidazole 
L634,549, both compounds apparently produced a small additional 
effect over that produced by the nitroimidazole alone, however, this 
effect was not statistically significant. In no case were all the 
parasites cleared.
3.2.1.1.2.(d) The effect of the 5-nitroimidazoles MK 436, L634,549 
and fexinidazole and suramin, alone and in combination, against 
L. donovani in mice
The treatment regimen and percentage suppression of parasites 
in liver are shown in Table 10. The results which are also 
illustrated in Figure 11 showed that suramin had a only a minor 
effect when used alone. When used in combination with the 
5-nitroimidazoles, MK 436, L634,549 and fexinidazole its action
appeared to reduce the effect of the nitroimidazole used alone.
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Table 9
The effect of L634.549, Berenil and Trimelarsan, individually and in
combination, against L. donovani in mice.
TREATM ENT REGIM EN
D R U G / DOSE % S U P P R E S S IO N
COM BINATION (m g/kg)
Infection —► 13 days —►
N i ” , ” , 0
DO D14 D17 D21
GROUP S IZ E
L 6 3 4 .5 4 9  [n ] 2 0 0 6 8 3 .4  i  9 .3
Infection —► 13 daye —*• 1 B l B l B l — 0
DO D14 D17 D21
B eren il [b ] 4 0 6 5 1 .5  i  1 8 .2
Infection —► 13 days —*■ T T T T — 0
DO D14 D17 D21
Trim elarsan  [t ] 3 0 6 4 5 .0  i  1 6 .6
T T T T
Infection —► 13 daye ► N N N N —► 0
DO D14 . D17 D21
L 6 3 4 .5 4 9  * T rim elarsan 6 8 7 .8  i  8 .5
B B B B
Infection —► 13 days —♦ N N N N —*• 0
DO D14 D17 D21
L 6 3 4 .5 4 9  + B eren il 6 9 4 .7  i  3 .2
B B B B
T T T T
Infection —► 13 days —► N N N N —► 0
DO D14 D17 D21
L .634 ,549  + B eren il ♦ T rim elarsan 6 9 1 .2  i  6 .0
[k]  : K ill
7 1
Fig. 10. Effect of the 5-nitroimidazole L634.549, Trimelarsan and 
Berenil, individually and in combination, on L. donovani -  infected 
Balb/c mice.
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Table 10
The effect of MK 436, L634,549, fexinidazole and suramin, individually
and in combination, against L. donovani in m ice/
TREATM ENT R EG IM EN
Infactlon —► 13 daya —►
0  0  
D14 D21
DRUG %  SUPPRESSION
Suram in 3 3 .7  ♦ 3 2 .2
Infaction (DO) —*• 13 daya —►
Infactlon (DO) —► 13
[s"l
daya —►
—  In |n | n | n | —  | k | _  n n In In i -► nri
D14 D17 D21 D14 D17 D21
DRUG % SUPPRESSION DRUG COMBINATION % SUPPRESSION
L 6 3 4 .5 4 9 7 8 .8  i  7 .5 L 6 3 4 .5 4 9  ♦ Suram in 6 7 .9  t 1 7 .7
MK 4 3 6 6 1 .0  i  2 0 .9 MK 4 3 6  * Suram in 5 4 .3  i  1 5 .4
Fexin idazo le 8 0 .4  i  5 .0 Fex in idazo le  * Suram in 7 0 .6  i  9 .1
|~s~]: Suram in (2 0  m g/kg) [ n ] : 1 .6 3 4 ,54 9 , MK 4 3 6 , Fex in idazo le  (2 0 0  m g/kg) group size : 6
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Fig. 11. The effect of the 5-nitroimidazoles L634.549, MK 436 and 
fexinidazole, individually and in combination with suramin, against 
L. donovani -  infected Balb/c mice.
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However, two way and one way analysis of variance and the Neuman 
Keuls multiple range test showed that there was no significant 
difference in the results obtained and the addition of suramin did 
not increase the effect of the nitroimidazole monotherapy.
3.2.1.1.2.(e) The effect of the 5-nitroimidazole MK 436 given at 
various dose levels alone and in combination with verapamil, against 
L. donovani in mice
It has been reported that verapamil affects drug uptake and efflux 
in a multiple drug resistant carcinoma cell line, resulting in drug 
accumulation within the cells (Fojo et. al., 1985). In order to
examine if it is possible to increase the effectiveness of the 
nitroimidazoles by combination with verapamil, mice infected with 
L. donovani were treated ip with four consecutive daily doses of
the 5-nitroimidazole MK 436 at different dose rates, alone and in 
combination with verapamil. The treatment regimen and the percentage 
suppression in liver parasite burden are detailed in Table 11. The 
results, also illustrated in Figure 12, showed that there was no 
statistically significant difference between the groups treated with 
the nitroimidazole alone and the nitroimidazole/verapamil
combination, with the exception of one in which MK 436 was given at 
the dose level of 4 x 50 mg/kg when an increase in effect was 
observed (F (9 f n ) =36.3, P<0.05). The results suggest that verapamil 
does not significantly affect the concentration of the
nitroimidazole MK 436 in the parasite.
3.2.1.2. THE 2-NITROIMIDAZOLES
3.2.1.2.(a) The effect of the 2-nitroimidazoles against the
promastigotes of L. donovani
The 2-nitroimidazoles tested were Ro 15-0216, Ro 15-6547, Ro 16-5304 
and Ro 17-1051 (benznidazole). The results are shown in Table 12 and 
Figure 13 and are from two experiments carried out in duplicate.
The 2-nitroimidazoles Ro 15-0216, Ro 15-6547, Ro 16-5304 showed
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Table 11
The effect of the 5-nitroimidazole MK 436, given at various dose levels
alone and in combination with verapamil, against L. donovani in mice.
TREATM ENT R EG IM EN
Infection —► 13 daye -
—  |v|v|v|v| — - 0
DM D17 D21
DOSE
3 0  m g/kg
% SUPPRESSION 
1 2 .8  t 2 3 .1
Infection (DO) — +■ 13 daye • 
— *■ | M | M | M IM | — ► 0
D14 017 D21
DOSE MK 436
2 0 0  m g/kg  
100 m g/kg 
5 0  m g/kg  
25 m g/kg
% SUPPRESSION
8 1 .9  * 9 .8  
6 1 .8  i  1 1 .9  
3 6 .3  i 1 2 .2  
2 5 .5  ± 1 1 .4
Infection (DO) —♦  13 daye —*•
V V V V
M M M M
DM D17 
% SUPPRESSION
7 8 .1  *  6 .0
6 7 .5  t 9 .4
5 4 .5  i  1 0 .9
3 7 .1  t 1 7 .6
0
D21
MK 4 3 6  0 :  Verapam il 3 0  m g/kg g r o u p  s i z e  : 6
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Fig. 12. The effect of the 5-nitroimidazole MK 436  (MK), given at 
various dose levels alone and in combination with verapamil (V), 
on L. donovani -  infected Balb/c mice.
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Table 12
The effect of the 2-nitroimidazoles, at various concentrations, 
against L. donovani promastigotes.
Drug conc. Percentage red uction  com pared to c on tro ls
|jg  /  ml Ro 17-105 RO 1 6 -5 3 0 4 Ro 1 5 -0 2 1 6 RO 1 5 -6 5 4 7
1 00 4 0 .0  i  7 .9 1 0 0 1 00 1 00
5 0 7 .2  1 2 .6 1 0 0 1 0 0 1 00
25 4 .9  i  9 .6 1 00 1 0 0 1 00
10 - 6 .7  1 1 0 .9 9 9 .9  1 0 .2 9 9 .9  1 0.1 9 9 .9  1 3 .0
5 4 .7  ± 1.1 9 9 .7  1 0 .3 9 8 .8  1 0 .9 9 9 .5  1 0 .5
2 .5 - 7 .4  1 1.2 9 9 .8  1 0 .1 9 4 .1  1 4 .9 9 9 .4  1 0 .7
1 .2 5 3 .3  -  1 5 .5 9 3 .6  1 3 .4 6 1 .7  1 2 9 .1 8 9 .6  1 5 .1
C ontro l 2 9 0 2 .5  1 1 8 0 .3 2 3 8 1 .0  1 6 0 2 .5 2 8 5 0 .0  1 2 1 2 .1 1 9 7 3 .3  t 8 3 .1
Drug conc. 
|jg  /  ml
Percentage red uction  com pared to con tro ls
Ro 1 6 -5 3 0 4 RO 1 5 -0 2 1 6 RO 1 5 -6 5 4 7
0 .5 8 4 .9  1 0 .4 3 8 .6  1 6 .6 7 3 .5  1 7 .9
0 .2 5 6 6 .8  1 3 .0 2 3 .8  1 1 5 .8 7 1 .7  1 6 .4
0 .1 2 5 4 1 .9  i  0 .2 2 1 .7  1 1 6 .8 5 6 .4  1 1 3 .7
0 .0 6 1 9 .0  i  2 .3 1 7 .0  1 2 0 .8 3 4 .0  1 1 4 .6
0 .0 3 1 9 .6  1 0 .2 1 7 .7  1 1 2 .0 3 8 .2  1 5 .2
0 .0 1 6 8 .2  H 2 . 3 2 .7  1 1 2 .0 1 0 .5  1 6 .7
0 .0 0 8 2 5 .4  1 3 .9 1 2 .5  1 8 .3 2 2 .0  1 2 1 .5
Contro l 1 9 6 6 .0  1 1 1 4 .8 2 8 5 0 .0 1  2 1 2 .1 1 9 7 3 .3  1 8 3 .1
4
Mean num ber of paras ites  x 10 /m l ± SD
7 5
Fig. 13. The effect of 2-nitroimidazoles against the promastigotes of 
L. donovani
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interesting antileishmanial activity in vitro. giving up to 100% 
reduction in promastigote numbers, at concentrations 2.5 JJg/ml and 
above (P<0.05). Benznidazole showed some activity at 100 Jlg/ml, the 
highest level tested.
3.2.1.2.(b) In vivo activity of Ro 15-0216 in monotherapy 
Infected mice were treated intraperitoneally with the 
2-nitroimidazole Ro 15-0216 at different dose levels. The treatment 
regimen and the percentage suppression in liver parasite load are 
shown in Table 13. The nitroimidazole at the dose levels tested, 
produced between 40-76% reduction in liver parasite load, 
however, there was no significant difference between the varying 
dose levels used. The activity of Ro 15-0216 in L. donovani-infected 
Balb/c mice is also illustrated in Figure 6. It can be seen that its 
in vivo activity is less than the 5-nitro compounds.
3.2.1.2.(c) In vivo activity of Ro 15-0216 in combination with 
diminazene diaceturate (Berenil**) and melarsonyl potassium 
(Trimelarsan**, Mel W**)
In this experiment, in order to overcome the putative problem of its 
rapid metabolism, the 2-nitroimidazole Ro 15-0216 was administered 
in the drinking water at different dose levels and the mice were 
kept under a 4 hours dark and 2 hours light regimen that ensured a 
more even intake of the drug. The treatment regimen and the results 
of using this alone and in combination with Trimelarsan and Berenil 
are given in Table 14 and Figures 14 and 15. Combination of 
Ro 15-0216 with Trimelarsan (4 x 30 mg/kg) was apparently less 
effective than giving the nitroimidazole alone, although the 
differences observed were not statistically significant (Figure 
14). When Ro 15-0216 was combined with Berenil, (four daily doses 
of 40 mg/kg), a statistically significant difference was found only 
at the dose level of 20 mg Ro 15-0216/100 ml drinking water 
(F (2 ,9 7 )=7.3, P<0.05), although the combination effect being less 
than additive (Figure 15). In no case were the parasites totally
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Table 13
The effect of the 2-nitroimidazole Ro 15-0216, given individually and 
at different dose levels, against L. donovani in mice?
TREATM ENT R EG IM EN
Infection 13 daye —*• |R | R j R jR | —► [T]
DO D14 D17 021
DOSE % S U P P R E S S IO N
(m g/kg)
2 0 0 7 6 .3  i 1 8 .7
1 00 5 9 .0  ± 2 3 .3
5 0 4 7 .8  i  2 0 .7
25 4 0 .8  t 2 9 .4
0  : Ro 15-0216  [k]  K ill a Group size: 6 * in je c te d  ip .
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Table 14
The effect of the 2-nitroimidazole Ro 15-0216, individually and in combination
a
with Berenil and Trimelarsan, against L. donovani in mice.
TR EA TM EN T REGIM EN
Infection (00)  —► 4 daye —*
| r | r | r | r | r | r | r | r | r | r | r | —► 0
D5 D15 D19
Ro 15-0216 * % SU PPR ES SIO N
2 0  ( m g/100m l) 4 5 .9  + 16 .9
4 0  5 8 .6  ± 10 .7
8 0  6 2 .9  t  10 .9
Infection (DO)
D8
DRUG
011
4 deye
0
D19
% S U PPRES SIO N  
B eren il © 0.5 + 14.5
Trim elarsan  5 5 .9  1  11 .2
Infection (DO) 4 daye
DS D8 m i  
Ro 15-0 2 1 6  + B eren il
20  ( m g/100m l)
4 0
80
0
D19D16
% S U P P R E S S IO N
6 9 .3  + 8 .2
5 7 .6  t  1 3 .0
6 5 .0  t 1 2 .5
Ro 15-0 2 1 6  ♦ Trim elarsan  % S U P P R E S S IO N
20 ( m g/100m l) 
40  
80
3 2 .3  ± 1 8 .6  
5 5 .6  t 1 2 .8  
5 4 .2  1  8 .8
0  : B eren il, 40  m g/kg, 0  :Trim elarsan, 3 0  m g/kg, 0  : K ill
* a
In the drin king  w ater. M ice kept under 4 hours dark  2 hours lig h t reg im en. Group size 6
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Fig. 14. The effect of the 2-nitroimidazole Ro 15-0216 (Ro), given at 
various dose levels alone and in combination with Trimelarsan (W), 
on L. donovani-infected Balb/c mice.
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Fig.15. The effect of the 2-nitroimidazole Ro 15-021 (Ro), given at 
various dose levels alone and in combination with Berenil (B), on 
L. donovani -  infected Balb/c mice.
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cleared.
3.2.2. THE GUANYLHYDRAZONES
3.2.2.(a) The effect of guanylhydrazones against the
promastigotes of L. donovani
A number of guanylhydrazones supplied by Profs. Ulrich and Cerami of 
the Rockefeller University were tested in vitro and the results 
are summarised in Table 15 and Figure 16. Four of these, TBG, 
5-amino-DBG, 5-decNH- DBG and DBG, all showed good activity against 
promastigotes giving up to 100% reduction of promastigotes at 
concentrations 5 jig/ml and above whereas TBHG had no significant 
activity even at the highest level tested (100 Jig/ml).
TBG's activity was monitored every day over the 5 day 
incubation period and these results are also shown in Table 15. 
This guanylhydrazone inhibited the growth of L. donovani at 
concentrations of 25 Hg/ml and above during the first 24 hours of 
the incubation period and at relatively low concentrations 
(2.5-5 (ig/ml) over the following 4 days, giving up to 100% reduction 
(F (7 / is) =9.3, P<0.05).
3.2.2.(b) The guanylhydrazones in combination experiments
Two of the guanylhydrazones, TBG and DBG, which had given 
promising results against promastigotes in vitro and which were 
available in sufficient quantity, were also tested in vivof in 
combination with sodium stibogluconate (Pentostam^) and DFMO. 
The treatment regimen and the percentage suppression in liver 
parasite load are detailed in Table 16. The results, which are also 
illustrated in Figures 17 and 18, showed that TBG produced no 
effect on liver parasite load of L. donovani when used alone. It 
also had little effect when used in combination with Pentostam 
and/or DFMO (Table 16, Figure 17). The results for DBG (Table 16, 
Figure 18), showed that this guanylhydrazone has some activity 
producing a 33.9% reduction in parasite load (F(3 f 3 5 )=4.97, P<0.05)
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Table 15
The effect of guanylhydrazones, at various concentrations, against
L. donovani promastigotes.
Drug conc. P ercentage reduction  com pared to c on tro ls
|jg  /  ml DBG 5-d ecN H -D B G AMPA-DBG 5 -am in o -D B G TBHG
1 00 1 00 1 00 1 0 0 4 0 .9  i  9 .1 3 1 .4  ♦ 4 1 .8
5 0 1 00 1 00 1 0 0 2 0 .9  2 0 .8 6 .5  2 2 .5
25 1 0 0 9 9 .4  i  0 .9 9 9 .9  2 0 .0 2 1 7 .6  ♦ 6 .9 - 6 .2  + 2 3 .8
10 8 6 .7  2 1 7 .2 9 9 .5  2 0 .9 9 7 .8  2 0 .2 14.1  2 1 3 .5 -8 .1  2 2 2 .3
5 5 3 .4  2 44 .1 9 3 .3  2 7.8 9 7 .1  2 4 .0 9 .7  2 7 .9 - 9 .7  2 5 .4
2 .5 2 0 .4  - 1 5 .6 5 1 .0  + 5 .2 8 4 .6  ♦ 1 5 .2 1 3 .0  i  8 .6 - 2 6 .1  ♦ 4 0 .4
1 .2 5 1 3 .2  2 10 .7 2 8 .9  i  2 0 .2 1 9 .0  + 1 9 .8 7 .4  ♦ 1 .5 - 1 4 .4  + 2 7 .9
0 .5 1 1 .0  *  19 .7 1 5 .6  i  3 .2 1 3 .7  ♦ 12 .9 - -
0 .2 5 1 .3  ♦ 3 3 .2 - 1 .4  ♦ 10 .4 1 5 .8  1 1 7 .7 - -
0 .1 2 5 - 0 .9  ♦ 9 .1 0 .2  i  1 0 .7 0 .3  i  2 .8 - -
0 .0 8 - 6 .4  1 1 9 .6 - 1 1 .1  i  19.1 1 6 .7  ♦ 1 1 .7 - -
0 .0 3 7 .8  2 13 .5 - 1 1 .9  i  17.6 1 0 .0  2 0.1 - -
0 .0 1 8 - 7 .9  2 2 4 .6 - 1 4 .5  2 15 .7 10.0 2 7.8 - -
0 .0 0 8 6 .0  2 2 6 .5 - 6 .7  2 0 .51 2 5 .7  2 1 8 .8 - -
C ontro l 2 8 2 0 ,0  2 2 9 2 .7 2 4 4 7 .5  ♦ 7 4 .2 1 6 6 6 .0  *  2 1 0 .7 2 8 8 2 .5  i  4 7 0 .2 2 7 9 0 .0  1 3 4 6 .5
The effect of the guanylhydrazone TBG at different concentrations and 
time intervals against L. donovani promastigotes.
Drug conc. P ercentage reduction  com pared to co n tro ls
|jg  /  ml DAY 1 DAY 2 DAY 3 DAY 4 DAY 5
1 00 9 3 .0  2 0 .9 9 9 .3  2 0 .2 9 9 .7  2 0 .2 1 0 0 1 0 0
5 0 8 5 .8  2 5 .2 9 4 .9  2 0 .8 9 9 .9  2 0.1 9 9 .9  i  0 .1 1 0 0
25 7 4 .2  2 3 .4 9 5 .9  * 0 .2 9 8 .8  2 0 9 9 .9  + 0.1 9 9 .9  + 0 .1
10 5 0 .6  2 8 .3 8 6 .6  2 0 .4 9 8 .5  2 0 .5 9 9 .8  2 0 .3 9 9 .8  2 0 .6
5 1 6 .0  2 1 3 .7 7 9 .9  2 3 .7 9 7 .5  2 1.5 9 8 .1  2 0 .4 9 9 .2  2 0 .7
2 .5 6 .2  2 12 .4 6 2 .6  ♦ 2 .8 2 8 .9  + 14 .6 8 0 .9  + 1 1 .3 9 3 .0  1 1.8
1 .2 5 1 9 .3  2 2 7 .2 9 .7  * 3 .2 1 .8  *  5 .7 1 4 .2  1 5 1 .0 4 3 .8  + 3 .3
0 .5 - 5 8 .9  2 2 4 .6 5 .5  1 1 6 .4 2 4 .5  + 2 2 .3 - 1 5 .6  + 4 .6 1 .0  1 2 5 .0
C ontro l 4 3 .0  2 5 .7 1 8 4 .0  t 19.8 3 4 7 .5  + 1 0 2 .5 8 2 5 .0  ♦ 2 2 6 .0 1 3 1 7 .5 +  3 .3
4
M ean num ber of paras ites  x 10 /m l + SO
80
Fig.16. The effect of guanylhydrazones against the promastigotes of
L. donovani
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Table 16
The effect of TBG and DBG against L. donovani in mice, individually
and in combination with Pentostam and DFMO.
TR EA TM EN T REGIM EN
Infection (DO) —*• 4 daye —►
|d | p | d | p 1p | d | d | d | d | d | d | p | d | d | —► [k]
DRUG
DFM O
%  SUPPRESSION 
3 7 .1  i. 1 2 .0
Infection (DO) —*■ 14 daye — *■ Infection (DO) 14 daye —♦
P P P P
P P P P 0
D15 D18 D22
DRUG COMBINATION %  SUPPRESSION 
Pentostam  + TBG 4 6 .9  i  1 3 .7
Pentostam  + DBG 3 8 .9  i  1 5 .2
0
D22D15 D18
DRUG % SUPPRESSION
Pentostam  3 6 .1  i  12 .3
Infection (DO) 4 daye Infection (DO) 14 daye
1d 1d | d | d | d | d | d | d | d | d | d | p | d d] 0
D22
0
D22
DRUG COMBINATION 
Pentostam  * DFM O
% SUPPRESSION 
4 6 .9  i  10 .9
D16 D18
DRUG *  SUPPRESSION
TBG  
DBG
6 .0  i  16 .6  
3 3 .9  1 16 .9
Infection (DO) 4 daye
Infection (DO) 4 daye
|d | d | d | d | d | d | d | d | d | d D D D D
D6
DRUG COMBINATION 
D FM O + TBG  
DFM O * DBG
D16 D18
% SUPPRESSION 
2 9 .2  i  18 .4  
3 4 .1  i 19 .5
0
D22
|0 j P | P | P |P | P | P | P | D | D
D6 D18
-  0
D22D18
DRUG COMBINATION % SUPPRESSION
Pentostam  + D FM O ♦ TBG 5 0 .5  i 1 3 .0
Pentostam  * D FM O ■* DBG 5 5 .4  i  1 5 .0
□  TBG 10 m g/kg □  DBG 10 mg/kg
[ p]  Pentostam  5 m g/kg, 1000  hrs & 1500 hrs each day 0  K ill * G roup size 6 
0  D FM O 2% soln . in d rin king  w ater. M ice kept under 4 hours d a rk , 2 hours lig h t regim en
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Fig. 17. The effect of guanylhydrazone TBG alone and when used in
combination with DFMO and Pentostam, on L. donovani -  infected
Balb/c mice.
P ercen tage  reduction  in liver p aras ite  load
■ I  A: TBG M  B :P en to stam (P )! !H  C: D F M O  H I D: TBG + (P)
C D  E:DFMO + T B G C ]  F: D F M O  + (P) B l  G :DFM O + (TBG) + (P)
TBG  : 4 x 10 mg/kg Pentostam  : 4 x 5  mg/kg tw ic e  daily
D FM O  : 2%  soln. for 14 days
Fig.18. The effect of guanylhydrazone DBG alone and in combination
with Pentostam and DFMO, on L. donovani -  infected Balb/c mice.
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at the dose level used although in combination it did not produce 
any additional effect over that produced by the other drug(s) 
alone. These results are in contrast to the in vitro activities of 
the two guanylhydrazones: DBG cleared the parasites only at high 
concentrations (5-100 Jig/ml) whereas TBG was found to be active
against promastigotes of L. donovani at concentrations as low as
1.25 Hg/ml.
3.2.3. TESTING OF OTHER POTENTIAL INHIBITORS OF TRYPANOTHIONE
METABOLISM
3.2.3.1. DL-a-DIFLUOROMETHYLORNITHINE (DFMO) (EFLORNITHINEr )
3.2.3.1.(a) Effect of DFMO against L. donovani promastigotes and 
amastigotes in vitro
The results of in vitro studies on DFMO are shown in Tables 17 and 
18, Figures 19 and 20. Against promastigotes, at DFMO concentrations 
as low as 50 |ig/ml, growth was completely blocked (Table 17, Figure 
19) (F (7 f 3 i) =26.6, P<0.05). DFMO showed some activity upon growth 
of L. donovani amastigotes in PECs which, however, it was not
statistically significant (Table 18, Figure 20).
3.2.3.1.(b) Effect of DFMO against L. donovani in mice 
Particular attention has been given to DFMO's antileishmanial 
activity in vivo and its efficacy in clearing tissues other than the 
liver. This new antiproliferative drug is especially effective in 
the treatment of human African trypanosomiasis but it has not been 
tested extensively for antileishmanial activity. DFMO is known to be 
metabolised very quickly and so has to be administered frequently 
and in large quantity. It was tested at 2% and 4% in the drinking 
water and for different lengths of time (7, 14, 30 days) using the 
L. donovani-Balb/c mouse model, and the parasite load in the liver, 
spleen and bone marrow was assessed. The treatment regimen and 
the percentage of parasites as compared to the untreated controls
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Table 17
The effect of Trimelarsan, DFMO, Pentostam, buthionine sulfoximine
(BSO), nitrofurazone, Lomidine and Berenil, at different concentrations,
against L. donovani promastigotes.
Drug conc. Percentage red uction  com pared to contro ls
|ug /  ml T rim elarsan DFMO Pentostam BSO
1 00 6.1  1 8 .9 9 9 .4  i  0 .4 1 6 .2  1 5 .2 3 0 .5  1 3 .9
50 - 8 .2  1 1 2 .0 9 9 .1  1 0 .7 9 .2  1 2 .7 2 1 .2  1 4 .2
25 - 1 .8  1 1 2 .6 9 8 .8  ± 0 .6 6 .6  *1 4 .1 2 0 .8  1 9 .9
10 - 1 3 .7  1 16.1 9 5 .9  i  3 .9 9 .0  1 1 2 .3 2 7 .2  1 4 .5
5 - 1 2 .5  ± 7 .2 6 7 .6  1 36 .1 2 .5  1 3 .1 11.8  1 4 .3
2 .5 - 4 .0  i  1 3 .5 3 8 .5  1 4 0 .9 0 .3  * 1 4 .6 1 2.6  1 3 .1
1 .2 5 - 1 3 .9  - 16 .7 1 3 .5  t 1.6 - 0 .3  1 1 0 .3 7 .0  1 4 .2
C ontro l 1 8 0 5 .0  i  1 8 3 .8 2 1 6 5 .5  1 2 7 2 .2 2 0 7 1 .5  1 1 6 3 .5 2 6 3 1 .2  i  2 2 7 .6
Drug conc. P ercentage reduction  com pared to con tro ls
jug /  ml B erenil Lom idine n itro fu razo ne
1 0 0 1 00 100 100
5 0 100 100 100
25 9 9 .7  1 0.1 100 100
10 9 8 .5  1 0 .8 1 00 100
5 9 7 .0  t 1.1 100 9 9 .9  1 0.1
2 .5 9 8 .1  i  0 .6 100 9 9 .9  1 0.1
1 .2 5 8 7 .9  - 2 .9 1 00 9 9 .9  1 0.1
0 .5 5 3 .9  1 10 .8 1 0 0 5 8 .1  ± 16.1
0 .2 5 11.5  1 0 .6 1 00 3 6 .1  i  4 2 .1
0 .1 2 5 8 .7  1 1.2 9 9 .7  1 0 .2 4 5 .5  1 1 0 .2
0 .0 8 3 .1  1 3 .5 5 0 .3  1 1 0 .4 3 6 .7  1 1 8 .6
0 .0 3 0 .5  i  2 .4 1 8 .9  ± 2 7 .4 3 3 .9  i 4 .8
0 .0 1 8 - 9 .7  i  4 .1 1 0 .2  ± 1 5 .2 1 8 .7  1 27 .1
0 .0 0 8 0.1  i  9 .2 4 .5  i  4 .6 7 .8  ± 2 6 .0
C ontro l 2 6 2 7 ,5  i  2 2 2 .7 2 8 6 3 .8  1 2 8 0 .7 1 9 8 5 .0  1 2 6 9 .6
4
M ean num ber of parasites  x 10 /m l + SD
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Fig.19. The effect of Berenil, Trimelarsan, DFMO, Pentostam, Lomidine 
buthionine sulfoximine (BSO) and nitrofurazone, against promastigotes 
of L. donovani
120
P ercen tag e  reduction
100
80
60
40
20
0
-20
0.01 0.03 1.25 2.5 5 10 50 100 pg/ml
Berenil “4— Trimelarsan D F M O  ~s ~ Pentostam
Lomidine BSO N itro furazone
Table 18
The effect of DFMO, fexinidazole, Pentostam, Berenil, Trimelarsan and
BSO, individually at various concentrations against L. donovani in PECs.
I. Number of cells infected
Drug conc. N um ber of c e lls  in fec ted as p ercen tag e  of contro ls
jug /  ml Pentostam DFMO Fexin idazole B eren il T rim elarsan BSO
1 00 4 .3  1 0 .7 9 2 .6  i  13.6 . . .
5 0 5 .4  i  5 .7 9 9 .4  1 6 .6 * 6 7 .6  i 1 2 .8 •
25 1 0 .3  i  7 .3 1 1 0 .2  1 7 .4 1 0 3 .5  1 1 4 .6 9 8 .1  ± 5 .5 1 1 5 .6  i 3 .9
10 8 .6  i  1 .2 1 02 .1  ;  9 .0 1 0 2 .6  - 6 .4 9 1 .0  i  6 .3 1 1 9 .4  - 9 .0
5 3 4 .7  i  10 .9 1 1 1 .2  i 4 .3 1 0 0 .9  ± 2 .6 5 2 .1  ± 1 1 .8 9 1 .6  i  8 .6 1 0 7 .7  1 7 .2
2 .5 5 0 .2  i  16 .9 1 1 2 .5  ± 4 .8 1 0 0 .6  i  4 .7 7 0 .6  - 1 3 .4 9 5 .5  S 9 .4 9 7 .6  i 9 .9
1 .2 5 9 3 .9  1 6 .2 1 0 1 .6  1 1 2 .1 9 9 .4  1 9 .9 8 2 .7  i  9 .8 9 1 .5  1 7.9 1 0 9 .2  1 6 .2
C ontro l 8 1 .1  i  5 .0 8 5 .1  i  3 .9 8 7 .8  t 8 .6 7 6 .9  1 8 .4 8 5 .8  1 7.8 7 6 .3  ± 7 .1
II. Number of amastigotes per 100 infected cells
Drug conc. Num ber of am astigotes /  100 in fec te d  c e lls , as % of contro ls
pg /  ml Pentostam DFMO Fexin idazole B eren il T rim elarsan BSO
1 00 1 5 .3  1 8 .8 6 9 .1  ± 4 .6 . . .
5 0 1 7 .5  1 6.1 7 3 .0  1 16 .7 * * 4 9 .1  t 7 .0 *
25 2 0 .4  1 4 .6 7 9 .9  1 3 .2 5 7 .7  1 4 .6 * 8 2 .4  i  13.1 8 1 .4  i  10.1
10 2 6 .4  1 2 6 .4 8 1 .5  1 1 0 .4 6 2 .0  t 7 .2 * 8 9 .2  t 9 .5 1 0 1 .8  1 1.0
5 4 3 .8  1 5 .3 7 8 .7  i  9 .9 7 4 .2  ± 8 .9 3 2 .9  i  9 .5 8 3 .9  -  1 5 .2 9 9 .7  t 7.6
2 .5 3 7 .1  i 6 .9 8 0 .7  i  8 .0 9 6 .7  1 6 .6 4 5 .3  ± 9 .0 8 5 .2  ± 9.1 7 5 .5  i 1 6 .9
1 .25 7 0 .2  1 6.1 8 6 .4  1 1 5 .5 7 7 .7  1 8 .6 6 4 .8  i  1 2 .8 8 3 .3  1 1 0 .8 1 0 4 .5  1 5 .4
C ontro l 9 8 3 .9  i 2 7 1 .0 8 1 3 .2  i  3 0 .2 7 0 5 .3  i 4 2 .8 9 7 7 .4  i 2 0 5 .0 8 7 3 .0  i  1 2 5 .6 6 5 2 .6  1 1 1 6 .6
Drug co n c e n tra tio n  tox ic  to m acrophages M ean num ber of paras ites  - SD
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are summarised in Table 19. The data are also illustrated in Figure 
21. The effect of DFMO on liver, spleen and bone marrow parasite 
load observed at the end of the administration period (DAI 20), was 
similar to that observed 4 days later (DAI 23). DFMO was found to 
have good activity against the liver parasites (F(3 ,8 6 )= 
76.8, P<0.05), although they were not all eliminated even after
prolonged drug treatment. The effect of DFMO administration was less 
profound on spleen parasite load (F(3 f qq )=3.9, P<0.05) and a small 
effect was observed on DAI 39 on bone marrow parasite load 
(F (3 f 7 7 ) =10.9, P<0.05). Administration of the 4% solution of DFMO 
was more beneficial than the 2% solution, in reducing the parasite 
load of spleen (F (1 ,8 8 ) =23.7, P<0.05) but not of liver and bone 
marrow.
3.2.3.2. DIAMIDINES
3.2.3.2.1. Diminazene diaceturate (Berenil**)
3.2.3.2.1.(a) Effect of Berenil(**) against L. donovani 
promastigotes and amastigotes in vitro
The effect of Berenil, an inhibitor of S-adenosyl-L-methionine 
decarboxylase (Bitonti gJL aJL., 1986), upon growth of L. donovani
in vitro. is shown in Tables 17 and 18, Figures 19 and 20. Against 
promastigotes (Table 17, Figure 19), growth was completely blocked 
at concentrations of 2.5 |ig/ml and above (F (7 f 1 5 )=243.9, P<0.05).
Against amastigotes infecting mouse PECs (Table 18, Figure 20), the
inhibition was also marked but without giving a total clearance of 
the parasites and it was associated with toxicity to macrophages. 
At concentrations of 10 Hg/ml and above, macrophages themselves
were all killed (F (4 f 1 3 )=19.4, P<0.05).
3.2.3.2.1.(b) Effect of Berenil(**) against L. donovani in mice 
Berenil was also tested at various dose levels against
L. donovani in Balb/c mice. The treatment regimen and the percentage
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Table 19
The effect of DFMO against L. donovani in mice, after 7, 14 and 30 days 
of administration. Effect on liver, spleen and bone marrow parasite load.
TR EA TM EN T R EG IM EN  
Infection (DO) —► 7 daye —►
DFMO for 7 daya
D6 0DieD12
% SU P P R E S S IO N  : L IV E R  S P LE E N  B. MARROW
DFM O 2% SOln. 3 4 .1  ♦ 1 7 .8  | 3 2 .5  * 2 7 .7  I 2 1 .2  *  2 7 .4
D FM O 4% SOln. 4 8 .6  2 1 0 .7  2 0 .9  2 3 1 .1  1 .8  2 5 4 .9
Infection (DO) —♦  7 daye Infection (DO) —»■ 7 daya
DFMO for 14 daya -  0
D6 D19 D20
% S U P P R E S S IO N  : L IV E R  SPLEEN  B. MARROW
D FM O 2% soln . 5 5 .2  i  10.1 I 3 6 .5  i  22 .1  I 2 .3  i  3 7 .6
DFM O  4% so ln . 4 8 .1  2 8 .3  | 7 7 .2  2 1 4 .3  | 2 4 .9  2 34.6
DFMO for 14 daye
D6 DIO
-  0
D23
L IV E R  S P LE E N  B. MARROW  
5 2 .5  i 2 0 .3  I 1 7 .2  5 3 9 .5  I 6 3 .4  *  2 0 .4  
6 0 .4  2 11.4 53.6 2 30.3 6 1 .6  2 1 7 .2
Infection (DO) —♦  7 daya
| I DFMO for 30 daya
% SU PPR ES SIO N  
D FM O 2% soln. 
D FM O 4% soln .
D6
LIV E R  
8 1 .1  i  1 0 .4  
8 3 .8  2 10.1
0
D30D36
S P LE E N  B. MARROW  
2 0 .4  2 49.6 I 5 7 .1  *  2 8 .2  
7 3 .9  * 2 6 .0  I 7 5 .7  i  2 5 .0
D FM O : 2%, 4% soln. in the d rin king  water
M ice  kept under 4 hours d a rk , 2 hours lig h t reg im en. 0  : K ill Group size 6
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suppression of liver parasites as compared to untreated controls, 
are detailed in Table 20. The results, also illustrated in Figure 
22, showed a marked 30-80% reduction in liver parasite load at drug 
concentrations up to 40 mg/kg (F(g f 7 5 ) =124.3, P<0.05), although 
concentrations above 40 mg/kg did not significantly increase the 
percentage suppression.
3.2.3.2.2. Pentamidine methanesulfonate (Lomidine^)
3.2.4.2.2.(a) The effect of pentamidine against L. donovani 
promastigotes
The effects of pentamidine upon growth of L. donovani promastigotes 
are shown in Table 17 and Figure 19. Pentamidine inhibited growth 
at relatively low concentrations giving a 50-100% inhibition at 
concentrations of 0.08 |ig/ml and above (F (7 f 1 5 ) =37.14, P<0.05).
3.2.3.3. DL-BUTHIONINE-(S,R)-SULFOXIMINE (BSO)
3.2.3.3.(a) Effect of BSO against L. donovani promastigotes and 
amastigotes in vitro
DL-buthionine-(S,R)-sulfoximine, an inhibitor of glutathione (GSH) 
synthesis (Arrick ££. sX,, 1981), was relatively inactive in vitro. 
showing some activity only against promastigotes when used at high 
concentrations, whereas amastigote growth in mouse PECs was 
unaffected. The results from the in vitro testing of BSO are shown 
in Tables 17 and 18, Figures 19 and 20. It can be seen that against 
promastigotes, BSO had some activity at concentrations of 10 (Ig/ml 
and above (F(7 ,15)=5.6, P<0.05) but it was inactive against
amastigotes in PECs, showing only an apparent activity at 25 |ig/ml 
which, however, was not statistically significant. In addition, it 
was toxic to. macrophages at concentrations above 25 fig/ml.
3.2.3.3.(b) Effect of BSO against L. donovani in mice
The iii vivo activity of BSO was better than its activity
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Table 20
The effect of Berenil and buthionine sulfoximine (BSO) given individually
at various dose levels, against L. donovani in mice.
TR EA TM EN T REGIM EN
Infection (DO) —► 14 daye —► Infection (DO) —*■ 14 days —►
—  1B | B | B|B | —  I K | b b b b
D16 D18 D22 b b b b
—► b b b b -  0
DOSE BERENIL % SUPPRESSION D16 D18 D22
10 m g/kg 3 5 .3  i  6 .2 DOSE BSO % SUPPRESSION
20 m g/kg 4 4 .1  i  3 .2 10 m g/kg 4 5 .3  i  9 .9
3 0  m g/kg 6 2 .8  i  1 3 .2 2 0  m g/kg 7 3 .0  *  7 .9
4 0  m g/kg 7 9 .4  ± 10.1 3 0  m g/kg 6 8 .3  t 8.0
6 0  m g/kg 8 0 .5  ± 6 .9 4 0  m g/kg 6 4 .8  i  6 .4
8 0  m g/kg 8 3 .1  * 5 .1
[il : B eren il [b] : B uth ionine su lfoxim ine  (B SO ) g r o u p  s i z e : 6
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Fig. 22. Effect of Berenil, given at various dose levels, against 
L. donovani in Balb/c mice.
100 I-------------------------------- :--------------------
P ercen tag e  reduction  in iiver p aras ite  load
A: B eren il 4  x  10 m g/kg C: B eren il 4  x 3 0  m g/kg E: B eren il 4
B: B eren il 4  x 20  m g/kg D: B eren il 4  x 4 0  m g/kg F: B eren il 4
x 6 0  m g/kg  
x  8 0  m g/kg
in vitro, although it did not eradicate all the parasites even when 
used at high levels. It was tested at dose levels ranging between 
10-40 mg/kg, three times daily and it produced a 45% to 70% 
reduction in liver parasite load (F(4 f 5 5 j=126.7, P<0.05). The
treatment regimen and the results obtained are shown in Table 20 and 
Figure 23.
3.2.3.4. NITROFURANS
3.2.3.4.1. 5-nitro-2-furaldehyde semicarbazone, nitrofurazone
This compound normally associated with the treatment of T. cruzi and 
some bacterial infections, was also tested as it is now being used 
more frequently in the treatment of chronic sleeping sickness.
3.2.3.4.1.(a) In vitro activity
The in vitro activity of nitrofurazone has been investigated against 
promastigotes and the results are shown in Table 17 and Figure 19. 
At concentrations of 1.25 Hg/ml and above this compound had shown 
marked activity giving up to 100% reduction (F ( 3 ,17)=8.55, 
P<0.05), while at concentrations 0.08 Mg/ml and below did not affect 
promastigote growth.
3.2.3.4.1.(b) In vivo activity
Nitrofurazone activity has been investigated as a monotherapy and in 
combination with Berenil and Trimelarsan. The treatment regimen and 
the percentage suppression in liver parasite load are given in Table 
21 and Figure 24 (see also Figure 6). It can be seen that when it 
was given as 4 x 200 mg/kg (max. tolerated dose) there was a 
reduction in liver parasite load of about 25%. However, this 
reduction was not statistically significant. Berenil monotherapy 
again gave about 51% reduction (F (5 1 55 j =10.5, P<0.05), but when 
this was given in combination with the nitrofurazone this was 
reduced to less than 10%. Trimelarsan monotherapy gave a reduction 
in liver parasite load of 45%. There was also a marked decrease in
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Fig. 23. Effect of buthionine sulfoximine, given at various dose levels,
against L. donovani in Balb/c mice.
P ercen tage reduction  in liver p aras ite  load
A: B uth ion ine sulfoxim ine: 4 x  10 m g/kg, th re e  tim es daily
B: B uth ionine sulfoxim ine: 4 x 20  m g/kg, th ree  tim es d a ily
C: B uth ionine sulfoxim ine: 4  x 3 0  m g/kg, th re e  tim es d a ily
D: B uth ionine sulfoxim ine: 4  x 4 0  m g/kg, th re e  tim es d a ily
Table 21
The effect of nitrofurazone (5-nitro-2-furaldehyde semicarbazone), alone and
in combination with Berenil and Trimelarsan, against L. donovani in mice.
TR EA TM EN T REGIM EN  
Infection 13 deye —*■
—  | n | n | n | n | —  (7]
D14 D17 D21
DRUG GROUP SIZE % SUPPRESSION
N itro fu razone  6 2 6 .7  i 2 4 .3
B erenil 6 5 1 .4  1 2 2 .3
Trim elarsan  ® 4 5 .0  i  2 0 .3
Infection (DO) —► 13 deye —*•
* * * •
N N N N
D14 D17 D21
DRUG COMBINATION GROUP SIZE *  SUPPRESSION
N itro fu razone  + B eren il 4 6.8 * 2 6 .8
N itro fu razone  + Trim elarsan  5 0 .5  i  2 8 .5
I7T1 : N itro fu razone , 2 0 0  mg/kg Q  : B eren il, 40  m g/kg Q  : T rim e la rsan , 3 0  m g/kg
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Fig. 24. Effect of nitrofurazone, Trimelarsan and Berenil, individually
and in combination, on L. donovani -  infected Balb/c mice.
60
50 r  
40 
30 
20 
10 
0
Percen tag e  reduction  in liver p aras ite  load
A B
N itro furazone (N) Trimelarsan (T)  
EHH (N) + (B)
D E
1 1 1  Berenil (B)
(N) + (T)
N itro fu razone: 4 x  2 0 0  mg/kg Trim elarsan: 4 x 3 0  m g/kg B erenil: 4  x 4 0  mg/kg
efficacy of Trimelarsan when combined with nitrofurazone and the 
effect of Trimelarsan was completely reversed. The activities of 
these combinations were not significantly different when compared 
with the liver parasite load of controls. The above combination
treatment regimens were also associated with mortality of some of
the mice.
3.2.3.5. ANTIMONIAL COMPOUNDS
3.2.3.5.1. Sodium stibogluconate (Pentostam^)
3.2.4.5.1. (a) The effect of Pentostam^) against L. donovani 
promastigotes and amastigotes
The in vitro activity of sodium stibogluconate (Pentostam^) is shown 
in Tables 17 and 18, Figures 19 and 20. It can be seen (Table 17, 
Figure 19) that against promastigotes it was totally inactive. 
Against amastigotes growing in murine PECs (Table 18, Figure 20) 
showed some activity reducing the number of infected cells at 
concentrations of 5 Hg/ml and above (F(7716)= 69.6, P<0.05) and the 
number of amastigotes/100 infected cells, at concentrations of 
2.5 |ig/ml and above (F(7.16)= 13.9, P<0.05).
3.2.3.5.1. (b) In vivo activity of Pentostam^)
The treatment regimen and the percentage suppression in liver 
parasite load are given in Table 22 and Figure 6 . It can be seen 
that a 40 to 93% reduction in liver parasite load can be achieved 
at dose levels ranging between 10-200 mg/kg (F(g f 9 9 )=97.7, 
P<0.05). However, the results obtained after treatment at dose 
levels of 50 mg/kg and above were not significantly different to 
each other.
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Table 22
The effect of Pentostam, given at various dose levels, against
L. donovani in mice.*
TR EA TM EN T R EG IM EN
Infection (DO) —► 13 diyc —►
—  |p p Ip |p I 0
D12 D16 D19
DOSE %  SUPPRESSION
2 0 0  m g/kg 0 3 .5 3 .5
150 m g/kg 9 2 .9 3.1
100 m g/kg 9 1 .0 4 .3
75  m g/kg 8 2 .9 6 .7
5 0  m g/kg 8 4 .2 7 .0
2 5  mg/kg 6 6 .2 15.1
10 mg/kg 4 7 .8 2 1 .2
5 m g/kg 3 .5 2 3 .0
[p~1 *• Pentostam  (ip ) [k]  K ill *  Group size 6
9 2
3.2.4. DETECTION OF ADDITIVE OR SYNERGISTIC INTERACTIONS IN 
CHEMOTHERAPY BETWEEN COMPOUNDS THOUGHT TO INTERFERE WITH 
TRYPANOTHIONE METABOLISM IN VIVO AND IN VITRO
A main approach of this project was to evaluate combination therapy 
using compounds thought to interfere with trypanothione metabolism 
and for this reason, combination experiments involving 
nitroimidazoles and compounds known to interfere with trypanothione 
synthesis were carried out.
3.2.4.1. Effect of fexinidazole, DFMO, Pentostam^), Berenil^), 
and Trimelarsan^^, alone and in various combinations, against 
L. donovani promastigotes
Fexinidazole, DFMO, Pentostam, Berenil, and Trimelarsan have been 
tested, both alone and in various combinations, against L. donovani 
promastigotes in culture. This was carried out to see whether or not 
any of the compounds were synergistic against the parasite itself. 
The results, shown in Table 23 and Figure 25, are from one 
experiment, drugs were used at concentrations expected to give
around 40% reduction in parasite numbers. It appeared that most of 
the compounds showed less than additive activity when in 
combination. There were no indications of synergistic effects. 
Trimelarsan apparently reduced the effect produced by the other 
drugs when it was used in combination. In no case were all the
parasites killed.
3.2.4.2. Effect of fexinidazole, DFMO, Pentostam^), Berenil^), 
buthionine sulfoximine and Trimelarsan^), alone and in various 
combinations, against L. donovani amastigotes growing in PECs 
Experiments similar to those carried out with promastigotes were
performed using the standard conditions for amastigote-initiated 
infections of PECs in vitro, as described in section 2.3.. The
results of these studies are shown in Tables 18 and 24 and Figures 
20 and 26. Of the compounds used, only Pentostam and Berenil showed
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Table 23
The effect of DFMO, Pentostam, fexinidazole, Berenil and Trimelarsan,
alone and in various combinations, against L. donovani promastigotes.
Drug /
Drug C om bination
% reduction  
com pared to contro ls Drug C om bination
% red uc tion  
com pared to con tro l
0 4 9 .6 i  1 1 .5 0 *  0 5 2 .2 - 3 .0
0 - 6 .5 i  1 7 .2 0 * 0 - 1 2 .1 i 1 9 .0
0 4 5 .5 i 21.1 0 *  0 * 0 4 8 .4 ♦ 1 3 .2
0 4 7 .0 t 5 .0 0 * 0 * 0 4 8 .0 ± 1 8 .4
0 8 .0 ♦ 11 .3 0 * 0 * 0 3 3 .4 ± 1 7 .2
0 -  0 3 4 .6 t 1.7 0 * 0 *  0 1 8 .3 ♦ 8 .6
0 * 0 6 4 .2 1 14.4 0 *  0 * 0 *  0 1 5 .9 i 1 .7
0 * 0 5 7 .7 ♦ 7.5 0 *  0 *  0 *  0 2 6 .9 ± 1 5 .5
0 *  0 4 4 .1 i 17.3 0 *  0 *  0 *  0 6 1 .0 *  9 .2
0 * 0 3 7 .7 i  3 0 .3 0 *  0 *  0 *  0 * 0 1 8 .7 ♦ 2 0 .0
0  + 0 1 7 .9 1 5 .0
0 * 0  
0  * 0
4 6 .4
2 8 .8
♦ 2 3 .0
♦ 6.1
Mean num ber of p a ras ites  
in co n tro ls  x 104/m l i  SD
6 1 5 .0 ± 3 1 2 .7
fp~| : DFM O (1.25 MO/ml) 0  ■ Fexin idazo le  (1.25 fjg /m l)
j~p~l : Pentostam  (100 j jg /m l)  0  : B erenil (1 .25  |jg /m l)  [7 ]  : T rim e la rsan  (100  jjg /m l)
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Fig. 25. Effect of fexinidazole, DFMO, Berenil, Pentostam and Trimelarsan,
alone and in various combinations, against L.donovani promastigotes.
80
P ercen tag e  reduction  in liver p aras ite  load
60 -
4 0 -
20 -
-20
A: Fex in idazo le  (1.25 p g /m l) M:
B: D FM O  (1.25 p g /m l) N:
C: Pentostam  (100 (jg /m l) O:
D: B eren il (1.25 jug/ml) p :
E: T rim elarsan  (100 p g /m l) q ;
F: Fex in idazo le  + D FM O  R:
G: Fex in idazo le  + Pentostam  S:
H: Fex in idazo le  + B eren il T:
I: Fex in idazo le  + Trim elarsan  U:
J: B eren il + T rim elarsan  V:
K: T rim elarsan  + DFM O  X:
L: B eren il + Pentostam
Pentostam  + D FM O
Trim elarsan  + Pentostam
Berenil *  D FM O
Berenil + Pentostam
Fexin idazole  + B eren il + D FM O
Fexin idazole  + T rim elarsan  * D FM O
Fexin idazole  + B eren il + T rim elarsan  + D FM O
Fexin idazole  + T rim elarsan  ♦ Pentostam  + D FM O  ■*
Fexin idazole  + P entostam  + B eren il + D FM O
Fexin idazole  *  T rim elarsan  * B eren il
Fexin idazole  + P entostam  + B eren il + T rim elarsan
B eren il
good anti leishmanial activity in this in, vitro system, giving up to 
85% at 100 Hg/ml (F(7,23)= 13.9, P<0.05) and 67% at 5 Hg/ml 
(F (4 f 13 j=19.4, P<0.05) reduction of amastigotes respectively (Table 
18, Figure 20). Berenil, however, proved to be toxic to macrophages 
at concentrations of 10 Mg/ml or above. Toxicity to macrophages was 
also observed with fexinidazole (50-100 fig/ml), Trimelarsan 
(100 (ig/ml) and buthionine sulfoximine (BSO) (50-100 flg/ml). DFMO 
was relatively inactive in this in vitro system. Table 24 and 
Figure 26 show the results from the drug combinations against the 
amastigotes in peritoneal exudate cells (PECs) at the end of the 5 
day exposure period. The drug concentration used in each 
combination was the one that in monotherapy was found to give 
approximately 20% reduction of amastigotes compared with controls. 
Many of the combinations showed approximately additive effect. 
Exception were combinations involving Trimelarsan, which apparently 
reduced the effect produced by the other drug alone. Combinations 
involving five or more drugs proved toxic to macrophages. In no 
case were the parasites totally cleared.
3.2.4.3. Effect of DFMO, fexinidazole, Pentostam^^, Berenil^) and 
Trimelarsan^), alone and in various combinations, against
L. donovani in mice
In order to maximise the detectability of synergistic and additive 
effects of the compounds used in combinations, it was decided to 
use relatively low drug concentrations in these combination 
experiments, such that each drug alone would be expected to give 
only approximately 20% reduction in liver parasite load. The 
compounds used were DFMO (1% soln. x 14 days), the 5-nitroimidazole, 
fexinidazole (4 x 10 mg/kg), Pentostam ( 4 x 5  mg/kg twice daily), 
Berenil (4 x 20 mg/kg) and Trimelarsan (4 x 20 mg/kg). The 
treatment regimen and the results produced, which are given in 
Table 25 and Figures 27a and 27b, showed that there was no more
than an approximately additive effect in combinations involving
DFMO, fexinidazole, Berenil and Pentostam. However, when Trimelarsan
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Table 24
The effect of DFMO, Pentostam, fexinidazole, Berenil, Trimelarsan and
BSO, alone and in various combinations, against L. donovani in PECs.
Drug /
Drug C om bination
N um ber o f ce lls  
in fec te d . % contro l C ontro l
A m astigo te  num ber 
/  100 in fec ted  c e lls  
% co n tro l
C ontro l
0 9 1 .4 !  3 .2 9 3 .7  * 6.1 7 7 .9
4 2 .6 8 2 8 .5 8 8 .9
0 9 3 .2 i 7 .5 9 3 .7  * 6.1 7 6 .5
4 2 1 .9 8 2 8 .5 8 8 .9
0 9 9 .6 ♦ 6 .7 9 3 .7  1 6.1 6 5 .4 4 2 .6 8 2 8 .5 8 8 .9
0 8 0 .5 ♦ 1 6 .0 9 3 .7  ♦ 6.1 7 4 .1 4 2 0 .1 8 2 8 .5 8 8 .9
0 9 8 .2 * 6 .1 9 3 .7  ± 6.1 8 1 .9
4 2 .6 8 2 8 .5 8 8 .9
0 8 7 .6 *  15.1 9 3 .7  t 6.1 76.1
4 2 .8 8 2 8 .5 8 8 .9
0 *  0 9 9 .8 t 5 .7 8 5 .5  ± 2.1 6 0 .4 4 0.1 7 3 8 .5 3 3 .3
0 *  0 1 0 2 .3 * 7 .5 8 5 .5  i 2.1 7 2 .6 4 1 0 .8 7 3 8 .5 3 3 .3
0 * 0 1 0 5 .fi 1 7.4 8 5 .5  * 2.1 1 0 6 .4 4 3 2 .9 7 3 8 .5 3 3 .3
0  * 0 1 0 0 .0 * 8.1 9 1 .0  * 7 .0 5 5 .4 4 1 6 .7 8 1 8 .5 1 1 3 .9
0 + 0 1 0 2 .5 * 7 .7 9 1 .0  * 7 .0 5 9 .8
4 6 .8 8 1 8 .5 1 1 3 .9
0 * 0 9 0 .1 ♦ 1 5 .3 9 1 .0  * 7 .0 4 4 .6 4 9 .7 8 1 8 .5 1 1 3 .9
0  * 0 9 7 .0 i 1 .4 9 8 .3  * 2 .0 7 9 .3 4 9 .9 7 7 1 .3 1 4 0 .9
0  * 0 7 8 .0 * 5 .2 9 8 .3  i 2 .0 4 8 .7 4 7 .8 7 7 1 .3 1 4 0 .9
0 * 0 8 1 .7 * 1 0 .2 9 8 .3  t 2 .0 5 3 .0 4 4 .9 7 7 1 .3 1 4 0 .9
0  * 0 9 6 .6 t 4 .5 9 8 .3  i 2 .0 1 0 1 .3 4 2 7 .2 7 7 1 .3 1 4 0 .9
0 * 0 9 2 .6 * 3 .1 9 8 .3  * 2 .0 5 4 .4 4 11.1 7 7 1 .3 1 4 0 .9
0 * 0 9 3 .6 *  7 .2 9 8 .3  ♦ 2 .0 5 8 .9 4 2 .0 7 7 1 .3 1 4 0 .9
0 * 0 9 7 .2 ± 9 .0 9 5 .7  * 5 .7 7 8 .6 4 1 4 .2 7 5 9 .4 3 2 .5
0 * 0 9 3 .0 * 6 .6 9 5 .7  * 5 .7 6 0 .2
4 8.1 7 5 9 .4 3 2 .5
0 * 0 8 2 .0 *  7 .0 9 5 .7  i 5 .7 6 6 .1 4 1 4 .7 7 5 9 .4 3 2 .5
0 *  0 *  0 9 9 .6 * 6 .8 9 3 .7  ♦ 6 .4 5 6 .0 4 5 .4 8 2 8 .5 8 8 .9
0 *  0 *  0 1 0 5 .9 ♦ 7 .4 8 5 .5  i 2.1 6 7 .5 4 3 .7 7 3 8 .5 3 3 .3
0  * 0 *  0 *  0 9 7 .7 i 7 .5 9 5 .7  t 5 .7 5 7 .8 4 3 .2 7 5 9 .4 3 2 .5
0  * 0 *  0 *  0 5 1 .6 *  1 1 .0 9 5 .7  i 5 .7 3 3 .0 4 6 .0 7 5 9 .4 3 2 .5
0 * 0 *  0 * 0 * 0 6 1 .1 ♦ 4 .0 9 5 .7  * 5 .7 3 5 .0 4 6 .4 7 5 9 .4 3 2 .5
0 * 0 *  0 * 0 * 0 * 0 9 8 .3  * 2 .0 *• 7 7 1 .3 1 4 0 .9
* • •
M ean -  SD Drug com bination to x ic  to m acrophages. Few p a ras ites  presen t
|~o~] D FM O  100 |jg /m l j j j j  B eren il 1 iug/ml
0  Pentostam  1.25 iug/ml 0  Trim elarsan  2 5  pg /m l
0  Fexin idazole  5 jjg /m l 0  B uth ion ine  su lfoxim ine  (B S O ) 5 (jg /m l
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Table 25
The effect of DFMO, fexinidazole, Pentostam, Berenil and Trimelarsan,
individually and in various combinations, against L. donovani in mice!
M O N O TH E R A P Y  
TR EA TM EN T R EG IM EN
Infection (DO) —*• 6 d«y* —*•
| d | d | d | d |d | d | d | d | d | d | d |d | p | d | —*■ |~k]
DRUG
DFM O 0
%  SUPPRESSION 
2 1 .3  i  1 2 .7
Infection —*■ 1® d*y* —•
DO 016
DRUG
Pentostam  0
- 0
D23
*  SUPPRESSION 
2 5 .8  1 12.1
Infection
DO
16 days —► M i l l
D16 D19
0
D23
DRUG
Fexinidazole 0  
Berenil 0  
Trimelarsan 0
% SUPPRESSION
2 7 .9  i  1 4 .5
3 5 .9  i  1 7 .8  
3 1 .5  ± 1 7 .6
DUAL C O M B IN ATIO N S
0
D23
Infection (DO) — *■ 16 days —»
D16 D19
DRUQ COMBINATION % SUPPRESSION
B e r e n i l0  ♦ Fexinidazole 0  4 8 .7  ± 8 .8
Trimelarsan 0 +  Fexinidazole 0  2 8 .0  1 8 .6
Berenil 0 *  Trimelarsan 0  3 4 .6  - 16.1
0
D23
Infection (DO) —♦  16 days —►
D16 D19
DRUQ COMBINATION % SUPPRESSION
Pentostam 0 *  Fexinidazole 0  4 0 .8  i  1 4 .7
Pentostam 0 - *  Berenil 0  5 5 .7  + 24 .1
Pentostam 0 +  Trimelarsan 0  2 3 .8  1 1 6 .8
Infection (DO) 6 days
| p | d | p | p | d | p | d | p | d | d -  0
D6 D16 D19 023
DRUQ COMBINATION % SUPPRESSION
D FM O 0 *  Fexinidazole 0  4 6 .2  i  8 .2
D FM O  0 *  Berenil 0  3 8 .4  1 1 0 .0
DFM O 0  ♦ T r im e la rs a n 0  3 3 .8  ± 11.4
Infection (DO) —► 6 days —►
1d | d | d | d |d | d | d | d | d 1d | d |d 1dT d | —+■ 0
D6 D16 D19 D23
DRUG COMBINATION % SUPPRESSION
Pentostam  0 *  D FM O  0  4 0 .8  1 1 4 .7
M ULTIPLE CO M B IN ATIO N S
Infection (DO)
f F F F
B B B B
| d | p | d | d |d | d | d ( d | d | d D D D D
D6 D16 D19 D23
DRUQ COMBINATION % SUPPRESSION
D FM O 0  + Fexin idazo le  0  ♦
B eren il 0 3 6 .8  1 12 .3
Infection (DO) —► 6 days —►
p P P P
F F F F
p P P P
|d I D I D I D ID I 0 I D I D I d I d D D D D 0
D23
DRUQ COMBINATION
Pentostam  0 +  D FM O  [d | < 
Fexin idazo le  0
D19
«  SUPPRESSION
6 0 .6  1 1 2 .6
Infection (DO)
Infection (DO)
6 days
6 days —►
| d | p | d | p |p | d | d | d | p 1o 0
D23
|P | D | D | D | P | P | D | P | P | P 0
D23
DRUQ COMBINATION
D19
% SUPPRESSION
Pentostam 0  ♦ DFM O 0  + 3 7  9 + 1 1 9
Fexinidazole 0  ♦ T r im e la rs a n 0
DRUQ COMBINATION
P e n tO 8 ta m 0 +  D FM O  0  ♦ 
Fexin idazo le  0 +  B eren il 0 +  7 8 ' 9
D19
% SUPPRESSION
t 8.6
97 Contd.
Table 25 (contd.)
M ULTIPLE C O M B IN ATIO N S (con td .)
Infection (DO) 6 days M p lD D D D D I d
DRUG COMBINATION
023D19
% SUPPRESSION
Pentostam  0  ♦ D FM Orio | +
L-—I t--1   QQ A * 12 9
Fexin idazo le  0  ♦ B eren il 0  +
Trim elarsan  [T]
I I B eren il 10 m g/kg 0  Trim elarsan 20 m g/kg 0  Fex in idazo le  10 m g/kg  
0  Pentostam  5 m g/kg, 1000  hrs & 1500 hrs each day 0  K ill Group size 6 
0  D FM O 1% soln. in drin king  w ater. M ice kept under 4 hours d a rk , 2 hours lig h t regim en
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Fig. 27a. The effect of DFMO, fexinidazole, Pentostam and Berenil,
alone and in various combinations on L. donovani -  infected Balb/c mice.
100
8 0 -
60
40
20 -
P ercen tage reduction  in liver p aras ite  load
F exin idazole  (4  x  10 m g/kg)
D FM O  1% soln in d rink ing  w ater G: D FM O  «■ P entostam  * F ex in idazo le
Pentostam  (5  mg/kg tw ic e  d a ily  fo r 4  days) H: B eren il (4  x  20  m g/kg)
D FM O  + Fexin idazole I: B eren il *  Fex in idazo le
D FM O  + Pentostam J: B eren il ♦ P entostam
Pentostam  + Fexin idazole K: B eren il *  D FM O
C om binations s ig n ific a n tly  d iffe re n t to each o th e r, a t the  .0 5  level:
(B ) d iffe re n t to (G ). (K ), (E), (I), (D) and (F), <F.(9 .108) 10.5)
(A ) d iffe re n t to (G), (K), (E ), (I) and (D ), (F(9(108)" 10.5)
(C ) d iffe re n t to (G ), (K), (E ), (I), <D), (J), (L ) and (E), (F(910e)-  10.5)
(F ) d iffe re n t to (G), (F(9<108)-  10.5)
(H ) d iffe re n t to (G ), (J) and (L), (F (7 .8 6 ) 4 .7 )
(K ) d iffe re n t to (G ), (J), (L ) and (F), (F (7 ee)-  4 .7 )
Fig. 27b. The effect of DFMO, Trimelarsan, fexinidazole, Berenil and
Pentostam, in various combinations, on L. donovani -  infected Balb/c
mice.
100
8 0 -
6 0 -
4 0 -
20 -
P ercen tag e  reduction  in liver paras ite  load
M
I
R S
L: D F M O  ♦ Fexin idazo le  ♦ Pentostam  + B eren il 
M: T rim elarsan  (4  x  20  m g/kg)
N: D F M O  1% soln ♦ T rim elarsan  
O: T rim elarsan  + Fexin idazo le  (4  x 10 m g/kg)
P: T rim elarsan  ♦ Pentostam  ( 4 x 5  m g/kg, Tw ice  D a ily )
Q: Pentostam  + Fexin idazole  + D FM O  * T rim elarsan  
R: T rim elarsan  + B eren il (4  x 2 0  m g/kg)
S: D FM O  ♦ Pentostam  + Fexin idazole  + Trim elarsan  ♦ B eren il 
T: B eren il + D FM O  + Fexin idazole
C om binations s ig n ific a n tly  d iffe re n t to each o th e r at the  .0 5  level:
(L ) d iffe re n t to (P), (O ), (M ), (S ), (N), (R ), (Q ) and (T ) <F(9 106)-  2 5 .4 ) .
was used, it appeared to reduce the effect produced by all the 
other drugs. The overall conclusion from these experiments was that 
although combinations involving DFMO, fexinidazole, Berenil and 
Pentostam have interesting activity against L. donovani in mice, 
they were not apparently synergistic.
Thus, the results at this stage had shown that the combinations 
were less effective against L. donovani than had been hypothesised. 
There are several possible explanations for this and the potential 
of drug combinations as antileishmanials had been pursued in other 
ways.
3.3. IN VIVO EXPERIMENTS INVOLVING THE DRUGS OF CURRENT USE, SODIUM 
STIBOGLUCONATE (PENTOSTAMR ) AND PENTAMIDINE (LOMIDINER )
Sodium stibogluconate and pentamidine were tested in vivo in some 
detail, by using them individually and in combination experiments. 
It was hoped that in this way it would be possible to maximise the 
effectiveness of drugs already available for use in humans.
3.3.1. Effect of sodium stibogluconate (PentostamR ) and pentamidine 
(LomidineR ) on liver parasite load, after 5, 6 , 7 and 8 days of
administration, against L. donovani in mice
The results of this experiment are detailed in Table 26 and Figure 
28. The parasite loads of the two control groups, as determined on 
day 27 and day 29 after infection, were not significantly different. 
Pentamidine, at the dose level and length of treatment used, had no 
effect on liver parasite load and showed toxic side effects, 
particularly with prolonged treatment. Pentostam itself produced a 
60-87% reduction in liver parasite load (F (g, 85)=99.8, P<0.05).
Under the conditions used, combination of Pentostam with pentamidine 
did not result in any additional effect over that produced by 
Pentostam alone.
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Table 26
** ***
The effect of Pentostam and pentamidine on liver parasite load, after
5, 6, 7 and 8 days of administration, against L. donovani in mice.*
TR EA TM EN T R EG IM EN
Infection (DO) —► 18 deye —♦ Infection (DO) —► 18 deye —♦
t | DRUG for 6 deye | _ ^  f^ | | | DRUG for 6 deye | _  ^ j-p-j
D19 D23 D27
DRUG % SU PPR ES SIO N  
Pentostam  5 8 .8  * 6 .7  
P entam id ine  0.1 i  1 6 .3
D19 D24 D27
DRUG % S U P P R E S S IO N  
P entostam  6 1 .1  i  7 .8  
P entam id ine  3 .6  -  13.1
Infection (DO) —► 18 deye —♦ Infection (DO) —■* IS deye —■»
( j DRUG for 7 deye t j DRUG for 8 deye | _^
D19 D26 D29
DRUG % SU PPR ES SIO N  
Pentostam  6 9 .3  l  1 0 .3  
P entam id ine «***
D19 D26 D29
DRUG % S U P P R E S S IO N  
Pentostam  8 7 .4  * 5 .8  
P entam id in e  *•»•»
Infection (DO) —+ 18 deye —»
| Pentoetem lor 6 deye | _  day ,n„ ry. ,  _  | pentemldlne for 2 deye | |7 |  
019 D23 D24 D26 029  
DRUG COM BINATION  ^ % S U P P R E S S IO N  
Pentostam  ■* pentam id ine 6 0 .2  t 1 9 .4
_ *
| k | K ill Group size 6 A ll the  m ice d ied  during trea tm e n t
* *  5 m g/kg T W IC E  DAILY * * *  25  m g/kg T W IC E  DAILY, w ith  the  excep tion  of the f irs t  day of 
trea tm en t when it  was given on ly  once.
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Fig. 28. Effect of Pentostam (5 mg/kg, twice daily) and pentamidine 
(25 mg/kg, twice daily), given for different lengths of treatment 
time (5, 6, 7, 8, days), against L. donovani in Balb/c mice.
P ercen tag e  reduction  in liver p aras ite  load
A: Pentostam  5 x 5  m g/kg tw ic e  d a ily
6: Pentostam  6 x 5  m g/kg tw ic e  d a ily
C: Pentostam  7 x 5  m g/kg tw ic e  d a ily
D: Pentostam  8 x 5  mg/kg tw ic e  d a ily
E: P entam idine 1 x 25  m g/kg + 4  x 2 5  m g/kg tw ic e  d a ily
F: P entam id ine 1 x  2 5  m g/kg + 5 x  2 5  m g/kg tw ic e  d a ily
G: P entam id ine 1 x 2 5  mg/kg + 6 x 2 5  m g/kg tw ic e  d a ily  *
H: P entam id ine  1 x 2 5  m g/kg + 7 x 2 5  m g/kg tw ic e  d a ily  *
I: Pentostam  5 x 5  m g/kg tw ic e  d a ily  *  P en tam id ine  2 x 2 5  m g/kg
• A ll the  m ice d ied  before the com pletion  o f tre a tm e n t
3.3.2. Effect of sodium stibogluconate (Pentostam**), pentamidine 
(Lomidine**) and DFMO, on liver parasite load, alone and in 
combination, against L. donovani in mice
Another possibility that was investigated was the combination of 
DFMO with Pentostam** and pentamidine. These results are shown in 
Table 27 and Figure 29. Pentamidine did not significantly reduce 
the liver parasite load and in combination with DFMO did not produce 
any additional effect over that produced by DFMO itself. When in 
combination with Pentostam, it reduced the effect produced by the 
other drug alone. In contrast, Pentostam gave a 25% reduction when 
tested alone and the combination of Pentostam with DFMO was additive 
in effect (F (9 f n o )  =13.7, P<0.05). Surprisingly, when pentamidine 
was combined together with Pentostam and DFMO, this resulted in 
reduction of the effect produced by the combination of the latter 
two drugs.
3.3.3. Effect of sodium stibogluconate (Pentostam**), pentamidine 
(Lomidine**) and buthionine sulfoximine (BSO), on liver parasite 
load, alone and in combination, against L. donovani in mice
These results are shown in Table 27 and Figure 30. It can be seen 
that a 50% reduction in liver parasite load was achieved when 
buthionine sulfoximine was used alone with a dose regimen involving 
3 daily doses (see also section 3.2.3.3.b). However, in combination 
with DFMO and pentamidine, a decrease in its efficacy was observed 
(p (9,110)=13.7, P<0.05).
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Table 27
The effect of DFMO, Pentostam, pentamidine and buthionine
sulfoximine (BSO), individually and in combination, against
L. donovani in mice.
TR EA TM EN T R EG IM EN
Infection (DO) —► 6 day* —»
|d | d | d | d |d | d | d | d | d | d | d |d I d Tp I  —*  |~k |
D6
DRUG
DFMO
D19 D23
% SUPPRESSION 
2 1 .3  t 1 1 .7
Infection (DO) 16 day* —►
p P P P _  r . i .  i i .  i
p P P P —  0 ^  1 p 1 p 1 p 1 p 1
D16 D19 D23 Die D19
DRUG
Pentostam
%  SUPPRESSION 
2 5 .8  * 12.1
D23
DRUG % SUPPRESSION
P entam idine 8.1 - 14.1
Infection (DO) —*  16 daya —►
Infection (DO) —*  6 daya —►
—
p p p p
p p p p
|d 1 D 1 D 1 d |d 1 01 D 1 D 1D 1 d d | d d | d
D6
^  0
D23
DRUG
BSO
% SUPPRESSION 
4 9 .8  - 9 .8
Die D19
DRUG COMBINATION % SUPPRESSION
Pentostam  ♦ D FM O  5 2 .0  ♦ 6 .6
Infection (DO)
Infection (DO) 6 daya —►
p P P P
| d | d | d | d |d | d | d | d | d | d D D D D -  0
D23D6 D16 D19
DRUG COMBINATION % SUPPRESSION
D FM O  ♦ pen tam id ine  2 3 .4  i  1 1 .5
|d |p|p|d |p |p|p|d |dTd 0
D23
DRUG COMBINATION
Pentostam  ♦ D FM O  + 
pentam id ine
D19
%  SUPPRESSION
2 6 .1  t 1 1 .4
Infection (DO) 6 daya
Infection (DO) 16 daya —►
D16 D19 D23
DRUG COMBINATION % SUPPRESSION
|p | p | d | d |d { p I d I p Id I d
D6
Pentostam  * 
pentam id ine 1 7 .2  i  14 .2
D16 D19
DRUG COMBINATION % SUPPRESSION
DFM O ■* pen tam id ine  * 4 2 .4  i  1 1 .5
BSO
0
D23
0  pentam id ine  25 mg/kg
[~p] Pentostam  5 m g/kg, 1000 hrs S 1500  hrs each day 0  K ill * Group size 6 
0  DFM O 1% soln . in d rinking  w ater. M ice kept under 4 hours d a rk , 2 hours lig h t reg im en  
|~b] BSO 10 m g/kg 1000  hrs, 1300 hrs & 1500 hrs each day
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Fig. 29. Effect of DFMO, Pentostam and pentamidine, individually and
in combination, against L. donovani in Balb/c mice.
Percen tag e  reduction  in liver p aras ite  load
Hi D FM O
CZH D FM O  + (P) + (p)■ H  D FM O  + (p)
Pentostam  (P) : 4 x 5  m g/kg Tw ice D a ily  pen tam id ine  (p ) .- 4 x 25  m g/kg  
D FM O : 1% soln. in d rink ing  w ater fo r 14 days
Fig. 30. Effect of buthionine sulfoximine, alone and in combination with
pentamidine and DFMO, against L. donovani in Balb/c mice.
60
P ercen tage  reduction  com pared to con tro ls
50
40
30
20
(p) ■  BSO ill (p) + BSO +DFMO
D FM O  1% soln. in d rink ing  w ater fo r 14 days p en tam id in e  (p ) : 4 x 2 5  mg/kg  
b uth ionine su lfox im ine (B SO ) : 4 x 10 m g/kg T h re e  T im es D a ily
3.4. A STUDY ON THE PREVENTION OF THE RELAPSE OF VISCERAL 
LEISHMANIASIS IN THE MOUSE MODEL, USING COMPOUNDS THOUGHT TO 
INTERFERE WITH TRYPANOTHIONE METABOLISM
One of the drawbacks of the currently used drugs in the chemotherapy 
of visceral leishmaniasis, is the relapse of the disease after an 
apparently successful treatment. This is believed to be due to the 
fact that parasites located in sites other than the liver, such as 
the spleen and the bone marrow, are difficult to eradicate. Thus, it 
was of interest to test the efficacy of the new compounds and 
combinations in clearing the parasites not only from liver but also 
from spleen and bone marrow. In order to test this possibility it 
was decided first to develop an experimental relapse model of 
leishmaniasis in the Balb/c mouse which could be used to test the 
efficacy of the most promising drug combinations. Particular 
attention was given to DFMO to assess the potential of the drug for 
preventing relapse of visceral leishmaniasis. The results of this 
experiment are described in subsection 3.2.3.1.(b).
3.4.1. Development of a relapse model in Balb/c mice 
The treatment regimen and the results produced are given in Table 28 
and Figure 31. It can be seen that treatment with sodium 
stibogluconate solution (Pentostam^) greatly reduced the number of 
parasites found in liver but to a lesser extent the parasite load in 
the spleen and bone marrow, as determined on day 23 after infection 
(DAI 23). In general, in the Pentostarn-treated groups, there was a 
progressive increase in parasite load between DAI 51 and and DAI 80 
in all organs screened other than the bone marrow, with the number 
of parasites present in the spleen and bone marrow not being 
significantly different from the numbers in the controls on DAI 51 
and DAI 80. One way and two way analysis of data and the Neuman 
Keuls multiple range test were used to analyse the data and the 
results from this analysis are given below.
Results from liver: The % suppression obtained on DAI 51,
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Table 28
The effect of Pentostam (iv/ip) against L. donovani in mice8, after 23, 38, 
51, 65, and 80 days of infection on liver, spleen and bone marrow parasite 
load.
TR EA TM EN T R EG IM EN % S U P P R E S S IO N
Infection (DO) 16 day* —♦ LIV E R SPLEEN B. MARROW
| Pentoatam Iv /lp 0 Pentostam  (iv )  P entostam  (ip ) **
9 7 .8
9 7 .6
4 0 .7 ,  
0 .6  |
8 0 .3  i  1 2 .3  
8 8 .8  t 6 .6
6 6 .3  * 
5 0 .9  2
2 0 .8
2 6 .9D16 D17/D18 D 23 "
Infection (DO) —► 16 day* —*•
Pentoatam iv /lp
0
D 38
Pentostam  (iv ) 9 7 .7 2 .5  I 8 1 .6  i  1 6 .5 I ' 1 7 -4 :
5 8 .1
D16 D17/D1S Pentostam  (ip ) **
9 8 .3 1.5  | 9 6 .6  1 4 .9 7 8 .5  - 1 7 .8
Infection (DO) —► 16 daya —►
. Pentoatam Iv /lp
0
D51
Pentostam  (iv ) 8 7 .4 4 8 .9  I 2 5 .7  1 4 5 .6 2 2 .4  1 3 8 .2
D16 D17/D18 P entostam  (ip ) ** 9 7 .6 t -2  | 4 3 .1  i  3 2 .6 8 2 .8  i 1 2 .8
Infection (DO) —*■ 16 day* —*•
Pentostam  (iv ) 
Pentostam  (ip ) **
8 0 .5
9 2 .1
4 6 .2  * 5 3 .8  
6 1 .0  t 2 1 .1
6 5 .0  1
6 2 .1  -
2 9 .2
1 1 .2-
Pentoatam Iv /lp
0
D 65
4
4 .1 1  
4 .5  |
D16 D17/018
Infection (DO) —♦  16 day* —►
| Pentoatam Iv /lp |
0
D 80
Pentostam  (iv )  
P entostam  (ip ) **
7 4 .7 4 - 2 .8  *  3 3 .5 I -  "14.6 i 6 0 .3
D16 D17/D18
8 2 .7 9 .5  | 4 .6 9  ± 3 2 .6 5 3 .O i 3 4 .3
P entostam  iv : 2 x 100 m g/kg, Pentostam  Ip ; 4  x  100 m g/kg T W IC E  DAILY 
OH : K ill 8 Group size :4 fo r D 23  & D 3 8 , 5 fo r D51, D 65  and D 80
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DAI 65 and DAI 80 with ip treatment was significantly higher than 
that obtained after iv treatment (F(4 f 82)=24.5, P<0.05). Iv and ip 
treatment effects were significantly different when compared with 
the untreated controls (F(9 f 82)=34.3, F (9 f 3 4 ) =40.8, P<0.05).
Interestingly, an increase in the number of parasites was observed 
on day 51 after infection in the sodium stibogluconate (Pentostam**) 
treated groups.
Results from spleen: The percentage suppression resulted with ip 
treatment was significantly higher than that obtained with iv 
treatment (^(1 ,80)=5*1> P<0.05). Iv and ip parasite loads
determined on DAI 23 and DAI 38, were significantly different when 
compared with the untreated controls (F (9 f is) =14.6, F (9 f 3 2 ) =18.7, 
P<0.05), but they reached the control levels on DAI 51 and onwards.
Results from bone marrow: The percentage suppression resulted
with ip treatment was significantly higher than that obtained with 
iv treatment (F(i^ 67) =8.58, P<0.05). Treatment effects were
significantly different when compared with the untreated controls on 
DAI 51 (ip) and DAI 65 (iv, ip) (F (9 f 5 3 ) =10.7, F (9 f 7 0 ) =19.1, 
P<0.05).
In most organs of control groups screened, there was an increase 
in parasite load after DAI 51. An exception was the parasite load in 
liver, where a decrease was observed.
3.4.2. The effect of DFMO, sodium stibogluconate (Pentostam**), 
fexinidazole, diminazene diaceturate (Berenil**) and buthionine 
sulfoximine (BSO) in combination, against L. donovani in mice: 
Effect on liver, spleen and bone marrow parasite load 
In this experiment the drugs were used at high concentrations in 
order to test the potential of the combinations to remove all 
parasites and prevent relapse. The treatment regimen and the results 
from use of the drug combinations are given in Table 29 and Figures 
32, 33, 34 and 35. It can be seen that these combinations reduced 
significantly the number of parasites, giving up to 99% reduction in 
parasite load, but without giving a total clearance of parasites
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Table 29
The effect of DFMO, Pentostam, fexinidazole, Berenil and buthionine 
sulfoximine (BSO) in combination, against L. donovani in mice*. Effect 
on liver, spleen and bone marrow parasite load on day 23 and 39 or 
70 after infection.
TR EA TM EN T R EG IM EN
Infection (DO) — *■ 6 day*
p p p p|
p p p p
|d | d | d | d |d | d | d | d | d | d d |d | d D |
PI ^  u<
a <•. R
a
D23:
0  D39:
Pentostam * DFMO
% S U P P R E S S IO N  
LIV E R  SP LE E N  B. MARROW
9 0 .3  t 0 .7  
9 8 .6  t 1 .9
9 4 .7  * 4 .8
6 5 .2  1 4 9 .3
9 3 .9  t 2 .8  
9 4 .2  i  2 .8
Infection (DO) 6 day* —►
b b b b
F F F F
b b b b
b b b b
|d 1 D 1 D 1 D 1D 1 D 1 D 1 D 1D 1 d D D D D < 00 D23:D39*:
DFMO + BSO + Fexinidazole
% S U P P R E S S IO N  
LIV E R  SPLE E N  B. MARROW
5 4 .2  i 1 8 .0  
8 1 .5  t 1 2 .9
7 8 .3  * 1 6 .7  
3 2 .5  t 3 5 .4
8 3 .2  t 8 .7
8 1 .3  t 5 8 .3
Infection (DO) —► S day*
b b b b
B B B B
b b b b
b b b b
|d | d | d | d |d | d | d | d | d | d D D D D
DFMO + BSO ♦ Berenil
% S U P P R E S S IO N  
LIV E R  SPLE E N  B. MARROW
< 00 D23:D39? 6 6 .5  i  1 3 .8  9 9 .7  * 0 .5 6 2 .6  i  3 0 .0  4 .1  i  1 2 .6 5 9 .3  i 4 0 .69 4 .4  i  2 6 .3
Infection (DO) 6 day* —♦ BSO + Fexinidazole ♦ Berenil
b b b b
F F F F
B B B B
b b b b
b b b b
% S U P P R E S S IO N  
LIV E R  SPLE E N  B. MARROW
D23:
D70:
8 8 .6  i 7 .8
9 0 .5  * 1 1 .5
9 1 .6  ± 5 .8
1 3 .8  i 1 6 .2
8 5 .4  * 5 .5
6 6 .0  t 2 1 .7
|~p| Pentostam  5 m g/kg, 1000  hrs A 1500  hrs each day
0  DFM O 2% soln . in d rin king  w ater: 1. x 14 days (D 6-D 19 , m ice s a c rific e d  on D 23 ),
2 . x 3 0  days (D 6 -D 3 5 , m ice s a c rific e d  on D 3 9 ),
M ice  kept under 4 hours d a rk , 2 hours lig h t regim en.
0  BSO 10 m g/kg 1000 hrs , 1300  hrs & 1500  hrs each day
0  Fexin idazo le  2 0 0  m g/kg, 1000  hrs each day
0  B eren il 4 0  m g/kg, 1000  hrs each day
0  K ill * Group size 6 , a: 5 & b, C: 4 a & c-. b a c teria l in fec tio n
1 0 6
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present in the tissues tested. The best results were obtained with 
the combination of Pentostam with DFMO. The data were analysed with 
two way analysis of variance and the Neuman Keuls multiple range 
test and the results of this analysis are given below.
Effect on liver: Liver parasite loads determined on day 23 after 
infection (DAI 23) were significantly different to those determined 
on DAI 39 or DAI 70 (F (3 / 77 ) =11.8, P<0.05). Also, the effects of 
the combinations were significantly different to each other 
(F (3 / 7 7 ) =18.9, P<0.05), with the exception of the combination
involving DFMO, BSO and fexinidazole which was similar in effect to 
the combination of DFMO, BSO and Berenil.
Effect on spleen: Spleen parasite loads determined on DAI 23, 
DAI 39 and DAI 70, were not significantly different from each other. 
Of the combinations tested, only that involving DFMO, BSO and 
Berenil was different in effect when compared with the others 
(p (3,74)=6*1» P<0.05).
Effect on bone marrow: Bone marrow parasite loads, determined
on DAI 23, DAI 39 and DAI 70, were not significantly different from 
each other. Of the combinations tested only, that involving DFMO, 
BSO and Berenil was different in effect when compared with the 
others (F(3 / 3 2 )=2.64, P<0.05).
Thus, the results obtained, presented in section 3.4. above, have 
showed that many of the compounds thought to inhibit the synthesis 
or interfere with the activity of trypanothione, have 
antileishmanial activity. However, none of the combinations appeared 
to be synergistic under the conditions used even though they 
appeared to be more effective than Pentostam itself.
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3.5. THE EFFICACY OF A DRUG-CARRIER SYSTEM, OCTYL DEGROL OIL, IN 
THE CHEMOTHERAPY OF VISCERAL LEISHMANIASIS
In one attempt to overcome the rapid metabolism of sodium 
stibogluconate (Pentostam^) and achieve effective drug levels for 
longer periods, a new experimental compound, octyl degrol oil, 
reported to be effective in allowing slow release of drugs (Prof. 
N.B. Graham, Department of Pure and Applied Chemistry, Strathclyde 
University, Glasgow), was investigated. Here, representative results 
of a preliminary study are presented. Two experiments were carried 
out in order to test the possibility that the material could be 
beneficial in the chemotherapy of leishmaniasis: the drug was
administered as suspension in the oil at a ratio of 0.01 ml/g of 
body weight subcutaneously, (I) at various dose levels and (II) for 
different numbers of doses. For a direct comparison of the octyl 
degrol oil system with the free sodium stibogluconate, the efficacy 
of the free drug was assessed in parallel using the experimental 
model of leishmaniasis. The experimental procedure for the infection 
of mice and the determination of the antileishmanial activity was as 
described earlier (section 2.). The treatment regimen and the 
results obtained are given in Table 30 and Figures 36 and 37.
In the first experiment (Table 30, Figure 36), infected mice 
were treated with a single dose of sodium stibogluconate 
(Pentostam^) at dose levels ranging from 200 mg/kg to 25 mg/kg. 
Statistical analysis of the results showed that the drug in 
suspension with the oil gave significantly higher suppression of 
parasite numbers than the free drug, at each dose level tested 
(F (1,8 8 ) =3«7, P<0.05), indicating that the oil had a beneficial
effect. However, there was no significant difference in effect 
between the different dose levels tested.
In the second experiment, Pentostam(^) was administered for 
different numbers of doses (Table 30, Figure 37) given at two days 
intervals so that the last dose was on day 20 after infection 
(DAI). Statistical analysis of data showed that treatment effects
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Table 30
The effect of Pentostam, as free drug and with octyl degrol oil,
against L. donovani in mice.
I. Different dose levels of Pentostam
TREATM ENT REGIM EN
Infection —.  13 day* —► |P | P | P | P I —*• 0
DO D14 D17 D21
PENTOSTAM DOSE GROUP S IZ E % S U P P R E S S IO N
(m g/kg)
2 0 0 6 5 0 .0 4 1 3 .9
1 00 6 4 7 .5 * 1 6 .6
FR EE 5 0 6 5 7 .4 * 1 9 .4
25 6 5 6 .0 * 2 1 .6
2 0 0 6 6 9 .7 4 2 0 .2
1 00 6 7 4 .5 4 1 6 .0
W IT H  O C TYL 50 6 5 3 .5 4 2 5 .7
DEGROL O IL 25 6 4 6 .8 4 1 4 .6
O C T Y L  DEGROL O IL  C ONTROL 6 1 0 .5 4 25 .1
II. Different length of treatment time with Pentostam
Infection (DO) 10 day* —►
o o o o o o o o o o 0
D24
DRUG
O c ty l Degrol O il
%  SUPPRESSION 
- 4 9 .1  i 7 9 .2
Infection (DO) 10 day* —«■
|P| I iPl I |P| I |P|
D ll D14 D17 D20
0
D24
DRUQ
Pentostam
% SUPPRESSION 
8 .8  i  4 3 .1
Infection (DO) 10 day*
D ll D14 D17 D20
DRUQ COMBINATION % SUPPRESSION
2 4 .4  ♦ 3 4 .5
0
D24
Pentostam  ♦ O c ty l 
D egrol O il
Infection (DO) 10 day*
Infection (DO)
|P| I
10 day* —►
1 1 0 - 0  
D24D20
DRUQ
Pentostam
%  SUPPRESSION 
15 .0  i 4 1 .7
DRUQ COMBINATION
Pentostam  ■» O c ty l 
D egrol O il
-  0
D20 D24
% SUPPRESSION 
5 2 .8  i 4 3 .7
Infection (DO)
Infection (DO) —► 10 d*y*
—  M  I kl 0
D24
DRUQ
Pentostam
% SUPPRESSION
- 4 .6  * 4 6 .4
DRUQ COMBINATION
Pentostam  *  O c ty l 
Degrol O il
-  0  
D20 D24
% SUPPRESSION 
3 2 .6  1 1 4 .9
Infection (DO) —> 10 day* —.
—  0 — 0  
D20 D24
DRUQ % SUPPRESSION
Pentostam  - 1 0 .0  ♦ 2 5 .0
Infection (DO)
DRUQ COMBINATION
Pentostam  + O c ty l 
Degrol O il
1 0
D24
%  SUPPRESSION
4 5 .0  t 2 4 .0
0  : Pentostam  25 mg/kg 
0 :  O c ty l Degrol O il .01 m l/g  
0  : K ill ‘ Group size: 6
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Fig. 36. Comparison of Pentostam (P) and (P) /  Octyl Degrol Oil (O) on
L. donovani -  infected Balb/c mice. I. Various dose levels of Pentostam.
Percentage reduction in liver parasite load 
compared to controls —
A: O c ty l D egro l oil (O ) B: (P )I C: (P)1 + (O ) D: (P )2  E: (P )2  + (O )
F: (P )3  G: (P )3  + (O ) H: (P )4  I: (P )4  + (O )
(P)1 : 1 x 2 0 0  m g/kg (P )2  : 1 x 100 m g/kg (P )3  : 1 x 5 0  m g/kg (P)4 : 1 x 2 5  m g/kg
Fig. 37. Comparison of Pentostam (P) and (P) /  Octyl Degrol oil (O) on
L. donovani -  infected Balb/c mice. II. Various numbers of doses of
60 
40 
20 
0 
-20 
-4 0  
-6 0
A: Octyl Degrol oil (O) B: Pentostam (P)1 C: (P)1 + (0) D: (P)2 
E: (P)2 + (O) F: (P)3 G: (P)3 + (O) H: (P)4 I: (P)4 + (O)
(P)1 : 4 x 2 5  m g/kg (P )2  : 3 x 25  mg/kg (P )3  : 2 x 2 5  m g/kg (P )4  : 1 x 25  m g/kg
Pentostam.
Percentage reduction in liver parasite load 
compared to controls
using the drug in oil, were significantly better than the effects
produced by the free drug (F (i^ gg) =23.3, P<0.05). However, no
significant difference was observed between the different lengths of 
treatment time at the dose level tested.
3.6. ASSESSMENT OF THE ANTILEISHMANIAL ACTIVITY OF DNA 
INTERCALATORS, PLATINUM AND RHODIUM DRUG COMPLEXES AND 
8-HYDROXYQUINOLINE COMPOUNDS, AGAINST PROMASTIGOTES OF L. DONOVANI
A number of experimental compounds, available for testing as 
potential antitrypanosomals, were screened as potential 
antileishmanials against promastigotes of L. donovani. These 
included a number of DNA intercalators (diminazene derivatives), 
platinum and rhodium drug complexes and 8-hydroxyquinoline 
compounds. The microscopically observed effects of these compounds 
upon the growth of L. donovani promastigotes are summarised in 
Table 31, Figures 38, 39 and 40. The extent of growth inhibition, as 
assessed after 5 days of incubation, was dependent upon drug 
concentration and group and/or compound used. With the exception of 
BSU-1041, all the DNA intercalators showed interesting 
antileishmanial activity (Table 31, Figure 38). BSU-1021 ^ ( 7 ^1 5 ) = 
802.9, P<0.05), BSU-1006 (F (7 f 1 5 ) )=1798, P<0.05), BSU-1030
<F(7,15)S7041.9, P<0.05) and BSU-1002 (F (7 # 1 5 ) =29.1, P<0.05)
appeared to be very active, giving 100% reduction at concentrations 
5 Mg/ml and above. In contrast, BSU-1041 showed some activity at 
concentrations ranging between 10-100 Mg/ml (F(7 f 3.5 )=7.8 , P<0.05). 
Growth of L. donovani was relatively unaffected by the platinum and 
rhodium drug complexes even at the highest concentration tested 
(100 |ig/ml) (Table 31, Figure 39). Only Rh(III)-BT showed some 
activity, giving only 25% inhibition of growth at 100 |ig/ml. All 
the 8-hydroxyquinoline compounds showed very good antileishmanial 
activity giving up to 100% reduction. Compound 1 (F (7 f 1 5 )=1084, 
P<0.05) and compound 2 (F (7 f 1 5 ) =109.8, P<0.05) showed similar
activities giving 100% reduction at concentrations 2.5 |ig/ml and
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Table 31
The effect of a number of DNA intercalators, platinum and rhodium drug
complexes and 8-hydroxyquinolines, at various concentrations, against
L. donovani promastigotes.
I. DNA INTERCALATORS
Drug conc. P ercen tage  red uction  com pared to c on tro ls
|ug /  ml BSU-1041 BSU-1021 B S U -1006 B S U -1002 B S U -1037 B S U -1030
100 2 8 .5  * 1 1 .4 100 100 100 9 7 .0  t 0 .7 100
SO 2 2 .4  1 0 .7 9 9 .5  t 0 .2 100 100 9 6 .7  t 1.2 100
25 1 8 .2  t 1 .5 9 9 .2  ± 0 .2 100 100 88.8 i  0 .3 100
10 1 7 .3  i  6 .6 9 8 .7  ± 0 .2 100 100 3 3 .4  ± 0 .7 100
S 14.1  ♦ 0 .4 9 6 .6  i  2 .4 9 8 .7  t 0 .7 7 8 .5  ± 7 .9 1 5 .2  i  1.5 9 9 .4  ± 0.1
2 .5 1 1 .5  i  0 .4 6 5 .0  - 3 .3 3 4 .4  t 1 .8 3 8 .6  * 12.1 8 .7  1 1.0 4 0 .7  t 3 .2
1 .2 5 1.9  1 1.1 2 9 .1  ♦ 0 .5 0 .7  i  4 .6 1 1 .3  - 2 5 .3 - 0 .7  i  1.0 2 6 .1  i  0 .8
C ontro l 2 9 6 8 .0  1 7 .3 2 8 3 3 .5  i  9 8 .3 2 9 4 9 .0  t 9 9 .7 2 8 1 4 .O i 7 2 .1 2 9 3 8 .0 -  1 7 .0 3 0 4 1 .0  i 9 8 .9
II. PLATINUM  AND R HO DIUM  DRUG C O M P LE X E S
Drug conc. P ercentage reduction  com pared to c on tro ls
pg /  ml p t(ll)-D A P -S S H S p t(ll)-D A P -S D I R h (lll) -E th y l-X a n th a te R h (lll)-B T
100 2 .9  1 1.8 - 0 .4  ± 3 .2 0 .7  i  1 .3 2 3 .5  i 1 0 .7
5 0 1.9  i  1.6 2 .5  ♦ 1 0 .5 - 0 .0 2  * 1 .5 7 .1  i  1 9 .4
2 5 3 .9  t 5 .1 1.6 i  2 .1 1 .0  *  5 .3 3 .7  * 7 .5
10 3 .4  * 0 .7 2.1 ♦ 0 .5 - 1 .9  * 2 .4 1.1 ± 0 .4
5 3.1  * 3 .4 4 .3  t 9 .6 - 1 .2  ± 0 .3 0 .1  - 0 .4
2 .5 2 .3  - 2 .8 - 1 .2  - 0 .6 - 4 .0  t 2 .0 - 0 .9  - 0 .4
1 .2 5 3 .0  t 0 .1 - 1 .4  i  0 .1 - 3 .7  i 1 .0 - 0 .7  t 1 .0
C ontro l 2 4 0 2 .0  1 6 8 .0 2 3 5 4 .0  t 4 .0 2 3 4 2 .0  -  2 .1 2 3 6 2 .0  i  3 6 .1
II I .  8 -H Y D R O X Y Q U IN O L IN E S
Drug conc. Percentage  reduction  com pared to co n tro ls
pg /  ml Com pound 1 Com pound 2 Com pound 3 Com pound 4
100 100 100 100 100
5 0 100 100 100 100
2 5 100 100 100 100
10 100 100 9 3 .7  i  4 .4 9 3 .3  ± 2 .3
5 100 100 5 .6  ± 4 .3 5 .4  - 4 .8
2 .5 9 0 .3  i  11.9 9 3 .7  ± 9 .7 1 .0  ± 1.7 4 .5  ± 2 .8
1 .2 5 2 .5 7  i 2.1 1 1 .6  * 1 2 .5 -1 .1  1 1.9 2 .3  i  4 .3
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Fig. 38. The effect of DNA intercalators against promastigotes of
L. donovani.
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Fig. 39. The effect of platinum and rhodium drug complexes against the
promastigotes of L. donovani.
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above whereas compound 3 (F (7 f 1 5 )=45.2, P<0.05) and compound 4
(F (7 ,1 5 ) =51.1, P<0.05) were also giving 100% reduction at
concentrations of 10 |ig/ml and above (Table 31, Figure 40).
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Fig. 40. The effect of 8-hydroxyquinoline compounds against the
promastigotes of L. donovani.
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4. DISCUSSION
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4.1. EXPERIMENTAL METHODS USED
Promastigotes similar to the stages of Leishmania that occur in the 
sand-fly can be cultivated easily in a wide range of media, with 
high yields of organisms and for this reason have been used
extensively for biochemical, immunological and drug screening 
experiments (Hendricks and Childs, 1980). They do not, however,
represent the parasite form present in the mammalian host and their
drug susceptibility, as reported in many early chemotherapy screens, 
contrasts markedly with that of the amastigote, most importantly to 
the clinically used pentavalent antimonials - sodium stibogluconate 
(Pentostam^) and meglumine antimoniate (Glucantime^) (Croft, 1988). 
It is possible, however, that this in vitro model can provide useful 
information on the drug sensitivity of the parasite and may prove 
useful in studies on the mechanisms of drug action. For this
reason, promastigotes of L. donovani were used in this study, in 
testing the antileishmanial activity of a number of potential 
metabolic inhibitors of trypanothione metabolism as well as a
limited number of other potentially antitrypanosomal compounds.
Amastigote infections of macrophages respond to the clinically 
used antileishmanial compounds (the pentavalent antimonials, 
amphotericin B and pentamidine) and so this model resembles more the 
situation of the parasite in vivo than do promastigotes in vitro. 
Thus this test has good predictive value for antileishmanial 
activity and it is also possible that it can provide some
information on the role of the host cell as well as the importance
of parasite form in determining the drug sensitivity of the 
parasite. Also, since the aim of future drug development for
leishmaniasis is to find less toxic drugs, any toxicity signs to 
the macrophage per se will be a useful indication that the drug 
under consideration may have potentially toxic side effects. In 
this study, two methods of assessing antileishmanial activity using 
this model have been used: determining the proportion of macrophages 
which become infected with parasites and the mean number of 
amastigotes per infected macrophage.
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The culture technique used to support growth of intracellular 
L. donovani amastigotes in mouse PECs was a modification of that 
described by Neal and Croft (1984). Using this method, infected 
macrophages were 76-98% infected with amastigotes and each infected 
macrophage contained a mean number of 8.1 + 1.0 amastigotes at the 
end of the experiment. These numbers are higherthanthose reported by 
Neal and Croft (1984), although the ratio of infecting amastigotes 
to macrophages was lower and the incubation period was shorter in my 
experiments. This difference in infectivity may be attributed to the 
different origin of peritoneal macrophages and the procedure which 
was used in order to obtain them. The different strain of parasite 
and the different culture conditions may also have contributed to 
observed differences (i.e. 20% HIFCS).
For convenience of handling, laboratory animal house space and 
economical use of drugs, the in vivo model used in this study was 
visceral leishmaniasis in inbred Balb/c mice and not the classical 
hamster model established by Stauber (1958). Bradley and his
colleagues have shown (1972; 1977) that a number of inbred mouse
strains are highly susceptible to infection by the intravenous route 
and mouse models have been employed for recent chemotherapeutic 
studies by several workers (Black ££. » 1977; New ££. ., 1978;
Trotter q ! ., 1980a; Bray, 1987; Neal, 1987; Hunter £t. &1., 1988). 
The mouse strains fall into two categories on the basis of liver 
parasite counts at the end of the 1st or 2nd week after infection 
which is referred to as the "acute phase" of the infection (Bradley 
and Kirkley, 1977). Among those mouse strains allowing rapid 
parasite proliferation during acute phase, the subsequent course 
also varies and some mice recover completely (i.e. NMRI) while 
others (i.e. B10.D2) support a continually increasing amastigote
load during this second phase which is referred to as the "chronic 
phase" of infection. This distinction between acute and chronic 
phases is important for subsequent analysis and comparison of 
results from chemotherapeutic studies and it must be also take into 
account that the clinical and not the subclinical cases of visceral 
leishmaniasis are more difficult to treat with the standard drug
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treatments (see section 1.2.). The Balb/c mouse strain is 
susceptible to infection with L. donovani and carries the H-2^/^ 
haplotype which is associated with persisting heavy infection, with 
the prediction that the majority of infected mice will succumb by 
130 days after infection (Blackwell ££. ul.., 1980; Bradley, 1987). 
The prime need in any iji vivo chemotherapeutic study is an 
experimental model which reflects the disease, at least in certain 
essentials, in humans and dogs, and in this respect the chronic 
Balb/c mouse model was found suitable for this study. The pattern 
of infection in the L. donovani-Balb/c visceral leishmaniasis 
model observed in th,is study was similar to that described by 
Blackwell ££. & l . (1980).
4.2. TRYPANOTHIONE METABOLISM AS A CHEMOTHERAPEUTIC TARGET FOR 
LEISHMANIASIS: THE EFFECT OF COMPOUNDS THOUGHT TO INHIBIT
TRYPANOTHIONE METABOLISM IN VIVO AND IN VITRO
Drugs designed against those parasitic enzymes which are essential 
for the survival of the parasite and absent from the host, are 
widely regarded as a rational approach to chemotherapy. Recent work 
in trypanosomatids has shown that trypanothione metabolism meets 
these criteria and its potential role as a chemotherapeutic target 
is highlighted by the fact that a number of trypanocidal drugs such 
as DFMO (Bacchi £t sJl. , 1983; Bacchi and McCann, 1987; Fairlamb 
et al.. 1987; Bellofatto £t. al., 1987) and arsenicals (Fairlamb 
et al.. 1989) interfere with the metabolism and functions of this 
important metabolite. Moreover, current research in the chemotherapy 
of experimental trypanosomiasis (Jennings, 1988a, b; Jennings, 1990) 
supports the hypothesis that a number of compounds thought to 
interfere with polyamine/trypanothione metabolism are likely to act 
synergistically. These findings are consistent with the concept that 
the trypanothione oxidation-reduction system of the trypanosomes is 
the main target of these drug combinations (Henderson and Fairlamb, 
1987; Jennings, 1990). DFMO blocks the polyamine biosynthetic 
pathway at ornithine decarboxylase and so gradually the pool of
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trypanothione is reduced. Trypanothione can react irreversibly with 
the arsenicals to give the Mel-T adduct (Fairlamb et al., 1989) and 
therefore, the efficiency of arsenical treatment should depend upon 
the pool of trypanothione present at the time of arsenical 
chemotherapy and on how quickly it can be replaced by biosynthesis. 
Since arsenicals combine with trypanothione and effectively remove 
it from the system, a stage should be reached when it requires only 
minimal quantities of the arsenical drug to complete the destruction 
of the parasite. For this reason it has been suggested (Jennings, 
1990) that a period of DFMO treatment is required before the 
arsenical is given, so that the depletion of trypanothione pool can 
take place. For the same reason it has been suggested to give the 
arsenical towards the end of the DFMO therapy (Jennings, 1990).
As arsenic and antimony are similar in some ways, another 
possibility is that antimony could replace the arsenic in the 
trypanocide (Jennings, 1990). This was initially recognised by 
Friedheim (Friedheim, 1953) who prepared analogues of melarsen (MSb) 
and melarsoprol (MSbB). These compounds were very effective against 
I. gambiense trypanosomiasis (Friedheim, 1953), however, were never 
exploited. In view of this, the possible potentiation of the 
existing available antimonial compounds with DFMO was investigated 
(Jennings, 1988a, b; Jennings, 1991a, b) but the potentiation 
observed against T. brucei. although 100% cures could be obtained, 
was not as obvious as that found with the arsenical compounds. 
However, no cures with antimonial monotherapy were obtained in the 
CNS-trypanosomiasis mouse model (Jennings, 1990; 1991a, b).
The synthesis of trypanothione can also be affected by blocking 
the polyamine pathway at S-adenosylmethionine decarboxylase 
(SAM-decarboxylase) by the guanylhydrazones (Ulrich al., 1982;
Ulrich and Cerami, 1984) and also by diminazene diaceturate 
(Berenil^) and pentamidine (Lomidine^). Jennings e£. al» (1987), 
obtained cures of CNS-trypanosomiasis with a combination of DFMO and 
1,3,5, triacetylbenzene tris (guanylhydrazone) trihydrochloride 
(i.e. TBG) and it has been also shown (Jennings, 1988a, b) that it 
was possible to reduce the DFMO administration period by using a
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combination of DFMO, TBG and the arsenical melarsoprol and still 
obtain satisfactory cure rates.
Diminazene diaceturate, as well as binding to DNA, also affects 
SAM-decarboxylase (Bitonti jat al., 1986a, b) and has been reported 
to be potentiated by DFMO (Bacchi and McCann, 1987; Jennings, 1990).
Another way of embarrassing the trypanothione oxidation- 
reduction pathway of trypanosomes could be by increasing the amount 
of peroxide which has to be detoxified by this system. A number of 
nitro-compounds such as nitrofurans and nitroimidazoles have been 
reported to undergo "futile redox cycling" producing oxygen radicals 
and hydrogen peroxide (Henderson ££. al., 1988). If this is so, then 
the combination of such nitroimidazoles with any of the potential 
other inhibitors of trypanothione metabolism such as for instance 
the arsenical drugs, should be synergistic. A combination of the 
5-nitroimidazoles, MK 436 (12.5 mg/kg), L634,549 (25 mg/kg) and
fexinidazole (30 mg/kg) all were curative when used with a dose of 
2.5 mg/kg Trimelarsan (Jennings, 1990).
The above mentioned compounds including DFMO, a number of
2-nitroimidazoles and 5-nitroimidazoles, guanylhydrazones, the 
diamidine Berenil(^), the arsenical Trimelarsan (^) and also the 
pentavalent antimonial sodium stibogluconate (Pentostam^) and 
buthionine sulfoximine (BSO), have been used in this study in 
order to test if they are similarly synergistic against Leishmania 
species and in particular L. donovani. as they have been shown to 
be against T. brucei. Suramin has also been included as it has been 
shown to act synergistically with the 5-nitroimidazoles against 
CNS-trypanosomiasis (Jennings £JL &!• > 1983).
4.2.1. THE NITROIMIDAZOLES
4.2.1.1. The nitroimidazoles in monotherapy experiments in vitro 
and in vivo
Nitroheterocyclic compounds are known for their selective toxicity 
towards anaerobic and micro-aerophilic organisms although several 
are active against supposed aerobes (Hamilton-Miller and Brumfitt,
118
1976; Coombs, 1977; Muller, 1981; Hof gt il., 1986).
Susceptible anaerobes such as trichomonads, are assumed to 
reduce the nitro-group of these drugs in ferredoxin-linked reactions 
leading to the formation of cytotoxic products (Moreno ££. al. f 
1984). Against African trypanosomes, nitro-compounds are thought to 
exert their cidal action by "futile redox-cycling" (Docampo and 
Moreno, 1984). Several of these compounds, such as the
5-nitroimidazoles and 2-nitroimidazoles, have been reported to have 
useful antitrypanosomal activity when used alone (Jennings and 
Urquhart, 1983; Jennings et. al., 1984) or in combination with other 
compounds (Jennings and Urquhart, 1983; Jennings at. al., 1984;
Zweygarth and Rottcher, 1987a, b; Jennings, 1988a, b; Jennings,
1990). The results of chemotherapeutic studies (Jennings and 
Urquhart, 1983) with three of the 5-nitroimidazoles, L611,744, 
L634,549 and MK 436, against early (3-day) mouse infections of 
X. brucei showed them to have varying trypanocidal activities and 
confirmed the initial observations of Cuckler aL al« (1970) on the 
anti-trypanosome activity of nitroimidazoles.
The 5-nitroimidazole MK 436 was found to be fully effective
at less than 250 mg/kg/day in treating the chronic and acute stage 
of Chagas disease in mice and in dogs (Miller at &!• > 1979; Wyvratt, 
1990). At therapeutic doses, the compound appeared superficially to 
be free from toxic effects (Malanga at fll•, 1981). It was effective 
against T. cruzi-infections unresponsive to nifurtimox and 
benznidazole (Wyvratt, 1990). In three months oral toxicity studies 
in rats at the level of 3000 mg/kg/day, a number of drug-related 
toxic effects were observed. MK 436 was found to be mutagenic in the 
Ames test and in some in vivo cytogenic tests (Wyvratt, 1990).
MK 436 was also tested against L. donovani in mice in this 
study and showed interesting but not curative antileishmanial
activity (Table 5, Figure 6).
Among the nitroheterocyclic compounds tested against leishmanias 
were the nitroimidazoles metronidazole and benznidazole. 
Metronidazole, a 5-nitroimidazole, has been reported to have good 
activity against L. m. mexicana in hamster peritoneal exudate cells
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when the compound was at very high concentrations (Mattock and 
Peters, 1975b) but it was found to be inactive on L. infantum in 
NMRI mice (Peters at. al., 1980a). Moreover, Keithly and Langreth 
(1983) tested the drug against L. donovani and L. mexicana in 
hamsters and found no activity against either. Neal and Croft (1984) 
also tested the activity of metronidazole against L. donovani in 
mouse peritoneal exudate cells and found it totally inactive. 
Metronidazole has been tried in the treatment of patients with 
cutaneous leishmaniasis (Wahba and Cohen, 1977) and Ethiopian 
mucocutaneous leishmaniasis (Belehu £& sX 1978) but without any 
success. In this study metronidazole was found to be ineffective 
against growing promastigotes, in agreement with the earlier results 
(Table 3, Figure 4).
There have been differing reports concerning the antileishmanial 
activity of the 2-nitroimidazole, benznidazole. Peters gt. al. 
(1980a,b) found it to be inactive against L. infantum in mice, but 
active against L. major and L. m. amazonensis in mice and tissue 
culture and it has been suggested that this compound may be useful 
in treating the cutaneous disease. In this study, benznidazole was 
found to be inhibitory to growing promastigotes, but only at the 
highest level tested (100 pg/ml) (Table 12, Figure 13).
Other nitroimidazoles tested in this study were the 
5-nitroimidazoles, L611,744, fexinidazole, L634,549, Go 10,213 and 
dimetridazole and the 2-nitroimidazoles Ro 15-0216 and Ro 15-6547. 
There were not any previous reports on the activity of these 
nitroimidazoles against Leishmania species. The majority of the 
nitroimidazoles tested in this study, showed better activity 
in vitro, giving up to 100% reduction in parasite numbers, than 
in vivo. It may be possible to attribute this to differences of 
their catabolism by the host (i.e. pharmacokinetic profiles) and/or 
to pharmacokinetic problems limiting exposure of the parasite to the 
drug. With the exception of benznidazole, the 2-nitroimidazoles 
showed relatively better activity (Table 12, Figure 13) than the 
5-nitroimidazoles (Table 3, Figure 4). This correlates well with the 
fact that the 2-nitroimidazoles can be reduced more easily than the
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5-nitroimidazoles by the cells. With the exception of dimetridazole, 
all the nitroimidazoles showed interesting antileishmanial activity 
in vivo (60-80% reduction in liver parasite loads).
The in vivo activity of the 2-nitroimidazole, Ro 15-0216 was 
less than that of the 5-nitroimidazoles and was apparently dose
independent (Table 13, Figure 6). This was almost certainly due to 
its more rapid metabolism by the host (see also section 4.2.1.2.e). 
Experiments in dogs and sheep revealed a short half-life for
Ro 15-0216 (unpublished observations quoted by Zweygarth and 
Rottcher, 1987a).
The trypanocidal activity of Ro 15-0216, has been previously 
tested in stocks of T. b* brucei. T. b» evansi. T. vivax and
T. congolense and T. simiae (Zweygarth and Rottcher, 1987a, b),
revealing different sensitivities. Due to the short half life, 
administration of the compound continuously in the drinking water 
was superior to a single intraperitoneal injection (Zweygarth and 
Rottcher, 1987a). Ro 15-0216 has also shown promising activity 
against acute infection of rats with T. rhodesiense and
X. gambiense, remarkable activity against chronic X* rhodesiense in 
rabbits, but inconsistent results were obtained with X* rhodesiense 
in vervet monkeys (Stohler, 1990). Acute infections of sheep with 
X. brucei. X* evansi and X« congolense. also responded well to
treatment (Stohler, 1990). Acute and chronic infections of sheep 
with X. brucei as well as chronic infections showing CNS involvement 
were cured by treatment for six days. In vitro. only low 
concentrations were required to inhibit growth of X* rhodesiense, 
X. gambiense. T. congolense or X» vivax (Stohler, 1990).
Ro 15-0216 has not been reported, so far, to show any
pharmacological properties which might preclude its use in man. It 
had low acute oral toxicity in mice, rats and dogs .after oral
administration, and was well tolerated in rats at 300 mg/kg/day and 
dogs at 50 mg/kg/day in 13-week oral tolerance studies (Stohler, 
1990). In pharmacokinetic studies of Ro 15-0216 in mice, rats, dogs 
and sheep, important species differences were observed (Stohler,
1990). A major drawback of the compound is that it was mutagenic in
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the Ames test (£. typhimurium) and induced genetic damage in 
S.. cerevisiae in the range 0.3-3 Hg/ml (Stohler, 1990).
The 5-nitroimidazole, fexinidazole differs from other standard 
compounds of the same type by its high activity against T. cruzi r 
lower toxicity and comparative ease of chemical synthesis (Raether 
and Deutschlander, 1979; Raether and Seidenath, 1983). Like all
5-nitroimidazoles, it exhibits a strong in vitro and in vivo action 
on trichomonads and Entamoeba histolytica and was also found to be 
moderately active against several gastrointestinal nematodes 
(Raether and Seidenath, 1983). In this study, it has shown 
interesting antileishmanial activity against L. donovani. being 
superior to the other nitroimidazoles tested in vivo (Table 5, 
Figure 6). This, however, was not unexpected since it has been 
reported (Raether and Seidenath, 1983) to possess perfect 
requirements concerning stability and metabolisability and its main 
metabolites proved to be as active as the parent compound.
Various toxicological studies have been carried out with 
fexinidazole. The compound was well tolerated in mice, rats, 
guinea-pigs, rabbits and dogs and there is a wide range between the 
effective and the maximum tolerated doses (maximum oral dose: 10,000 
mg/kg body weight) (Raether and Seidenath, 1983). In this study it 
was shown to be well tolerated in mice (4 x 200 mg/kg) but it proved 
toxic to macrophages at concentrations of 50 fig/ml and above. These 
concentrations, however, are far higher than those that can be 
attained in serum (1.3 + 0.1 |Jg/ml). Fexinidazole, like other
nitroimidazoles, was shown to be mutagenic in various strains of 
bacteria at concentrations ranging from 2 to 500 Mg/ml (Gericke, 
referred to in: Raether and Seidenath, 1983).
The in vitro and in vivo results for the nitroimidazoles showed 
that many of these compounds have an interesting antileishmanial 
activity when used as monotherapy. Used in the experimental mouse 
model, they have shown no toxic effects and can be given at dose 
levels as high as 1 g/day. A number of similar drugs such as 
metronidazole and dimetridazole, used in the treatment of 
trichomoniasis and other protozoal and anaerobic bacterial
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infections, are also mutagenic to bacteria in other tests under 
anaerobic conditions, although it is considered by some that these 
tests have no predictive value as regards the mutagenic risk for man 
(Boisseau, 1987, personal communication). Metronidazole (Flagyl^) 
for instance, which is widely used in human medicine, is Ames test 
positive and yet has been used at relatively high dose rates and for 
prolonged treatment periods without any major side effects. 
Nevertheless, such mutagenic compounds are unlikely to be selected 
for treatment of human disease. It is possible, however, that they 
could be used for treating the disease in dogs. My results suggest 
that some of the nitroimidazoles are worth pursuing as possible 
drugs against canine leishmaniasis. The 2-nitroimidazole, Ro 15-0216 
which cured T. b* brucei infection in sheep, is under further 
development as antitrypanosomal agent (WHO, 1989).
Unfortunately, the other nitroimidazoles which have been used 
in this study are not generally available, as the pharmaceutical 
companies which produced them have suspended their development. 
Thus, it now seems probable that there is little prospect that they 
will be developed for clinical use either as antitrypanosomal drugs 
or as antileishmanials.
4.2.1.2. The nitroimidazoles in combination experiments ija. vitro 
and in vivo
The main approach of this project was to evaluate combination 
therapy using compounds thought to interfere with trypanothione 
metabolism. Large effects were observed although in no case were all 
the parasites eradicated. The following combinations were tested in 
this work.
4.2.1.2.(a) Effect of the 5-nitroimidazoles against L. donovani in 
mice in combination with DFMO
There are no previous reports on the combination of DFMO with 
5-nitroimidazoles against Leishmania species. These combinations 
have been shown to cure experimental murine T. brucei CNS-infections 
(Jennings, unpublished results).
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In this study, however, no potentiation was observed (Table 6, 
Figure 7). In some experiments this could have been due to the fact 
that the percentage suppression obtained with the 5-nitroimidazoles 
as monotherapy was very high and therefore DFMO addition could not 
show any potentiation. Only the combination involving the 
nitroimidazole MK 436, which gave the lowest suppression value as 
monotherapy, and DFMO resulted in a significant increase in 
efficacy. Probably, lower dose levels of the 5-nitroimidazoles and 
DFMO were required in order to determine whether or not these 
compounds are additive or synergistic.
The 5-nitroimidazole L611,744, which was available in sufficient 
quantity, was studied in a greater detail in combination therapy 
with DFMO. The results produced gave conflicting evidence of 
potentiation. This could have been caused by the lack of DFMO intake 
control (see also section 4.2.4.I.), which in this experiment 
resulted in a wide variation in the % suppression caused by DFMO. It 
may also have been influenced by the 5-nitroimidazole and the dosage 
regimen used. Four doses of L611,744 at 200 mg/kg gave a significant 
increase when used with DFMO (Table 8, Figure 9), while 12 daily 
doses of 100 mg/kg gave only a marginal increase (Table 7, Figure 
8). Thus, giving the nitroimidazole at higher dose levels and for a 
shorter period of time, at the end of DFMO therapy, appeared to be 
more beneficial. This suggests that an initial reduction of the 
trypanothione pool by DFMO is necessary and therefore giving the 
nitroimidazole at the end of DFMO therapy when the trypanothione 
pool has been reduced, makes the combination more effective.
4.2.1.2.(b) Effect of the 5-nitroimidazole L634,549, diminazene 
diaceturate (Berenil^) and melarsonyl potassium (Trimelarsan^), 
alone and in combination, against L. donovani in mice 
The results of chemotherapeutic studies against chronic mouse 
infections of T. brucei with two 5-nitroimidazoles, MK 436 (80 
mg/kg) and fexinidazole (30 mg/kg), showed them to be effective at 
four daily doses, when administered in combination with diminazene 
diaceturate (Berenil^) (Jennings gJL al., 1980). Also MK 436 (12.5
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mg/kg), L634,549 (25 mg/kg) and fexinidazole (30 mg/kg) all were 
curative when combined with doses of melarsonyl potassium 
(Trimelarsan^) (2.5 mg/kg) (Jennings, 1990; Jennings, 1991a). None 
of these drugs administered singly at these levels produced any 
permanent cures although a high percentage of the mice could be 
cured with four doses of fexinidazole at 250 mg/kg.
L634,546 and Trimelarsan have not been tested for activity 
against Leishmania species before. In this study, the activity of 
Berenil (Table 9, Figure 10) was similar to that reported 
previously (Keithly and Fairlamb, 1988). The 5-nitroimidazole, 
L634,549 markedly suppressed the number of parasites present in the 
liver but in no instance there was a complete suppression of the 
infection (Table 9, Figure 10). Combination of these compounds did 
not improve their ability to suppress infection. It seems likely 
therefore, that if these drugs act against similar targets in
trypanosomatids as has been hypothesised, they are either not
effective inhibitors of these targets in leishmanias, or they do not 
readily get to the targets. It is also possible that the importance 
of these metabolic reactors is not so crucial to survival and growth 
in leishmanias as it is in trypanosomes.
4.2.1.2.(c) The effect of the 5-nitroimidazoles MK 436, L634,549 
and fexinidazole and suramin, alone and in combination, against 
L. donovani in mice
These combinations did not improve the ability of the single
compounds to suppress experimental infections of mice with
L. donovani (Table 10, Figure 11). Permanent cures, however, were 
obtained in a mouse model of T. brucei CNS-trypanosomiasis when 
treatment was carried out with suramin (20 mg/kg) followed by 4 
consecutive daily doses of 250 mg/kg MK 436 or 70 mg/kg L634,549 or 
80 mg/kg L611,744 (Jennings aJL., 1983), or 30 mg/kg fexinidazole 
(Jennings and Urquhart, 1983), even though, none of these drugs 
administered singly elicited 100% permanent cures.
More recently Arroz and Djedje (1988) experimented with a 
combination of suramin and metronidazole, which had shown promise in
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mice (Raseroka and Ormerod, 1985; 1986), in a moribund patient with 
multidrug-resistant T. &. rhodesiense. The initial apparent cure, 
however, was followed by a relapse 3 weeks after the end of 
treatment.
Based on previous work in trypanosomes (see section 4.2.), a 
plausible hypothesis can be formulated for synergism between DFMO, 
arsenicals, diamidines and nitroheterocyclic compounds. However, 
this is not the case for suramin. Suramin may not have a clearly 
defined single target site of action since it inhibits a large 
number of enzymes (Fairlamb and Bowman, 1980). An early event noted 
previously is the progressive inhibition of glycolysis and 
respiration (Fairlamb and Bowman, 1977; Fairlamb and Bowman, 1980). 
More recently, suramin has been also shown to displace low density 
lipoproteins (LDL) from surface receptors of mammalian cells as well 
as that of trypanosomes (Furlong, 1989; Coopens £t al •, 1989). None 
of these observations, however, offer a clear biochemical link with 
the effects of the other classes of trypanocidal compounds. Despite 
this, suramin was screened in this study because of its known 
trypanocidal action, for any effects on polyamine and thiol 
metabolism in leishmanias. There is only one previous report on 
suramin as monotherapy and in combination against Leishmania species 
(Keithly and Fairlamb, 1988). Keithly and Fairlamb (1988) reported a 
70% reduction in parasite load by suramin alone when the compound 
was used against L. donovani in mice and this is considerably higher 
than that obtained in this study (34%). However, the standard 
deviation observed and the shorter length of treatment used in this 
study, make a direct comparison difficult. The combination of 
suramin with DFMO (3%) has been reported (Keithly and Fairlamb,
1988) to improve marginally their ability alone to suppress 
L. donovani infections in mice, however, the two compounds were in 
effect less than additive. It seems likely therefore that suramin 
does not affect polyamine and thiol metabolism in leishmanias.
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4.2.1.2.(d) The effect of the 5-nitroimidazole MK 436 given at 
various dose levels alone and in combination with verapamil against 
L. donovani in mice
Verapamil, a cardiac-active calcium antagonist used mainly as a 
coronary vasodilator, has recently been shown to affect drug efflux 
in a multiple drug resistant carcinoma cell line, resulting in drug 
accumulation within the cells (Slater aL a l • > 1982; Rogan al» > 
1984; Fojo at al. 1985). A similar effect was subsequently shown 
with chloroquine-resistant Plasmodium falciparum (Martin gl al» >
1987). It has also been found that in vitro verapamil can reverse 
nifurtimox-resistance in T. cruzi and, although to a lesser extent, 
antimony-resistance in L. donovani (Neal ejt al., 1989).
Verapamil alone appears to have mild antimalarial properties 
in vitro (Jacobs gl al., 1988), but only at toxic levels, and was 
found to be inactive against T. cruzi and L. donovani (Neal al al.,
1989). This was also confirmed for L. donovani in the present
study.
One attempt was made to examine if it was possible to increase 
the effectiveness of the nitroimidazoles by concurrent verapamil 
administration. Verapamil was used in combination with the 
5-nitroimidazole MK 436 (Table 11, Figure 12). The results showed no 
increased effect even when the nitroimidazole was used at the 
highest dose level (4 x 200 mg/kg). At all other levels there was a 
slight increase in percentage suppression which was statistically 
significant only at the dose level of 4 x 50 mg/kg. This suggests 
that verapamil does not significantly affect the concentration of 
the nitroimidazole in the drug-sensitive parasite. This is perhaps 
similar to the finding that verapamil did not exert potentiation of 
the drug effect when used with chloroquine against the 
drug-sensitive strain of P. falciparum (Jacobs at a l . » 1988).
4.2.1.2.(e) In vivo activity of Ro 15-0216 in combination with 
diminazene diaceturate (Berenil^) and melarsonyl potassium 
(Trimelarsan^, Mel W^)
Synergism of Ro 15-0216 (40 mg/100 ml of drinking water x 5 days)
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with diminazene diaceturate (Berenil^) (2.5-4 mg/kg) was 
demonstrated in T. congolense-infected mice resulting in complete 
cure (Zweygarth and Rottcher, 1987a). The combination of Ro
15-0216 with Berenil was also found to be successful in swine 
T. simiae infections (Zweygarth and Rottcher, 1987b). Ten mg/kg of 
Berenil and 50 mg/kg of Ro 15-0216 or 20 mg/kg Berenil and 25 mg/kg 
of Ro 15-0216 were equally effective, while either drug alone was 
ineffective. Multiple administration of compound Ro 15-0216 
(4 x 20 mg/kg; 3 x 50 mg/kg) at 2 hourly intervals did not cure the 
animals. Synergism of Ro 15-0216 with suramin was also demonstrated 
in T. b.. evansi-infected mice, (Zweygarth and Rottcher, 1987a).
In this study, in order to overcome the putative problem of 
rapid metabolism and increase its effectiveness, Ro 15-0216 was 
administered in the drinking water. Observations made by Jennings 
et al. (1984) in T. brucei infections showed that divided doses of 
5-nitroimidazoles were more effective than the same quantity given 
on a single occasion. Combination of Ro 15-0216 with Trimelarsan 
(4 x 30 mg/kg) did not improve the ability of the compounds to 
suppress the experimental infection in mice. When Ro 15-0216 
(20 mg/100 ml of drinking water) was combined with Berenil,
(4 x 40 mg/kg), a small potentiation was observed (Table 14, 
Figure 14).
The lack of efficacy of nitroimidazoles in the experiments 
discussed in section 4.2.1.2. above, suggests that such combinations 
have little potential for development for antileishmanial treatment.
4.2.3. THE GUANYLHYDRAZONES
Guanylhydrazones have received considerable attention as 
antineoplastic agents (Dave al., 1977). Their antineoplastic
activity was thought to be due, at least in part, to interference 
with polyamine biosynthesis via inhibition of mammalian 
S-adenosyl-L-methionine decarboxylase (SAM decarboxylase) (Pegg and 
Hibasami, 1979). Of particular significance was the finding that 
homogenates of T. brucei contained a high specific activity of
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methylglyoxal bis-guanylhydrazone (MGBG)-sensitive SAM decarboxylase 
(Dave £1, £lL •, 1978). The aminopropylation of putrescine to form
spermidine in T. brucei (Bacchi ££. al., 1979) requires
decarboxylated SAM, as is the case in other organisms. In several 
trypanosomatids including T. brucei. the important respiratory 
enzyme Ct-glycerophosphate dehydrogenase is selectively activated by 
spermidine and spermine in vitro (Bacchi gt al., 1978). Thus, the 
guanylhydrazones appeared to be an interesting class of substances 
warranting more extensive screening against African trypanosomes. 
Several aromatic guanylhydrazones have been tested (Ulrich al al. f
1982) for antitrypanosomal activity and significant differences in 
activity demonstrated that the nature of aromatic bridge linking the 
guanylhydrazone units was of considerable importance.
One of these guanylhydrazones, TBG tested against early 
T. brucei infections in mice (Ulrich and Cerami, 1984; Jennings
et al. r 1987) proved to be the most active of all. This was also
found to be the case in this study for L. donovani promastigotes 
in vitro (Table 15, Figure 16). However, in contrast to its
in vitro activity, TBG was found to be less active than the
guanylhydrazone DBG, when tested in, vivo (Table 16, Figures 17 & 
18). This could be due to differences in conformational flexibility 
between these two compounds (Ulrich and Cerami, 1984), with the 
conformation preferred for the uptake system being different from 
that preferred at the active site.
Jennings et q1. (1987) reported that treatment of late T. brucei 
infections in mice with TBG (4 x 15 mg/kg or 4 x 10 mg/kg, twice 
daily) in combination with DFMO (2% soln. for 14 days) or suramin 
(1 x 20 mg/kg) resulted in permanent cures. It has been also shown 
that if DFMO and TBG are combined with arsenical treatment, then the 
period of DFMO administration necessary to cure chronic murine 
trypanosomiasis can be reduced from 14 to 8 days (Jennings, 
1988a, b). In this study, however, combinations of TBG and DBG with 
Pentostam(^) and DFMO did not show any promising potentiation in 
activity against L. donovani in mice (Table 16, Figures 17 & 18).
There is only one previous report on the activity of
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guanylhydrazones against Leishmania species and this referred to the 
activity of MGBG alone and in combination with DFMO against 
L. donovani amastigotes in vitro (Neal and Croft, 1984). In both 
cases MGBG was inactive and in addition, when alone, was toxic to 
macrophages.
The lack of efficacy of the guanylhydrazones tested in vivo in 
this study suggests that these compounds have little to offer as 
antileishmanials. The antileishmanial activity of the compounds 
against promastigotes, however, provides some encouragement that 
other compounds of this series, with different pharmacokinetic 
properties, may have more promise.
4.2.4. TESTING OF OTHER POTENTIAL INHIBITORS OF TRYPANOTHIONE 
METABOLISM
4.2.4.1. DL-GC-DIFLUOROMETHYLORNITHINE (DFMO), (EFLORNITHINER )
DL-Ct-dif luoromethylorni thine (DFMO), a selective enzyme-activated 
irreversible inhibitor of ornithine decarboxylase, is a key enzyme 
for the synthesis of polyamines (Metcalf at al., 1978). It is
effective against T. h. brucei (Bacchi at al., 1980), T. fc..
gambiense (McCann al al., 1981a), T. &. rhodesiense (McCann et al.. 
1981b) and T. congolense (Karbe al al»» 1982) in mice.
DFMO has been extensively used against the Gambian form of human 
sleeping sickness with promising results. It was effective against 
the early and late stages of the disease and also against
arsenical-refractory cases (Van Nieuwenhove et. al., 1985).
DFMO acts synergistically with a variety of commercial 
trypanocides against early stages of murine T. 1. brucei infections 
(McCann at al* > 1983). Combination of DFMO with suramin (Clarkson 
at al., 1984), melarsoprol (Jennings, 1988a, b) and diminazene
diaceturate (Jennings, 1990; Zweygarth and Kaminsky, 1991) are 
effective even in cases with central nervous (CNS) involvement.
Against Leishmania species, DFMO was found to be able to block 
amastigote to promastigote transformation in vitro (Coombs at al..
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1983). DFMO, 1 mM, in the culture medium completely prevented
transformation of L. mexicana amastigotes. Promastigotes of this 
species, however, were far less sensitive to DFMO since 50 mM failed 
to block division. The high intracellular and extracellular
putrescine levels observed in L. mexicana late log phase
promastigotes (Coombs and Sanderson, 1985) may be responsible for 
the insensitivity of promastigotes of this species to DFMO (Coombs 
et al.. 1983). More recently Kaur at al. (1986) examined the
susceptibility of L. donovani promastigotes growth to DFMO. At DFMO 
concentrations as low as 50 mM, growth was completely blocked. Cells 
incubated with DFMO for 70 hrs were completely depleted of 
putrescine and had approximately 50% less spermidine than the 
controls. Keithly at ai* (referred to in: Bacchi and McCann, 1987) 
using promastigotes of L. donovani and L. braziliensis guvanensis 
grown in RE III medium, obtained >80% inhibition of growth with 5 mM 
DFMO.
In this study the high susceptibility of i. donovani
promastigotes to DFMO was also confirmed (Table 17, Figure 19). 
However, amastigotes growing in macrophages in vitro exhibited lower 
susceptibility to the drug than did promastigotes in vitro 
(Table 18, Figure 20). There was an apparent small reduction in 
amastigote numbers which, however, was not statistically
significant. The difference in susceptibility of L. donovani
amastigotes as compared to that of promastigotes could be due to 
possible stage differences in drug uptake, ODC turnover rates, the 
enzyme's affinity for DFMO, or the regulation of expression of ODC. 
Keithly and Fairlamb (referred to in: Keithly and Fairlamb, 1988) 
found no evidence for differential uptake or concentration of DFMO, 
nor utilisation of alternate enzymatic pathways for polyamine
biosynthesis in their in vitro testings with L. donovani. 
L. mexicana and L. h. guvanensis.
Neal and Croft (1984) found 13% reduction of infected
macrophages at 27 |ig/ml of DFMO. This result is different to that 
found in this study where, at this concentration, no reduction of 
infected macrophages was observed. This could be due to the longer
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treatment period and different origin of macrophages and method 
used to be elicited by Neal and Croft.
Keithly at al. (referred to in: Bacchi and McCann, 1987) have 
also used DFMO singly and in combination with Pentostarn(R ) , 
pentamidine, suramin and bleomycin against L. h. guvanensis and 
L. donovani infections in mice (BALB/c ByJ). Depending upon the
species DFMO can be synergistic, additive, or have no effect when
combined with other drugs (Keithly and Fairlamb, 1988). DFMO, given
at 3% in the drinking water for 2 weeks beginning 24 hrs 
preinfection, suppressed development of L. donovani in spleen cells 
by 51% (Keithly at al., referred to in: Bacchi and McCann, 1987) . 
DFMO was synergistic with the antitumor antibiotic bleomycin and 
showed an additive effect when in combination with suramin, 
allopurinol riboside, B e r e n i l a n d  Pentostam(R ) , in the
L. donovani mouse model (Keithly and Fairlamb, 1988). DFMO, given at
3-5% in the drinking water for 3 weeks starting 24 hrs postinfection 
to mice infected with L. &. guvanensis. was 50-74% suppressive to 
amastigote formation. DFMO was not synergistic with Pentostam(R ) 
and bleomycin in this model (Keithly £t. al., referred to in: Bacchi 
and McCann, 1987). These results coincided with the finding (Keithly 
and Fairlamb, 1988) that DFMO significantly reduces putrescine and 
trypanothione levels in leishmania and these DFMO-induced changes in 
metabolite levels were similar to those reported for T. h* brucei 
(Fairlamb et al., 1987). The effect of DFMO alone appeared to be 
cytostatic rather than cytocidal because non-dividing promastigotes 
could survive in culture for at least 11 days (Keithly and Fairlamb,
1988). This effect must be due to a depletion of polyamine levels 
and trypanothione, because its effect can be completely reversed by 
addition of putrescine (Keithly and Fairlamb, 1988). Thus it seems 
necessary to combine DFMO with a cytocidal drug to effect a complete 
cure.
With DFMO, the continuous presence of relatively high 
concentrations is necessary, since the target, ODC, is a rapidly 
inducible enzyme. The standard DFMO treatment regimen in vivo. used 
throughout this study, consisted of giving a 2% solution of DFMO in
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the drinking water continuously for a period of 14 days, starting 
approximately 4-5 days after infection. This regimen has been used 
since the first successful experiments against trypanosomes using 
combinations of DFMO and bleomycin (Bacchi ££. ai., 1980) and suramin 
and DFMO (Clarkson £t. al., 1984). Pharmacokinetic studies on DFMO 
in mice (Romijn gt. al., 1987) showed that oral administration of
DFMO during the day-time resulted in 10- to 15-fold lower levels 
than administration during night and discontinuation of treatment 
resulted in 50% decrease of DFMO levels in serum and tissues in 
approximately 6 hrs. For this reason the mice in this study were 
placed under a 2 hour light plus 4 hour dark routine, which was 
reported (Gillet gt al., 1986; Jennings, 1988a, b) to have the
effect of spreading the intake of DFMO more evenly throughout the 24 
hour period and also substantially increase its intake. However, a 
major problem with oral DFMO to mice via the drinking fluid is the 
lack of drug intake control, which may result in wide variations in 
drug concentrations between individual animals and thus making it 
difficult to quantitate the jja vivo effect of the drug combinations. 
Romijn a l .  (1987) found that the individual uptake of DFMO in the 
drinking water during a 14 hrs treatment period ranged between 
350-2800 mg/kg. They found, however, a significant correlation 
between the dose of DFMO which was taken up by each mouse and the 
concentration of DFMO in the serum and other tissues. This variation 
in drug uptake could explain the relatively large variation in 
parasite suppression by DFMO that was observed in some experiments 
of this study.
DFMO was also used in this study not only as a 2% but also as a 
4% solution and its effect on liver, spleen and bone marrow parasite 
load was assessed after 7, 14 and 30 days of administration
(Table 19, Figure 21). DFMO suppressed significantly parasites in 
the liver and to a lesser extent in the spleen and bone marrow. This 
was expected since pharmacokinetic studies in mice dosed with oral 
DFMO (2%) have shown that the highest concentrations of DFMO are 
present in organs which are part of the uptake and elimination 
pathway and these are the intestine, liver and kidney, whereas there
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was not an accumulation of DFMO in other tissues (Romijn et. al.. 
1987).
In this study, it was observed that the consumption of the 4% 
solution was reduced in comparison to the 2%, this finding
suggesting that the 4% solution was less palatableIto mice resulting 
in a reduced intake. This could explain why there was not a 
significantly different effect on liver and bone marrow parasite load 
between these two DFMO concentrations. However, it does not 
explain the finding that the 4% solution was more suppressive than 
the 2% solution, on spleen parasite load. More careful monitoring of 
fluid and so drug intake is required to help reduce these findings.
DFMO given continuously for 30 days had a very beneficial 
effect and all organs screened had very low parasite burdens. This 
indicates that it may be possible to clear all tissues with a 
treatment regimen involving a prolonged period of DFMO 
administration in combination with a cytocidal drug. The major 
disadvantage of this is the difficulty of DFMO administration and 
the quantities of the drug required for such a long treatment 
period. None of the combinations and day regimens I tested, however, 
had this effect (Table 29, Figures 32, 33, & 34).
4.2.4.2. DIAMIDINES
A number of diamidine compounds have been tested against Leishmania 
species showing moderate to low activity jji vivo (Hanson ££. al.. 
1963; Mattock and Peters, 1975b; Hanson £& al., 1977). The
differences observed in the activity of these compounds are thought 
to be related to the degree of their affinity to the transport 
system. Previous studies with T. brucei have shown (Damper and 
Patton, 1976) that the diamidine pentamidine, is accumulated in 
blood forms via a substrate-specific, carrier-mediated, 
concentrative, energy-coupled process and that other diamidines are 
competitive inhibitors of pentamidine uptake. Studies with 
structural analogues of pentamidine, used to characterise the 
pentamidine transport system in terms of structural specificity,
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have shown that diamidines containing a methylene chain as the 
bridge between the aromatic amidine moieties were the most effective 
inhibitors and compounds with the amidines in the meta position to 
the linkage bridge have a higher affinity for the transport site
(Damper and Patton, 1976).
The diamidine, diminazene diaceturate (Berenil^) is an 
antiprotozoal drug reported to be very effective against 
trypanosomes and babesia of cattle, sheep and several other domestic 
animals (Dalvi, 1988). Its good tolerance in cattle, sheep, dog and 
man is well documented, but camels and horses can show severe toxic 
reactions (Tacher, 1982). Chemically it is pp'-diamidinodi- 
azoaminobenzene diaceturate trihydrate, thus it is chemically 
related to diamidine compounds such as pentamidine and propamidine 
(Hawking, 1958). It binds non-specifically with serum and other 
proteins and from toxicological standpoint is neurotoxic and 
accumulates mainly in the liver, kidney and brain (Dalvi, 1988).
Although the exact mechanism of its action is not known, the drug
has been shown to inhibit trypanosomal SAM-decarboxylase (Bitonti 
et al. r 1986a, b) and has been reported to be potentiated by DFMO 
(Bacchi and McCann, 1987). Moreover, Jennings (1990) reported that 
DFMO (2% soln. in the drinking water x 15 days) in combination with 
diminazene diaceturate (1 x 40 mg/kg) 4 days after the start of DFMO 
treatment, cured 47 of a total of 49 mice infected with T. brucei. 
It was also possible to reduce the period of DFMO administration to 
6 days and still obtain reasonable cure rates (5/6 mice) (Jennings,
1990). Certainly Berenil does not work solely through polyamine 
metabolism, since it has been shown to block selectively 
kinetoplast DNA synthesis (Newton, 1972), but the irreversible 
inhibition of SAM-decarboxylase might contribute to the compound's 
overall efficacy as a trypanocide. At the very least, we can say 
that polyamines are somehow involved in the cytotoxicity of Berenil, 
pentamidine and similar compounds, since spermidine or spermine can 
block the curative effects of these compounds in vivo (Bacchi 
et al., 1983; Bitonti at al., 1986a). Further studies are needed to 
elucidate more fully the role of inhibition of SAM-decarboxylase by
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Berenil in the trypanocidal effect of the drug and the mechanism by 
which the inhibition occurs. Berenil has also been tested against 
Leishmania species in vivo and was found to be highly active 
against L. major and L. mexicana amazonensis in mice (Peters at al.f 
1980b) but with only moderate activity against L. infantum in mice 
(Trotter at al., 1980a). In the present study, Berenil showed
marked inhibition of promastigote growth (Table 17, Figure 19) and 
good antileishmanial activity against amastigotes of L. donovani 
growing in PECs, (67% amastigote reduction at 5 |ig/ml) (Table 18, 
Figure 20). However, it proved to be toxic to macrophages at 
concentrations of 10 l-lg/ml or above. This could be expected since 
it is known to be clinically toxic. Similar observations were made 
by Neal and Croft (1984) who found toxicity of Berenil to 
macrophages at concentrations of 9 |ig/ml and above. In this study, 
Berenil was also tested in vivo at various concentrations (Table 20, 
Figure 22). It showed good activity, however, it did not eradicate 
all the parasites even when used at high dose levels. Concentrations 
above 40 mg/kg did not increase significantly the percentage 
parasite suppression as determined on day 23 post infection. Trotter 
et al. (1980a) reported a delayed action of Berenil against
"L. infantum LV9" which suggests that an extended duration of the 
post-treatment observation period may be necessary in order to 
evaluate more accurately the results of high drug dose regimens. 
This could be due to the fact that the compound is not rapidly and 
completely metabolised in the body of certain species (cattle, 
rabbits, rats, mice) and the appreciable liver concentrations and 
the course of the blood/plasma levels may be responsible for a 
certain prophylactic effect of Berenil observed in cattle (Klatt and 
Hadju, 1976; Gilbert and Newton, 1982; Gilbert, 1983; Kellner 
et al.. 1985). Contrary to these findings, a rapid fall in blood 
levels of the drug following intramuscular dosage to dogs was 
reported (Bauer, 1958; Anika and Onyeyili, 1989) and for this reason 
it seems rather unlikely that Berenil could be effective as 
antileishmanial for treating the disease in dogs. Also, since its 
activity is compromised by the associated toxicity, it is not an
ideal drug for treating the disease in humans.
The diamidine, pentamidine (Lomidine^) can also affect the 
synthesis of trypanothione by blocking the polyamine pathway at 
SAM-decarboxylase (Bacchi and McCann, 1987). It has not been fully 
investigated in the CNS-trypanosomiasis mouse model, but it has been 
reported that with a dose rate of 100 mg/kg cures can be obtained 
with one or more consecutive daily doses given 4 days after the
start of DFMO administration (Jennings, 1990). Against Leishmania 
species, pentamidine has shown different activities in the hands of 
different workers and in different test systems. In vitro the drug
was active at high concentrations against promastigotes of
I*. pifanoi f L. braziliensis f L. tropica and L. enriettii (Jimenez 
and Ercoli, 1965). In this study, however, pentamidine 
methanesulfonate was found to be very active against L. donovani 
promastigotes even at very low concentrations (Table 17, Figure 19). 
Pentamidine diisethionate showed (Mattock and Peters, 1975b) only a 
moderate level of action against amastigotes of L. maior (in dog
sarcoma cell line) and L. mexicana (in hamster) and none against 
L. donovani (in dog sarcoma cell line). Contrary to that, Berman and 
Wyler (1980) found it very active (ED5q=0.02 |Jg/ml) against 
L. donovani growing in human macrophages. The differences in 
sensitivity reported, could be due to a combination of stage and 
species differences, different host cells employed or to the 
different chemical structure of the diamidine used, which could 
determine the drug sensitivity of the parasite. Pentamidine was also 
tested in vivo in this study (Tables 26 and 27, Figures 28 and 29) 
and showed no appreciable activity. In addition it caused toxic side 
effects and mortality of a few mice (see also section 4.3.).
4.2.4.3. DL-BUTHIONINE-(S,R)-SULFOXIMINE (BSO)
The formation of peroxides by cells appears to be an unavoidable 
consequence of aerobic metabolism and glutathione (GSH) plays a 
major protective role against the endogenous oxidant stress that 
results from high intracellular levels of H2O2 . Reports that
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trypanosomes lack catalase (Fulton and Spooner, 1956) focused 
attention on H2O2 and the regulation of its intracellular 
concentration. Buthionine sulfoximine (BSO) is a specific inhibitor 
of Y“glutamylcysteine synthetase, the first enzyme of glutathione 
synthesis (Griffith and Meister, 1979). Administration of BSO has 
been reported to lead to prolonged survival times or cures of
T. brucei infections in mice (Arrick ££. &JL., 1981).
BSO has not been tested previously against Leishmania species. 
In the present study, in which it was tested .in vitro against both 
promastigotes (Table 17, Figure 19) and amastigotes (Table 18, 
Figure 20) of L. donovani f it showed some activity but only against 
promastigotes. This could be due to the fact that the medium 
(RPMI-1640) used for growing macrophages contained GSH which could 
have replenished the intracellular GSH levels of amastigotes 
depleted by BSO.
BSO tested at various concentrations in mice infected with
L. donovani did not eradicate all the parasites even when used at
high levels,, although it caused marked reduction in parasite numbers
(20)
(Table I27 Figure 23). This finding supports the suggestion of 
interference of the host or the host cell in some other way.
Preliminary experiments indicated that BSO is metabolised very 
rapidly by the animal and it is necessary to administer the drug
very frequently (every 1.5 hrs) to maintain chemotherapeutic levels 
in the circulation (Arrick ££. q I ., 1981).
4.2.4.4. NITROFURANS
As well as the nitroimidazole compounds used in this study, I. also 
tested a nitrofuran, nitrofurazone, which has been used in patients 
with sleeping sickness resistant to arsenicals (Lowenthal jgJL al.r 
1977). In this context the drug has acquired a reputation for 
toxicity of almost unacceptable degree, although salvaging a number 
of patients with otherwise a hopeless prognosis (Lowenthal sJL al. f 
1977). A shorter hospital stay than that required for melarsoprol 
treatment and oral instead of intravenous therapy were the potential
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advantages of nitrofurazone. With the exception of nifurtimox, no 
other nitrofuran appears to have been tested against Leishmania 
species previously. Nifurtimox, which was not tested in this work, 
is an anti-T. cruzi compound. It has been reported to have moderate 
activity in vitro against L. mexicana and L. donovani amastigotes 
(Mattock and Peters, 1975b) and has been used to treat human 
cutaneous and mucocutaneous leishmaniasis (Guerra gt al., 1981;
Werner and Barretto, 1981), although it shows toxic side effects.
In the present study, nitrofurazone showed interesting 
antileishmanial activity against promastigotes, giving up to 100% 
reduction (Table 17, Figure 19). In contrast, it had no activity 
in vivo and indeed it showed an antagonistic effect when it was 
combined with Berenil and Trimelarsan (Table 21, Figure 24). This 
difference in the susceptibility between promastigotes and 
amastigotes may be due to permeability differences between these two 
stages of the parasite. The inactivity of nitrofurazone in vivo 
observed in this study together with its reported toxicity, 
suggested that further experimentation using this compound as a 
potential antileishmanial was not worthwhile.
4.2.4.5. ANTIMONIAL COMPOUNDS
The antimonial compound used in this study was sodium stibogluconate 
(Pentostam^). Sodium stibogluconate has been assessed as an
antileishmanial in a multitude of systems, both in vitro and in vivo 
and the extent of the information available on the clinical use of 
this compound is too large to allow a comprehensive coverage in this 
thesis. The compound has little or no activity against promastigotes 
in culture (Al-Khateeb ££. &1., 1977; Berman and Wyler, 1980) and 
this was also confirmed in this study against L. donovani (Table 17, 
Figure 19). Experimental in vivo infections, however, do respond to 
treatment with the drug (Beveridge, 1963). Trotter ££. & l . (1980a)
reported an ED50 of 22 mg Sbv /kg/day x 5, whereas Neal (1987)
found an ED50 of 11.2 mg Sbv /kg/day x 5, against L. donovani in
mice. Similar results were obtained in the present study where a
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dose level of 10-25 mg Sbv /kg/day x 4, resulted in 48-66% 
parasite suppression (Table 22, Figure 6 ). Methodological 
differences such as the size of inoculum and hence challenge to the 
host, route of administration, timing of treatment, strain of 
parasite and host animal used, may serve to explain differences in 
results reported by different workers.
The compound has been also incorporated in liposomes in attempts 
to potentiate its activity, and some hopeful results have emerged 
from this. Sodium stibogluconate in liposomes was shown to be 
700-fold more efficacious against experimental kala-azar in rodents 
than the free drug (Alving ££. al*, 1978). New ej: al* (1978),
however, found only 10-fold enhancement in mice infected with 
L. donovani and more recently (New et. al* > 1983) it was also
reported that free sodium stibogluconate did not clear L. donovani 
from the liver, but in the encapsulated form, the compound did clear 
the parasites. Experimental cutaneous leishmaniasis with L. maior 
and L. m. amazonensis was demonstrated to be more susceptible to 
sodium stibogluconate entrapped inside liposomes than the drug free 
in solution (New e£. al*> 1981). More recently, nonionic surfactant 
vesicles (niosomes) have also been investigated for their potential 
as antileishmanial drug carriers (Baillie £t a l ,, 1986; Hunter
et al* t 1988). Niosomes appear to be more stable and possess 
significant cost effective advantages over liposomes. Unfortunately, 
despite having a similar biodistribution, niosome encapsulated 
drugs are somewhat less effective than liposome preparations against 
animal models of leishmaniasis.
In earlier studies using free sodium stibogluconate, it was 
found that pre-dosing the host cells (dog sarcoma cells) prior 
their infection with amastigotes of L. donovani seemed to increase 
significantly the antileishmanial activity of this drug and it has 
been suggested that antimonials may exert an effect on amastigotes 
during their brief extacellular transit from one host cell to 
another in vivo (Mattock and Peters, 1975b). Similar results were 
found using L. m. mexicana in hamster peritoneal macrophages. Using 
cultured human monocytes infected with L. donovani and L. tropica.
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Berman and Wyler (1980) were able to demonstrate the high 
sensitivity of the intracellular amastigotes to this antimonial with 
an ED50 of 5 Jig Sbv /ml against L. donovani. I obtained similar 
results in my study using L. donovani in mouse peritoneal exudate 
cells (Table 18, Figure 20). Neal and Matthews (1982) reported total 
elimination of L. donovani from mouse peritoneal macrophages by this 
compound at 81 Jig/ml. I was unable to confirm this in my study, and 
there was not total elimination of parasites even at a higher drug 
level (100 flg/ml). This could be attributed to experimental 
variables such as length of incubation time and infecting ratio of 
amastigotes to macrophages. Coombs al. (1983) demonstrated that 
transformation of L. m. mexicana amastigotes to promastigotes was 
sensitive to the drug, suggesting that the amastigote itself is 
affected by sodium stibogluconate and that prior metabolism by the 
host cell is not essential for activity. The difference in the 
sensitivity of amastigotes and promastigotes observed could be 
explained by the differential permeability of this two distinct 
forms of the parasite. In spite of this drug having been used 
clinically for many years, there seems to be no conclusive evidence 
on how it exerts its effect and the mode of action of the antimonial 
compounds remains to be elucidated.
4.2.5. DETECTION OF ADDITIVE OR SYNERGISTIC INTERACTIONS IN 
CHEMOTHERAPY BETWEEN COMPOUNDS THOUGHT TO INTERFERE WITH 
TRYPANOTHIONE METABOLISM IN VIVO AND IN VITRO
The results of the monotherapy experiments showed that a number of 
compounds used in the present study have some antileishmanial 
activity when used alone. These compounds were investigated in 
more detail in combination experiments in vitro and in vivo by using 
relatively low drug concentrations so that the detection of 
synergistic and additive effects would be possible (Tables 23, 24 
and 25, Figures 25, 26, 27a and 27b). The results of these studies 
have shown that these combinations were less effective than had been 
hypothesised. There appeared to be no more than an approximately
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additive effect with any combination. Trimelarsan appeared to 
reduce the effect produced by all the other drugs in most cases. 
Combinations involving five or more drugs proved toxic to
macrophages. It should be noted, however, that combinations
involving so many drugs are impractical and have only a theoretical
value. The overall conclusion from these experiments was that 
although combinations involving DFMO, fexinidazole, Berenil and 
Pentostam have interesting activity against L. donovani in culture 
and in mice, they were not apparently synergistic. There are
several possible explanations for this. One possibility is that
some of the drugs used in the combinations are not as effective 
inhibitors of the same target sites in L. donovani as they are in
trypanosomes or even that these target sites differ between
trypanosomes and leishmanias. It is also possible that some of
these compounds such as the diamidines (see also section 4.2.4.2.1.) 
or nitroimidazoles may not act solely through polyamine and
trypanothione metabolism and that inhibition of these pathways plays 
only a part in the overall efficacy of the compounds as 
antileishmanials. For instance, it has been demonstrated (LaRusso 
QL al* y 1977) that reductively activated metronidazole binds to 
bacterial and phage DNA and yeast tRNA. More recently it has been 
demonstrated (Sorensen ££. al., 1990) that the 2-nitroimidazole
Ro 15-0216 targets mammalian DNA topoisomerase II and enhances 
enzyme-mediated DNA cleavage uniquely at specific DNA sequence 
elements.
Possible carrier-mediated processes or transport loci
participating in the uptake and transport of more than one of the 
compounds may explain the antagonistic and less than additive 
effects observed in some combinations.
There is only one previous report, by Keithly and Fairlamb 
(1988), on the use of combination chemotherapy targeting 
trypanothione metabolism in Leishmania species. Combinations 
involving Berenil (^) or Pentostam (^) and DFMO had an additive 
effect against experimental visceral leishmaniasis and this is in 
agreement with the results obtained in this study.
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In the final analysis, chemotherapy is only an adjunct to the 
process of host immunity and the immune response is an important
element in the activity of most antileishmanials. The disease
patterns produced by inoculation of Leishmania parasites in mouse 
strains of various genetic backgrounds vary considerably, depending 
on genetically determined factors contributed by both the host and 
the parasite. The immune response-linked genetic mechanisms
underlying susceptibility or resistance to leishmania infections
determine the capacity of the host to overcome, or not, an 
established infection through the development of immune effector 
mechanisms and thus critically decide the outcome of infection in 
its later stages. Thus the success of treatment should vary with the 
inherent ability of different hosts to mount an antibody response. 
This suggests that further studies involving testing of these 
compounds in different host species such as, in the case of 
L. donovani. the dog, may be needed to elucidate more fully the
role of inhibition of trypanothione metabolism in Leishmania species 
by these compounds and the mechanism by which the inhibition
occurs. In trypanosome infections it is well established that
antitrypanosomal antibodies are adequate to clear the bloodstream of 
parasites during DFMO therapy and that an intact immune response is 
necessary for cures of the disease to be obtained (de Gee ££. al.r
1983; Bitonti ai., 1985; Jennings, 1988a, b; Zweygarth and
Kaminsky, 1991). An additive effect iji vitro may be found to be 
potentiating jji vivo due to additional influence of the immune
response and this has been demonstrated in trypanosomes (Zweygarth 
and Kaminsky, 1991). Such potentiation, however, was not observed in 
this study. Therefore, a more adequate immune response in
trypanosome infections as compared to that in leishmania infections 
may also serve to help explain the potentiation of drug combinations 
observed against the former parasites.
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4.3. IN VIVO EXPERIMENTS INVOLVING THE DRUGS OF CURRENT USE, SODIUM 
STIBOGLUCONATE (PENTOSTAMR ) AND PENTAMIDINE (LOMIDINER ), IN 
COMBINATION WITH DFMO AND BSO
In one attempt to maximise the effectiveness of the drugs currently 
being used in the treatment of leishmaniasis, sodium stibogluconate 
(PentostamR ) and pentamidine, these drugs were tested in vivo in 
some detail in the Balb/c mouse model. They were used both alone, 
with different lengths of treatment time (Table 26, Figure 28) and 
in combination, by using different treatment regimens (Table 27, 
Figures 29 & 30). The results revealed that a more favourable 
response to treatment was achieved when an inhibitory concentration 
of the antimonial was maintained for most of the day, by using 
multiple low daily doses, than when a high single dose was employed. 
In addition, the total dose of Pentostam required to produce a 
particular level of suppression was lower when the drug was 
administered twice (rather than once) daily and for longer period 
of time. These findings are consistent with the known 
pharmacokinetics of antimony in man (Chulay ££. al • > 1988) after
parenteral administration of pentavalent antimonials. These 
pharmacokinetic data have been interpreted by Chulay at al., (1988) 
in terms of a three phase pharmacokinetic model representing an 
initial absorption phase (mean ti/2=0*85 hrs), a very rapid 
elimination phase (mean t;jy2=2.02 hrs) which is responsible for 
the removal of most of the drug from the body, and a slow 
elimination phase (mean ti/2= 38-76 hrs) which provides evidence 
for some accumulation of the drug. These results are also in accord 
with the findings of Chulay and his associates (1983) who reported 
that treatment of human visceral leishmaniasis in Kenya with sodium 
stibogluconate at a dose of 10 mg Sbv /kg every 8 hrs for 10 days 
appeared to be a safe alternative to conventional treatment.
Pentamidine by itself showed no appreciable activity in this 
mouse model and in addition it caused some toxic side effects and 
mortality of a few mice. The poor efficacy of pentamidine against 
leishmania in mice, however, has been noted previously by Trotter
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and his associates (1980a, b), who found it to be inactive at 50 
mg/kg/day x 5, against L. major, L. mexicana amazonensis and 
L. donovani.
Another possibility investigated in this study, was the 
combination of DFMO with Pentostam and pentamidine (Table 27, Figure 
29). The potential advantage of this combination is that all of 
these drugs have been passed for use in humans. These combinations 
were carried out with the hope that DFMO might lower the Pentostam 
or pentamidine dose necessary to suppress infection. Keithly and 
Fairlamb (1988) have previously reported the use of DFMO singly and 
in combination with Pentostam against L. b» guvanensis f L. m. 
mexicana and L. donovani infections in mice (BALB/c ByJ). The effect 
was additive at best, and in L. mexicana infections suppression was 
only marginally better than treatment with DFMO or Pentostam alone. 
Similar results were obtained in this study. Moreover, addition of 
pentamidine resulted in an antagonistic effect. The combination of 
Pentostam, pentamidine and BSO was also tested but showed little 
promise (Table 27, Figure 30). Thus, these combinations are also 
rather disappointing and not worth pursuing.
4.4. A STUDY ON THE PREVENTION OF THE RELAPSE OF VISCERAL 
LEISHMANIASIS IN THE MOUSE MODEL, USING COMPOUNDS THOUGHT TO 
INTERFERE WITH TRYPANOTHIONE METABOLISM
A problem in the chemotherapy of visceral leishmaniasis is the 
relapse of the disease after an apparently successful treatment. 
Thus it was of interest to develop an experimental relapse model 
of leishmaniasis in the Balb/c mouse and test the efficacy of the 
new compounds and most promising drug combinations, in clearing the 
parasites not only from liver but also from spleen and bone marrow. 
It is already known that the Balb/c mice maintain chronic heavy 
infections involving mononuclear phagocytes throughout the body 
(Blackwell e£. ill., 1980) and this was also observed in this study 
where parasite load maintained at high levels until the end of the 
experiment (DAI 80). The results clearly demonstrated (Table 28,
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Figure 31) that treatment with both iv and ip administration of 
sodium stibogluconate solution (PentostamR ) greatly reduced the 
number of parasites found in liver but to a lesser extend the 
parasite load in the spleen and bone marrow, as determined on day 23 
after infection (DAI 23) and this is in agreement with previous 
reports (Carter ££. al., 1988; Carter al al•» 1989). The low parasite 
loads found on DAI 23 persisted and no increase in numbers occurred 
over the next 15 days. Eventually, this apparent resistance does 
wane and liver parasite burdens in sodium stibogluconate-treated 
animals are known (Carter al al» > 1988; Carter al &1. > 1989) to
return to control levels by day 50 post drug treatment. In this 
study, however, this was confirmed only for spleen and bone marrow 
parasite loads, whereas liver parasite loads, although showing an 
increase, did not reach the control levels. This could be a 
consequence of the higher dose level of the antimonial used in this 
study and its known (Chulay. al ill •» 1988) slow terminal elimination 
phase suggesting that the drug persists in the liver for longer 
period of time. Although the total organ content of antimony might 
be unmeasurable, there could be sufficient accumulation of drug in a 
subcellular region such as the lysosomal compartment which would be 
sufficient to suppress parasite growth. There is also some evidence 
from other investigations on the phagocytic activity of macrophages, 
that liver macrophages might have been left in an activated state 
following chemotherapy using sodium stibogluconate (Carter il al.. 
1989). Treatment did not have a similar effect on spleen and bone 
marrow parasite load. This could reflect heterogeneity in macrophage 
populations as it has been shown that macrophages from different 
tissues vary in their susceptibility to L. donovani infection and 
that Lsh gene is expressed variably in different tissues (Olivier 
and Tanner, 1987). Thus it is not inconceivable that infection with 
L. donovani has different effects on different macrophage 
populations and that cells from these populations respond 
differently to drug treatment. It is also possible that the drug 
shows inability to reach the infected macrophages at spleen or bone 
marrow sites. The low rate of blood perfusion through spleen and
bone marrow compared with liver and the high initial clearance rates 
of drug through the urine (Chulay ££. al., 1988) tends to support
this latter proposition. However, it should be noted that neutron 
activated analyses showed that antimony reached the spleen of mice 
and 24 hrs post-dosing antimony concentrations in the liver and 
spleen were comparable (Hunter aL al., 1988).
The results from use of the drug combinations (Table 29, Figures 
32, 33, 34 & 35) showed them to reduce significantly the number of 
parasites not only in liver but also in spleen and bone marrow. They 
did not give a total clearance of the parasites but they proved to 
be more effective than Pentostam itself. The percentage suppression 
in liver as determined on DAI 39 was higher than that of DAI 23 in 
combinations other than the combination of Pentostam with DFMO. This 
could be due to the presence of residual drug with slow action such 
as has been reported with Berenil (see section 4.2.4.2.1).
In some groups of mice the presence of bacteria in the organs 
which were screened gave evidence of acquired infection with other 
organisms and a competitive relationship could have resulted in an 
apparent increase of the percentage suppression of the combination 
such as in the case of the combination involving Pentostam and DFMO. 
Epervthrozoon are known to affect immune responses to protozoa and 
the course of infection (Peters, 1965; Ott and Stauber, 1967).
Particular attention was given to DFMO to assess the potential 
of the drug for preventing the relapse of visceral leishmaniasis. It 
showed good activity but did not give a total clearance from all 
tissues (see section 4.2.4.1.).
Thus, the results obtained, presented in section 3.2. and 
discussed in section 4.2. of this thesis, showed that many of the 
compounds thought to inhibit the synthesis or interfere with the 
activity of trypanothione have antileishmanial activity. However, 
none of the combinations appeared to be synergistic under the 
conditions used although at high concentration they were better than 
sodium stibogluconate itself. At the very least, we can say that 
there are indications that the polyamine and trypanothione pathways 
of leishmanias are somehow involved in the cytotoxicity of most of
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the compounds tested.
Trypanothione metabolism has potential as drug target that has 
yet to be fully realised. Although studies on the metabolism and 
functions of trypanothione in trypanosomatids are still in their 
infancy, present work is helping to optimise combination therapy of 
existing drugs and to provide a rational approach for development of 
new and better drugs. This study was simply a step towards this 
direction. Where do we go from here? With the modern techniques now 
available for drug development and drug delivery, perhaps we should 
be updating our approach to the problem of chemotherapy. Many more 
metabolic studies are needed to unravel at the molecular level the 
biochemical pathways that occur in trypanosomatids. This information 
should enable an increasingly more rational approach to be taken in 
the design of molecules to be synthesised and tested. In 
trypanosomatids trypanothione reductase (TR) is essential for 
maintaining trypanothione as T[SH]2 and therefore represents a 
target for the design of new trypanocidal drugs. The gene encoding 
TR from the cattle pathogen T. congolense has been cloned, sequenced 
(Shames at al«, 1988) and expressed in Escherichia coli (Sullivan 
et al. 1989) and shows more than 50% homology with human glutathione 
reductase (GR) (Shames at. al•, 1988). Sequence data from L. donovani 
(Taylor al al., 1989) support these findings, suggesting similar
reaction mechanisms for GR and TR. However, there are also important 
differences. TR will not reduce GSSG, neither human GR will reduce 
T [S ] 2 t0 any significant extent (Shames e_t al., 1986). In addition, 
the mixed disulfide of N-^~glutathionylspermidine and glutathione and 
the Nl-glutathionylspermidine disulfide are substrates for TR but 
not GR (Henderson et al., 1988). Thus these findings suggest that 
TR targeting in trypanosomatids is a promising approach for drug 
design.
Molecular modelling of both enzyme and substrate and the 
accurate elucidation of the three dimensional structure of TR is 
necessary in order to assist in the design of its specific 
inhibitors. One such attempt is the recent modelling study of 
T. coneolense TR (Murgolo at al . , 1989).
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4.5. THE EFFICACY OF A DRUG-CARRIER SYSTEM, OCTYL DEGROL OIL, IN THE 
CHEMOTHERAPY OF VISCERAL LEISHMANIASIS
One alternative to finding new drugs involves improving delivery of 
existing compounds to the target cell, thus decreasing the toxicity 
to the host cell and improving the therapeutic index. During recent 
years several attempts have been made to improve the efficacy of 
existing anti-protozoal drugs by increasing their bio-availability 
to the parasite. For example, daunorubicin, a potent trypanocide 
in vitro but inactive in vivo, was conjugated to bovine serum 
albumin or ferritin and regained its iji vivo activity (Williamson 
and Scott-Finnigan, 1978). The most dramatic results of targeted 
chemotherapy, however, have been those obtained using liposome- or 
niosome-entrapped drugs against macrophage-inhibiting protozoa. 
Preferential uptake of drug-loaded vesicles by cells of the 
reticulo-enthothelial system target the drug passively to the
infected phagocytes of this tissue. The potential of drug-loaded 
vesicles for the delivery of pharmacological agents to macrophage 
dwelling parasites was quickly recognised. Liposomes (Alving, 1986) 
and niosomes (Baillie £l al., 1986) containing sodium stibogluconate 
were shown to be more effective than free drug in the treatment of 
experimental visceral and cutaneous leishmaniasis (see also section 
4.2.4.5.).
One of the drawbacks in using sodium stibogluconate in the
chemotherapy of leishmaniasis, is its rapid metabolism and very 
short half life in the mammals (Otto al al«» 1947; Pamplin al al * - 
1981; Chulay al al. > 1988). In one attempt to overcome this and
achieve effective drug levels for longer, a new experimental 
compound, octyl degrol oil, which was effective in allowing slow 
release of drugs, was investigated. The preliminary results I 
obtained (Table 30, Figures 36 & 37) showed the drug in suspension
with the octyl degrol oil to be more efficacious than the free
drug, suggesting that further experiments for evaluating octyl 
degrol oil as a slow-release drug carrying system for leishmaniasis, 
may prove to be worth pursuing. Unfortunately there is as yet no
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other information available on this new carrier system and lack of 
material prevented me from carrying out more experiments with it.
4.6. THE ANTILEISHMANIAL ACTIVITY OF DNA-INTERCALATORS, PLATINUM AND 
RHODIUM DRUG COMPLEXES AND 8-HYDR0XYQUIN0LINES
The results from testing these experimental compounds, showed the 
8-hydroxyquinoline compounds and the majority of DNA intercalators 
to have interesting antileishmanial activity against promastigotes 
of L. donovani f whilst the platinum and rhodium drug complexes were 
relatively inactive with the exception of Rh (III)-T which showed 
some activity at the highest level tested (100 Pg/ml) (Table 31, 
Figures 38, 39 and 40). There was insufficient material available to 
allow iji vivo testing. A number of related platinum and rhodium 
drug complexes, tested against trypanosomes in vivo (Osuna et. al.. 
1987; Jennings, unpublished results) and against L. donovani 
amastigotes in vitro and in vivo (Croft nL nl• > 1990) were reported 
to have some activity and it has been suggested (Croft nL al* > 1990) 
that the amastigote-mitochondrial complex is the primary site of 
their action. These compounds possibly warrant further study.
There have been no previous reports on the activity of the
8-hyroxyquinolines against Leishmania species, although several 
related quinoline compounds tested showed very interesting 
antileishmanial activity in vitro and in vivof being in some cases 
several hundred times more potent than the standard pentavalent 
antimonial meglumine antimoniate (Hanson at al* > 1977; Kinnamon
££. al* t 1978; Peters aL al* > 1980a). The highest activity was shown 
by the quinoline compound, WR 6026 which was 474 times as active as 
meglumine antimoniate when given im and 708 times as active as
meglumine antimoniate when given orally. WR 6026 was also tested
against visceral leishmaniasis in dog giving a 94% reduction in 
liver parasite load at 3.25 mg/kg/day for 5 days (Chapman al. f 
1979). Clearly these compounds have great potential.
There have been several reports on antiprotozoal drugs such as 
the diamidine compounds and some nitroimidazoles which themselves
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or their metabolic products interfere with DNA synthesis by binding 
and degrading intact DNA. There are no previous reports on these 
newly synthesised DNA intercalators tested in this study. The 
promising results obtained in this study with the DNA-intercalators, 
suggest that further evaluation of these compounds would be 
worthwhile.
Overall, the present study has provided information on the 
susceptibility of L. donovani to a number of drugs and drug 
combinations. Many were relatively ineffective but some deserve 
further study and possibly could lead to better ways of treating 
canine leishmaniasis.
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